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Colorectal cancer (CRC) is a major cause of cancer related mortality and is 
the second most common cause of cancer deaths in the UK (CRUK). 
Despite year on year improvements in survival, the five-year survival for all 
patients remains less than 60%. For locally advanced rectal cancer (LARC), 
surgical resection is a mainstay of management, alongside pre-operative 
long-course chemoradiotherapy (LCCRT). Tumour regression grade (TRG) 
in LARC is variable and patients’ tumours that fail to regress with radiation 
have much poorer prognosis. Understanding why patients have a poor TRG 
is critical to improving survival from rectal cancer.  
The proto-oncogene BCL-3 is upregulated in a subset of CRCs. BCL-3 
expression predicts patient prognosis in advanced disease and has been 
shown to protect colon cancer cells from apoptosis. However, little is known 
regarding the role of BCL-3 in rectal cancer, specifically, concerning BCL-
3’s role in promoting tumour cell survival or in the response to irradiation. 
Results reveal that BCL-3 is expressed in rectal cancer cells. BCL-3 
suppression was shown to increase expression of the pro-apoptotic BH3-
only BCL-2 family member Bim, leading to apoptosis. BCL-3 and p52 were 
identified at κB consensus sites on the BCL2L11 promoter. Moreover, BCL-
3 suppression increased acetylated histone 3 abundance at the BCL2L11 
promoter, suggesting BCL-3 loss, results in transcriptional activation of Bim. 
Additionally, BCL-3 protects rectal cancer cells from -irradiation and loss 
results in exacerbated and prolonged H2AX foci formation.  
These data suggest that BCL-3 plays an important role in the DNA damage 
response of CRC cells. Interestingly, immunohistochemistry of rectal cancer 
biopsies showed that BCL-3 expression may predict TRG to LCCRT. 
Excitingly, these data suggest a dual action for anti-BCL-3 therapeutics: 
targeting BCL-3 may be important for prevention and/or treatment, causing 
tumour cell death, whereas inhibiting BCL-3 function, in the subset of 
patients with increased BCL-3 expression in tumours, may increase the 
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1.1 Colorectal cancer 
Colorectal cancer (CRC) is a neoplasm that arises from the intestinal epithelial 
cells (IECs) lining the large bowel (colon and rectum). CRC is a major cause of 
cancer related mortality and is the second most common cause of cancer deaths 
in the UK (5). Despite year on year improvements in survival, the five-year net 
survival for male patients diagnosed with colon cancer is 58% (rectal cancer 
58.6%), while in female patients it is 57.6% (rectal cancer 60.8%) (6). In the UK, 
incidence is greatest in older age groups; although, there has been a reduction in 
incidence in these age groups as a result of large-scale public health initiatives 
such as the Bowel Cancer Screening program (BCSP). Worryingly though, overall 
Figure 1.1 Age-specific incidence of colorectal cancer between 1974 and 
2015 in England 
 
 3 
CRC incidence is rising, particularly in younger populations (<50 years old) (Figure 
1.1), similar to findings in other developed countries around the world (7). This 
disease remains a significant burden for patients and the NHS. 
CRC can be subdivided into hereditary and sporadic forms (Figure 1.2). Of the 
hereditary forms, Familial Adenomatous Polyposis gene (FAP) is defined by 
germline mutations in adenomatous polyposis coli (APC), while other syndromes 
such as hereditary non-polyposis colorectal cancer (HNPCC or Lynch Syndrome) 
have germline defects in mismatch repair (MMR) genes leading to microsatellite 
instability (MSI (8)) and result in hyper-mutated tumours (9, 10). Other rarer 
polyposis syndromes that predispose to colorectal cancer include MYH-associated 
polyposis (MAP), juvenile polyposis syndrome (JPS) and Peutz Jeghers syndrome 
(PJS) (11). Sporadic colorectal cancers develop from a series of somatic mutations 
combined with epigenetic changes in previously normal tissue, known as the 
adenoma-carcinoma sequence (12), and as such they tend to develop in an older 
population due to the lead time of 10 to 15 years required to develop a carcinoma 
from an adenoma (See 1.3). Recently, significant work has been performed to 
characterise colorectal tumours based on consensus molecular subtypes (13).  
 FAP HNPCC Sporadic 
Germline defect APC MMR genes nil 
MSI n/a >90% ~15% 
Tumour Initiation accelerated varied long 
Tumour 
Progression 
varied accelerated varied 
Prognosis Poor Good Moderate 
Age at diagnosis ~20-30yrs ~40yrs >55 
Figure 1.2 Characteristics of colorectal cancer based on inherited genetic defects in 
comparison to sporadic colorectal cancer. 
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Colorectal cancers (CRC) occur in patients with inherited genetic defects such as 
heterozygous APC mutation (FAP) or mutations in genes involved with MMR (HNPCC). 
Figure 1.3 Anatomy of the colon and rectum 
The rectum is the terminal portion of the large bowel that acts as a reservoir for 
storage of faecal matter. It is heavily colonised by bacteria which convert dietary fibre 
into short-chain fatty acids and is the final location where absorption of nutrients and 
water occurs. The rectum extends from the recto-sigmoid junction to the dentate line, 
where the anus originates. The rectum has portions covered by peritoneum and 
portions without a serosal covering, surrounded by pelvic organs, as it descends 
towards the anus.  
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However, CRC more commonly develops sporadically with an accumulation of genetic and 
epigenetic defects leading to cancer. Adapted from Kinzler and Vogelstein 1996 (9) and 
Haggar and Boushey (14). 
Colorectal cancer can be further subdivided based on anatomical location, which 
relates the tumour to its arterial supply, lymphatic and venous drainage.  
1.2 Rectal cancer 
The rectum is the terminal or distal-most portion of the large bowel that functions 
to store faecal matter and absorb the last nutrients and water contained within the 
stool. The rectum extends from the recto-sigmoid junction to the anus/dentate line 
and is around 15cm in length (Figure 1.3). Cancer of the rectum constitute around 
30% of all colorectal malignancies and are managed differently to colonic tumours; 
this is due to the anatomy, such as the close proximity of the rectum to other pelvic 
organs (seminal vesicles/prostate in men and the vaginal vault in women), pelvic 
autonomic nerves, the lack of a serosal/peritoneal layer covering the majority of 
the rectum and the genetic differences of these tumours (15). The difference in 
genetics is thought to be primarily the difference between non-hypermutated and 
hypermutated tumours, of these, hypermutated tumours are significantly more 
common in the right of the colon (16).  
Following diagnosis of a rectal lesion, staging of the tumour is critical to determine 
if it is early or advanced and the presence of metastatic disease. Staging of rectal 
cancer enables MDT (multi-disciplinary team) management decisions and all 
patients are offered standardised investigation including endoscopic evaluation 
(with biopsy for histopathological analysis), imaging including a computed 
tomography scan (CT) of the chest, abdomen and pelvis, a magnetic resonance 
imaging scan (MRI) of the pelvis (17) and additionally an endorectal ultrasound 
(EUS) (18). Subdivision into early disease, locally advanced and metastatic rectal 
 
 6 
cancer uses the TNM staging system (Tumour Nodes Metastasis, Figure 1.4 and 
Appendix 2), enabling treatment stratification. 
Locally advanced rectal cancer (LARC) is defined by the pathological extent of 
tumour (alongside lymph node involvement) leading to an increased risk of 
developing local recurrence, which has been the major cause of morbidity and 
mortality in these patients (19). Disease that threatens (within 1mm of mesorectal 
fascia) or involves the potential resection margin, is at high risk of local recurrence 
(20-22). These tumours, as defined by pelvic MRI, have a threatened (1 mm from 
mesorectal fascia) or compromised/breached mesorectal fascia/margin, but can 
also include very low tumours <5 cm from the anal verge (23). Pelvic MRI is critical 
to this assessment and has be shown to be highly sensitive and capable of 
predicting clear resection margins (>1 mm circumferential resection margin 
(CRM)) in 92 % patients (24). LARC has a high rate of local recurrence and 
significant research effort has been directed at reducing this. 
Figure 1.4 TNM staging of colorectal cancer 
Tumours of the colon and rectum are staged according to depth of involvement of the bowel 
wall of the primary Tumour, regional lymph Node involvement and whether the cancer has 
Metastasised to distant locations (Appendix 2). Shown here is T stage, determining extent 
of the primary tumour. T1 tumours invade into submucosa, T2 tumours invade into 
muscularis propria, T3 tumours invade into the sub-serosa or into non-peritonealised peri-
colic/rectal tissues and T4 tumours directly invade other organs or structures. Additional 
subclassifications have been developed which subdivide T1 and T3 lesions. Adapted from 
CRUK (www.cancerresearchuk.org) and UICC TNM staging (8th edition). 
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1.2.1 Current management of LARC 
1.2.1.1 Surgical resection 
Surgical management can be divided into those cases of early or advanced 
managed with curative intent and palliative disease. T1 tumours confined to the 
mucosa or submucosa would be suitable for local mucosectomy or full-thickness 
excision performed endoscopically or via TEM (transanal endoscopic 
microsurgery) (25). More advanced disease is managed with major resection. The 
aim of surgical resection of advanced rectal cancer is to achieve curative resection 
ensuring that the CRM is macro and microscopically free from tumour (R0 
resection, resection margin positivity strongly predicts tumour recurrence); the 
identification and preservation of pelvic autonomic nerve plexi to ensure the 
preservation of urinary, bowel and sexual function; the preservation of the anal 
sphincter complex to enable faecal continence. Developments in surgical 
technique, pioneered by Richard Heald in the late 1970s, to improve local 
recurrence rates of advanced rectal cancer, resulted in the widespread adoption 
of rectal cancer resection along the mesorectal plane (termed Total Mesorectal 
Excision, TME) (26). The principle of TME is the same, no matter the surgical 
technique being utilised, and has been shown to significantly improve survival from 
rectal cancer (26-28). When performing TME, it is still unclear whether it is 
necessary to perform resection down to the level of the pelvic floor muscles or only 
resect to 2-5 cm below the tumour. Distal spread to lymph nodes below the tumour 
is thought to be minimal but increases with tumour stage (29, 30), however it is 
unknown if the surgeon needs to resect these more distal nodes along with the 
primary tumour. 
Currently, there are two standard techniques for surgical removal of advanced 
rectal cancer; anterior resection (AR) resulting in bowel continuity or abdomino-
perineal resection (APR, including extra-levator APR) resulting in permanent 
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stoma formation. The choice of which surgical procedure to perform depends 
primarily on the height of the tumour from the ano-rectal junction (dentate line) and 
the length of rectum distal to the tumour that enables colo-anal anastomosis, the 
extent of invasion of the tumour and the preferences of the patient.  
Additional surgical techniques for performing TME, for advanced tumours less than 
T-stage 4, are currently being developed, such as the trans-anal TME (TaTME) 
operation (31, 32). The aim of TaTME is to improve the TME component in the 
distal pelvis and reduce rates of long-term surgical morbidity (such as low anterior 
resection syndrome – LARS) when TME can be difficult, particularly in male or 
obese patients and those patients who have undergone pre-operative 
radiotherapy. Critically, TaTME is still under evaluation to ensure its oncological 
safety and lack of inferiority with regard to morbidity and mortality in comparison to 
standard laparoscopic anterior resection (33). 
Open or laparoscopic surgical resection using the mesorectal fascial plane for 
locally advanced rectal cancer is still the gold standard treatment providing a 
potential cure for this disease.  
1.2.1.2 Treatment and response with long-course chemo-radiotherapy 
in rectal cancer 
Alongside the technical developments in surgical technique over the past 50 years, 
there has been significant debate regarding the utility of radiotherapy with or 
without chemotherapy to achieve improvements in overall and disease-free 
survival and local or systemic recurrence. Therapy can be administered pre-
operatively (neo-adjuvant) or post operatively (adjuvant). In rectal cancer, as 
opposed to colonic cancer, pelvic radiation was originally used to palliate patients 
with inoperable disease; although, early data suggested radiation therapy with X-
rays improved overall and disease-free survival in resectable tumours (34). Given 
the propensity of rectal cancers to recur locally, radiation was subsequently used 
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as an adjuvant therapy to prevent this (35). Radiation is utilised in two alternative 
regimens (discussion of the actual method of delivery of radiation is beyond the 
scope of this project); firstly, short course preoperative radiotherapy (SCPRT), 
which consists of 25 Gy in 5 fractions followed by surgery at an interval of 1 week 
(developed from protocols used by VA Surgical Adjuvant Group and Toronto Group 
trials (36)). Secondly, long-course radiation (LCRT), initially described in the 1970s 
(37-39) and consists of 45 Gy (1.8 Gy fractions per day to limit toxicity) in 5 weeks 
plus a 5.4 Gy boost followed by surgery 6-8 weeks later. A recent meta-analysis 
found prolonging the interval to surgery may increase therapy response rates (40). 
Treatment with fluoropyrimidines was added to LCRT with the aim of improving 
radiation efficiency (LCCRT) (41-43). 
Effort to reduce the high rates of local recurrence of rectal cancer using radiation 
led to a multi-arm study comparing surgery alone to adjuvant chemoradiotherapy, 
adjuvant radiation or adjuvant chemotherapy (44). This study showed that disease-
free survival was significantly prolonged in the group receiving post-operative 
LCCRT compared to surgery alone; however, without prolonging overall survival 
and with no difference to those patients receiving post-operative radiation alone. 
Later studies showed significant reductions in local recurrence with LCCRT 
compared to LCRT alone (43). Additionally, this work showed reductions in cancer-
related mortality and overall survival in patients undergoing adjuvant LCCRT. 
However, these studies were limited as the protocols used contained a drug, 
semustine, that was later shown to confer no benefit and lead to increased 
incidence of lymphoma (45). 
Concurrently to these studies examining postoperative LCRT and LCCRT, 
research was being performed analysing the effect of pre-operative radiation to 
control local recurrence. Data from North America suggested that for more 
advanced tumours (Dukes’ stage C) there was a reduction in local recurrence for 
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patients treated with SCPRT either as a single fraction or as multi-fractionated 
regimes (36, 46). These data were contrasted with data from a large randomised 
study in the UK analysing both single fraction (5 Gy) and multi-fractionated (20 Gy 
over 10 days), which showed no benefit to survival or local recurrence following 
SCPRT (47). Moreover, these studies were limited as they were performed before 
or during the improvements in surgical technique (meticulous TME/R0 resection) 
had been adopted. In the TME era, data from the Netherlands and Sweden has 
shown that SCPRT (25 Gy in 5 days) combined with surgical resection, ensuring 
TME, significantly reduced local recurrence over surgical TME alone (48-51). 
Additionally, the MRC-CR07 study showed SCPRT to be significantly better than 
the selective use of adjuvant LCRT, conferring benefits to local recurrence (61 % 
reduction) and disease-free survival (24 % improvement) (52). 
So how did we get to the current management paradigm? The rectal cancer 
research community recognised that the addition of a radiosensitiser (5-
fluorouracil) to LCRT was efficacious; however, it was also recognised that there 
was equipoise between SCPRT and neo-adjuvant LCCRT and when to utilise 
LCCRT to achieve the best reductions in local and distant recurrence as well as 
disease-free and overall survival. 
The German Rectal Cancer and National Surgical Adjuvant Breast and Bowel 
Project (NSABP) groups showed that neo-adjuvant LCCRT compared to post-
operative LCCRT decreased local relapse despite no improvements in disease-
free or overall survival (53-55). Data from the EORTC (European Organisation for 
Research and Treatment of Cancer) and the FFCD (Federation Francophone de 
Cancerologie Digestive) 9203 trial showed decreased rates of local recurrence with 
LCCRT compared to SCPRT (56, 57). Although, data from the Polish colorectal 
study group, published at the same time, showed no difference in disease-free 
survival or overall survival between SCPRT and LCCRT, challenging findings from 
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EORTC and FFCD trials (58). However, a recent Dutch registry study analysing 
almost 6000 patients treated with either SCPRT or neo-adjuvant LCCRT found that 
there was a significantly higher chance of achieving a pathological complete 
response (pCR, see below) with LCCRT despite those tumours treated with 
LCCRT being of a more advanced stage (59), which corroborated a meta-analysis 
performed in 2009 (60). In summary, evidence from the past 60 years of research 
suggests that in the era of TME for rectal cancer neo-adjuvant LCCRT confers 
benefits to patients in reducing local recurrence and critically results in 
downstaging of tumours, although it is still unclear why there is limited benefit to 
overall survival rates. 
Downstaging of the primary tumour is a term used to define a response to LCCRT 
(also downsizing or regression can be used). Assessment of this prior to resection 
can be made both clinically via endoscopy or radiologically. Post-operatively, 
downstaging of the tumour can be assessed pathologically, using a tumour 
regression grade (TRG). Various different grading systems are in use including 
Dworak’s (61), MSKCC system, Mandard (62), AJCC (63) and Ryan TRG (64), all 
of which measure proportion of tumour mass replaced by fibrosis and residual 
tumour cells (65) (Appendix 3). It is well recognised that there is a broad range of 
response to neo-adjuvant LCCRT. While pathological complete response (pCR) is 
well defined as no residual tumour cells in the primary tumour or lymph nodes, 
non-response has no consensus definition but tumours show a range of 
absent/minimal regression (66). Rates of pCR are thought to be in the region of 
12-15 % following LCCRT (67) with pCR accurately predicting long term OS and 
DFS following neoadjuvant therapy for rectal cancer (67, 68). All TRG systems 
predict recurrence, however the AJCC system was the most accurate in a study of 
563 patients with T3/4 or N1 LARC (65). Although, the AJCC system may 
outperform other TRG grades in predicting patient survival, it fails to consider 
 
 12 
pathological nodal status (ypN). ypN is a known determinant of poor prognosis 
despite good primary tumour response (69). Recent data suggests that a modified 
Dworak TRG system that takes into account nodal status, was a better predictor 
of survival compared to the other TRG systems (70). Additionally, TRG is also 
influenced by the length of delay to surgery; the Stockholm III trial analysed 
outcomes following SCPRT with or without delay to surgery and LCRT and showed 
that tumour regression could be augmented by allowing a 4-8 week delay to 
surgery in the SCPRT arm (71). 
There remains an absolute need to understand and stratify which patients will most 
benefit from neo-adjuvant chemoradiotherapy and ideally achieve clinical complete 
response (cCR) and more importantly pCR (72). Furthermore, improving cCR rates 
may lead to more patients being considered for non-operative management or the 
‘watch and wait’ approach as pioneered by the Habr-Gama group and others in the 
International watch and wait database (IWWD) consortium (73), where as many as 
70% of patients with cCR do not undergo surgery (74). Recent data from a large 
international registry has suggested that for those patients with cCR undergoing a 
‘watch and wait’ management strategy, 5-year disease specific survival was 
93.8 % (95 % CI 90.9-95.9) (75). Data from this registry shows that in centres with 
longer follow up (median 3.7-7.1 years), rates of local regrowth are around 40 %, 
while in centres with shorter follow up (median 2.3 years) regrowth rates are 
around 15 %; clearly suggesting that close follow up for several years is necessary 
to catch all episodes of local tumour regrowth.  
Therefore, the current use neo-adjuvant long-course chemoradiotherapy could be 
advocated in patients with high-risk locally advanced rectal cancer. LCRT is 
followed by surgery at 6-8 weeks to allow tumour regression/downstaging (as 
determined by a modified Ryan/AJCC TRG, Appendix 3). However, there are 
several questions that arise from this. Firstly, there are still many patients who have 
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a poor response or fail to respond at all to neo-adjuvant chemoradiation; therefore, 
it remains to be identified how best to both stratify use of radiation into those 
patients who would benefit most and improve the efficacy in patients who fail to 
respond. Secondly, predictive factors for response to therapy are not currently 
utilised and development of these is the key to future neo-adjuvant or adjuvant use; 
tumour biology, tumour microenvironment and the patient’s genetic and lifestyle 
factors may all have roles to play with this. Thirdly, it is unclear if modulation of the 
tumour biology may facilitate improved responses to LCCRT. These questions 
should be also researched with the understanding that pre-operative use of 
radiation does carry associated risks; patients have increased bowel dysfunction 
post operatively (76, 77) and higher rates of sexual dysfunction (76) following 
radiation. Surgically, whilst operative time and blood loss are increased, there is 
also some limited evidence in small case series that the incidence of anastomotic 
leakage increases (28), although a Cochrane review and recent meta-analysis has 
refuted this (60, 78). Therefore, the correct use of radiation, in those patients who 
will have the best chance of benefit, is the ultimate goal. Alternatively, in those 
patients with a lower chance of achieving a pCR or good TRG, efforts should be 
made to enhance the efficacy of this therapy. 
1.3 Colorectal tumorigenesis 
Colorectal cancer is classically described as a multistep tumorigenic process 
(Figure 1.5) (79). Malignant tumours arise over the course of at least 10-15 years 
from pre-existing benign adenomas (80). The risk of developing colorectal cancer 
is determined by both environmental and genetic risk factors (81). Tumours arise 
as a result of mutational inactivation of tumour suppressor genes coupled with the 
activation of oncogenes (82). These mutations can occur in up to 100 genes in a 
typical colorectal malignancy but tend to involve a select number of cell signalling 
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pathways, with at least 4 or 5 ‘driver’ mutations required for malignant 
transformation.   
1.3.1 Genetic drivers of colorectal cancer 
Throughout tumorigenesis cells will acquire mutations, which eventually lead to 
invasive carcinoma, but the order or sequence of acquisition of mutations is not 
fixed. Increasingly, understanding of all the mutations within CRCs has become 
more complex as high-throughput sequencing has been performed on greater 
numbers of tumours. Typically, sporadic CRC will develop mutations in the Wnt, 
RAS/RAF/MEK/ERK, TP53, PI3K and TGF- signalling pathways as the primary 
driver mutations of this disease. These mutations combined with a small number 
of alternative driver mutations and epigenetic changes are the biological basis of 
colorectal cancer. Focus of the introduction will be on the Wnt signalling pathway 
as a critical determinant of tumorigenesis, the RAS/RAF transduction pathway and 
the p53 tumour suppressor gene.  
Figure 1.5 The adenoma-carcinoma sequence 
The ‘adenoma-carcinoma sequence’ is a representation of the increasing burden of genetic 
and epigenetic changes that occur as normal colon progresses to becoming 
adenocarcinoma and metastasis. Critical early loss of APC or mutation of β-catenin is an 
initiating feature of colorectal cancer. Adenomas develop multiple further mutations, such 
as K-RAS or BRAF, and p53, which result in carcinoma, however these mutations do not 
need to be in a fixed order. Contiguous with these genetic changes are epigenetic changes 
such as DNA hypomethylation and CpG island hypermethylation which result in expression 





1.3.2 Wnt pathway mutations 
The canonical Wnt (Wingless) pathway is a critical pathway in colorectal 
tumorigenesis that regulates enterocyte stem cell homeostasis and embryological 
development in multiple tissue types but is also critical in cancer development (83). 
In colorectal cancer, almost all tumours harbour deficits in Wnt pathway genes, 
leading to constitutive activation of the pathway, principally through upregulation 
of -catenin, which mimics a Wnt-on state (84). Germline (rare) and somatic 
(common) mutations in APC lead to aberrant phosphorylation of -catenin reducing 
-catenin degradation and leading to its nuclear accumulation where it functions 
as a cofactor for TCF/LEF driven transcription. APC is a critical early mutation in 
CRC development, recent data has suggested that even in the presence of other 
Figure 1.6 Mutational burden in colorectal cancers and differences between non-
hypermutator (nHM) and hypermutator phenotypes (HM). 
The rates of acquired mutations in colorectal cancer split according to pathway involved and 
by nHM or HM. The majority of colorectal tumours harbour WNT pathway mutations (81% 
have APC mutations in nHM tumours), TP53 muations (59% of nHM tumours), KRAS 




mutated genes, restoration of functional APC within a tumour resulted in regression 
of tumour volume and a return to differentiated crypt architecture (85). Using 
mouse models, it has been further possible to validate that APC (and therefore the 
Wnt signalling pathway) is critical for the early development of CRC. APCMin/+ mice 
(heterozygous truncated APC mutation leading to multiple intestinal neoplasia - 
Min) has very high penetrance with all mice developing high numbers of intestinal 
polyps and succumbing early to colonic tumours (86).  
The Wnt signalling pathway is also critical for the development of the intestinal 
epithelium, driving the production and maintainence of the stem cell niche (87). 
Importantly, activated Wnt signalling also drives a cancer stem cell-like phenotype 
by promoting cell proliferation. 
1.3.3 RAS/RAF pathway mutations 
The RAS/RAF/MEK/ERK pathway is a signalling pathway, controlling proliferation, 
cellular differentiation and survival that transduces growth factor receptor signalling 
from cell surface to nucleus.  Mutations in pathway members, such as Kirsten rat 
sarcoma virus (KRAS) or BRAF (B-Rapid Accelerating Fibrosarcoma, typically 
V600E substitution resulting in hyperactive protein), occur commonly in CRC and 
lead to independence from growth factor signalling (88). BRAF mutation is mutually 
exclusive of KRAS mutations and are commonly found in tumours with MMR 
deficiency (89, 90). Given that downstream signalling in BRAF and KRAS mutant 
tumours is thought to be similar, it suggests tumours containing these mutations 
may have similar phenotypes. 
Colonic tumours are thought to have a 57% incidence of KRAS/BRAF mutation, 
while KRAS/BRAF mutations occur in 38% of rectal cancers (91), both of which 
leading to significantly worse patient prognosis (92). In wild-type KRAS tumours, 
cetuximab (a monoclonal antibody against EGFR (epidermal growth factor 
receptor also known as ERBB2) significantly improves patient survival (93, 94) and 
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is currently used as a first-line therapeutic agent for patients with metastatic CRC 
(NICE TA439, 2017). There is also some evidence to suggest that targeting EGFR 
in wild-type KRAS rectal tumours may improve response to radiation, although this 
is not used clinically (95). 
1.3.4 TP53 mutations 
It is suggested that p53 is an archetypical tumour suppressor gene and the 
‘guardian of the genome’, highlighting this function, once p53 is mutated, cells 
develop genomic instability promoting cancer (96). Additionally, p53 null mice 
develop normally but carry a high burden of cancer (97), particularly following -
irradiation (98).  
p53 binds DNA at specific sequences and regulates transcription of genes that 
promote cell cycle arrest and apoptosis (for example p21 and Puma respectively). 
It plays a critical role in the response to DNA damage and when mutated, enables 
damaged cells to continue through the cell cycle, propagating the defect in 
daughter cells leading to tumorigenesis (99).  
In colorectal tumours mutations in p53 or loss of 17p (carrying TP53) occur in just 
over half of all tumours and result in loss of the tumour repressor role of p53 (100). 
Mutations in p53 results in a significantly worse prognosis for patients (101), for 
example in rectal cancers it has been shown that p53 mutation results in poorer 
response to pre-radiation and a worse overall survival (102).  
1.3.5 Transforming growth factor signalling 
The transforming growth factor beta (TGF) family of cytokines are a key regulator 
of inflammation and immune homeostasis (103). In the intestinal epithelium TGF 
signalling has a complex role in tumorigenesis having effects as both a tumour 
suppressor and an oncogene (104). TGF cytokines activate signalling by causing 
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the assembly of receptor complexes at the cell surface that leads to the activation 
of the SMAD family of proteins (SMA and MAD-related protein) (105).  
In colorectal cancer, mutations occur in several members of the TGF signalling 
pathway including receptors and downstream proteins. Mutations in the TGFR2 
gene occur as a result of microsatellite instability (106), while mutations effecting 
the SMAD proteins, particularly SMAD4 occur late in colorectal carcinogenesis as 
a result of loss of heterozygosity on chromosome 18q. Additionally, in sporadic 
CRC SMAD4 is mutated as a result of entire chromosomal deletions, frameshift, 
nonsense or missense mutation leading to its inactivation and loss of function as 
a tumour suppressor (105).  Mutations in TGFR2 lead to more favourable 
outcomes following treatment with fluorouracil-based treatments (5-fluorouracil or 
capecitabine) in MSI deficient CRC tumours (107).  
1.3.6 PI3 Kinase signalling 
The phosphoinositide 3-kinases (PI3K) phosphorylate the inositol ring of lipid 
substrates known as phosphatidylinositols and are thought to be ubiquitously 
deranged in cancer (108). The PIK3CA gene has been shown to be mutated in 
several cancers, particularly CRC (109). PIK3CA mutations predict poor response 
to standard therapy in CRC (110), while the same mutations have been shown to 
induce sensitivity to the anti-inflammatory drug, aspirin (111). 
1.4 Epigenetic drivers of colorectal cancer 
In addition to the genetic alterations commonly observed in CRC, there are also 
significant epigenetic changes that contribute to tumorigenesis (112). In broad 
terms, these epigenetic changes do not involve alteration of the DNA sequence 
but modification of histone proteins, DNA methylation and levels of RNA 
interference, which results in changes to gene expression and therefore cancer 
cell phenotype (113). In colorectal cancer it has been known for many years that 
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there is hypomethylation of cytosine residues throughout the genome (114) leading 
to genomic instability, activation of oncogenes and loss of imprinting (LOI) (112). 
In combination with global hypomethylation it is recognised that some genes, in 
particular tumour suppressors, undergo epigenetic silencing through focal CpG 
island hypermethylation, such as TP53, APC and MLH1 (115). Promotor 
hypermethylation has been particularly associated with MSI tumour subtype in 
sporadic carcinoma (116). Those sporadic cancers with hypermethylation have 
been further classified into a CpG Island Methylator Phenotype (CIMP).  
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1.5 The NF-B signalling pathway 
1.5.1 An overview of NF-B signalling 
The NF-B proteins are key regulatory transcription factors in acute and chronic 
inflammation, the cellular stress response and immune response and were 
discovered in landmark work in 1986 (117). NF-B signalling is rapidly activated 
following cellular stress stimuli such as infection, pro-inflammatory stimuli (118, 
119), ionizing radiation (120) and chemical/physical stress . Importantly, NF-B 
also undergoes activation by cancer-related inflammation (121, 122) where it can 
be activated in cancer stem cells (123) or in BRCA1 deficient breast cancers which 
have constitutive NF-B activation (124).  
The NF-B proteins are a group of structurally-related subunits (RelA (p65), RelB, 
c-Rel, NF--B1 and NF-B2 (125, 126)). Structurally, all NF-B subunits contain 
an N-terminal Rel homology domain (RHD), which mediates DNA binding, 
dimerisation of subunits and inhibitory protein binding (119).  
NF-B signalling is highly regulated. In unstimulated cells, NF-B subunits are held 
predominantly within the cytoplasm due to binding of inhibitory proteins termed 
IBs (inhibitor of kappa B). These inhibitory proteins, IB, IB, IB, BCL-3, 
IBz, IBNS and the c-terminal portions of processed p100 and p105 (IB and 
IB respectively), function by binding to NF-B subunits through their ankyrin 
repeat domains. Specific pathway activation will be discussed below; broadly 
however, activation occurs when IBs are phosphorylated by IB kinase (IKK) 
complexes resulting in ubiquitination and degradation of IB. This releases the NF-
B subunit exposing the NLS (nuclear localisation sequence) and allowing the 
subunit to translocate and undergo dimerisation. 
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Dimerisation of NF-B subunits into homo or hetero-dimers follows activation 
through either the canonical, non-canonical or atypical pathways, although this is 
perhaps an oversimplification. It is recognised that up to 15 differing NF-B family 
complexes can be formed (127). Alternative dimer combinations may recognise 
individual B sites with variable affinity leading to alternative gene regulatory 
programs for different dimers. Additionally, the subunits p50 and p52 lack 
transactivation domains (TADs), unlike RelA, cRel and RelB, meaning that, once 
bound to DNA, they require additional cofactors or interaction with a NF-B subunit 
containing a TAD to activate transcription.  
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Specificity of NF-B signalling is derived through several mechanisms including 
receptor and ligand specificity, IB to NF-B subunit specificity (128), B target site 
Figure 1.7 Principal members of the NF-B signalling pathway 
NF-B signalling pathway members can be categorised as primary NF-B subunits 
(RelA/p65, RelB, c-Rel, p105/p50 and p100/p52), Inhibitor of kappa B (IB) proteins (IB, 
IB, IB, BCL-3 and the c-terminal portions of p100 and p105 (IB and IB 
respectively) or IB Kinase (IKK) proteins NEMO, IKK and IKK. The main structural 
components of each protein are shown with amino acid residue positions beneath each 
gene map. Important structural domains for NF-B subunits are the Rel Homology domain 
(RHD), Transactivation domain (TAD or TA1/2). In addition to these domains p100 and 
p105 subunits contain ankyrin repeat domains (ANK) like the IB family members. Another 
important IB domain is the PEST (proline P, glutamate E, serine S and threonine T) 
domains that IB and IB contain, which enables protein-protein interaction. Other 
domains contained in the NF-B protein family include leucine-zipper-like motifs (LZ), death 
domains (DD), coiled-coil (CC), NEMO-binding domain (NBD), helix-loop-helix (HLH) and 
zinc finger domains (ZF). Adapted from (4). 
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specificity, the epigenetic state of chromatin surrounding B sites (particularly the 
acetylation state of histones (129)) (130, 131) and subunit dimer exchange on DNA 
through the course of an inflammatory stimulus (132, 133).  
An important component of this complexity is the dimer-specific binding to B 
regulatory sequences on DNA (134, 135). There are thought to be a number of B 
consensus sites that have differing affinities for particular homo or hetero-dimers; 
B DNA binding sites for heterodimers have a higher similarity between dimers, 
whereas homodimer binding sites have a higher rate of specificity for each 
homodimer (135). Minimal structural differences in p50 and p52, for example, can 
lead to differences in binding affinity for p50 and p52 homodimers to DNA (136). 
Moreover, it is known that the B consensus sequence that a dimer binds to 
determines if there is activation or repression of transcription, for example p52 
homodimers bound to BCL-3 exhibit either activation or repression of target genes 
depending on the B sequence that the complex binds (137). 
These different components of NF-B signalling combine to give distinct pathways 




1.5.2 Canonical NF-B signalling 
Initiation of canonical NF-B signalling occurs through a variety of receptors, such 
as the TNF receptor super family, Toll receptors (see (138) for Toll-Like Receptor 
signalling review), interleukin (139) and T/B-cell antigen receptors (140) and their 
associated ligands (Figure 1.8). Canonical NF-B activation is quick and leads to 
nuclear translocation of RelA/p65:p50 heterodimers (119).  
Figure 1.8 The canonical NF-B pathway 
The canonical NF-B pathway is activated by diverse stimuli in diverse cell types with 
ligands binding at the cell surface to a number of different receptor families including T/B-
cell receptors (TCR/BCR), Toll-like receptors (TLRs), tumour necrosis factor (TNF) family 
receptors, RANK, CD30 and CD40 receptors. These receptors activate the IKK complex 
containing IKK, IKK and IKK/NEMO (NF-B essential modulator), which subsequently 
phosphorylates IB proteins leading to their ubiquitination and proteasomal degradation. 
Degradation of IBs releases p65:p50 as well as other canonical heterodimers such as c-
Rel:p50 enabling their translocation to the nucleus where they activate multiple genes 
leading to cell proliferation, cell survival, autophagy and a pro-inflammatory gene 
signature. Image adapted from (3) 
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The initial step in canonical pathway activation is post-translational modification 
and degradation of IB proteins following stimulus. The IKK complex (made up of 
IKK and IKK alongside a critical scaffold protein NF-B essential modulator 
(NEMO) (141)) phosphorylates IB on serine 32 and serine 36 (142) or IB on 
serine 19 and serine 23, leading to their poly-ubiquitination and degradation by the 
26s proteosome (143). Additionally, the IKK complex facilitates the release of p50 
from p105 through phosphorylation of p105 leading to its proteosomal 
degradation/processing. Release of the p65:p50 heterodimer, controlled by IB 
and IB, results in its nuclear translocation where it binds to canonical B motifs 
on DNA (4). Genes upregulated by the canonical pathway regulate cell survival, 
proliferation autophagy and inflammation (144).  
The canonical pathway is important in cancer development. For example in 
colorectal cancer, mice with an IKK deletion in intestinal epithelial cells formed 
75 % fewer colonic adenomas following AOM/DSS treatment (145). The 
underlying mechanism behind this was thought to be failed activation of the 
canonical NF-B pathway following stimulation, showing a critical role for early 
tumour development by canonical NF-B. 
1.5.3 Non-canonical NF-B signalling 
Non-canonical NF-B signalling is characterised by formation of p52:RelB 
heterodimers and is independent of IKK or NEMO (Figure 1.9) (119). The non-
canonical pathway, while also being a receptor-mediated pathway, is activated by 
a more limited subset of TNF superfamily receptors than the canonical pathway, 
such as CD40, lymphotoxin  (LT), BAFF receptor and RANK amongst others 
(146). Ligands for these receptors result in recruitment of members of the TRAF 
family into cell membrane complexes leading to activation of NF-B-inducing 
kinase (NIK) (147). NF-B2/p100 resides in the cytoplasm of cells in a large 
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complex (kappaBsome) (148). NIK phosphorylates dimerised IKK, which itself 
phosphorylates p100 (serines 176 and 180) enabling the proteolytic processing of 
p100 into p52 and a c-terminal domain that functions as an IB protein (IB) (149). 
Processed p52 complexes with RelB to form p52-RelB heterodimers (150) or can 
complex with itself to form p52 homodimers (see introduction 1.5.4 Atypical NF-B 
signalling). Importantly, RelB is stabilised by both processed p52 and its precursor 
p100 (151). However unlike p100, p52 is unable to retain RelB in the cytoplasm 
leading to the nuclear accumulation of RelB-p52 heterodimers following p100 
processing (152). RelB-p52 heterodimers are able to activate a gene specific 
transcriptional program (146) but have also been implicated in gene repression 
(153). Non-canonical NF-B signalling is critical for development, as mice with NF-
B2 gene knockouts exhibit early post-natal mortality, have defects in antibody-
mediated immunity and lymphoid architecture (154). Additionally, mice with a 
TRAF3 (TNF receptor-associated factor 3) deletion, which leads to constitutive 
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processing of p100 to form p52 (155), display early post-natal mortality, depletion 
of leukocyte numbers and hyposplenism (156). These models highlight the 
importance of p52 and the non-canonical signalling pathway in development and 
immune function. In cancer, elucidating the role of non-canonical signalling was 
initially challenging as IKK knockout (KO) mice were not viable following the 
perinatal period (150). Despite this limitation, the non-canonical pathway is 
implicated in cancer development, for example, in diffuse large B-cell lymphoma, 
dysregulation of NIK results in uncontrolled proliferation of tumour cells (157). 
Figure 1.9 The non-canonical NF-B signalling pathway 
The non-canonical NF-B signalling pathway is induced by a more specific group of ligands 
and their receptors including lymphotoxin  receptor (LTR), B-cell activating factor 
receptor (BAFF-R), RANK (not shown) and CD40 receptors. Ligand recognition results in 
receptors recruiting members of the TRAF family to the cell membrane leading to activation 
of NF-B inducing kinase (NIK). Activated NIK phosphorylates IKK, which subsequently 
phosphorylates p100, leading to the proteolytic processing of p100 into p52 which 
translocates to the nucleus as a heterodimer with RelB. Image adapted from (3). 
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Additionally, constitutively active p52 is known to transform murine fibroblasts to 
become tumorigenic (158). 
1.5.4 Atypical NF-B signalling 
The ‘atypical’ signalling pathway is not clearly defined in the literature. Some 
studies suggest that the atypical pathway consists of activation of canonical 
heterodimers in an IKK-independent mechanism directly through kinases such as 
ATM:Nemo (159), MEK1 (upregulated by p53 in response to cell stress) (160) or 
CK2 (casein kinase 2 in response to UV radiation) (161) (highlighting the 
multiplicity of canonical NF-B activation). Alternatively, other authors use the 
‘atypical pathway’ term to describe an NF-B pathway that is dependent on 
involvement of a co-factor, the atypical IB protein BCL-3 (Introduction 1.6 B-cell 
lymphoma 3 (BCL-3)). In this latter pathway, BCL-3 binds to processed p50 and 
p52 homodimers to activate or repress a subset of NF-B regulated genes. p50 
and p52 are thought to form strong homodimers with high affinity compared to 
other homodimer species (128). These homodimers bind to the majority of B sites 
at gene promoter regions and binding is known to occur at multiple sites within the 
same promoter (162)).In difference to other NF-B subunits, p50 and p52 lack 
TADs and subsequently require cofactors to induce activation of transcription 
(163). 
The p50 protein is constitutively produced as a result of ubiquitin-independent 20s 
proteosomal degradation of p105 (164). Conversely, p52 is not constitutively 
processed due to possessing a processing-inhibitory domain (PID) at its c-terminal 
region, which requires NIK phosphorylation to undergo processing in an inducible 
manner. p50 homodimers have a predominantly repressive role (but also activating 
(165, 166)), occupying B DNA sites when NF-B signalling is not activated (163, 
167, 168). BCL-3 has been shown to cooperate in transcriptional repression 
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induced by p50 homodimers (169). BCL-3 also associates tightly with p52 
homodimers resulting in transcriptional activation by these dimers (170). 
Additionally, it is likely that BCL-3 plays a role in a subset of genes conditional on 
B site and the presence of other co-regulatory proteins bound to the homodimers 
(137). 
In summary, the atypical NF-B pathway involves NF-B dimers and their 
activation, not under the umbrella of the canonical or non-canonical pathways. For 
the purposes of this thesis the atypical NF-B pathway will define p50 or p52 
homodimers and their associated co-regulatory protein, BCL-3. This pathway is a 
critical component of the broader NF-B response and plays a role in fine tuning 
of the canonical and non-canonical responses to an inflammatory stimulus. The 
role of BCL-3 in the atypical pathway will be discussed in detail below. 
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Atypical NF-B pathway dimers contribute in a context specific mechanism to 
cancer development or suppression in a variety of tumours such as nasophryngeal 
(171), prostate (172)and hepatocellular carcinoma (173). Genome-wide 
association studies (GWAS) have shown that polymorphisms in important 
members of this NF-B pathway contribute to the risk of developing colorectal 
cancer, further highlighting its critical role (174). 
  
Figure 1.10 Atypical NF-B homodimer signalling 
Homodimers of p50 and p52 are processed products of p105 and p100 respectively. The 
p50 protein is processed\ constitutively from p105 following its phosphorylation and partial 
degradation by the proteosome. p52 is processed in an inducible manner following 
phosphorylation of p100 by kinases such as NIK. Homodimers of p50 bind to B sites in 
DNA to repress or activate transcription with further dynamic regulation by BCL-3, which 
when bound, often leading to stabilisation of p50 homodimers on DNA and the activation 
of transcription. Homodimers of p52 bind to BCL-3 and activate or repress transcription 
based on the B site that the complex binds to and the association of the complex with 
additional co-regulators. It is not known if the mechanism for each homodimer is functional 
See text for references.  
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1.6 B-cell lymphoma 3 (BCL-3) 
BCL-3 is an atypical member of the IB family of proteins (175) and was initially 
shown to be overexpressed in B cell chronic lymphocytic leukaemia which contain 
the translocation,  t(14;19)(q32;q13.1) (176). BCL-3 is predominantly nuclear and 
functions as a co-regulator in multiple signalling pathways including AP1, STAT 
and NF-B. 
1.6.1 BCL-3 Structure 
The BCL-3 gene encodes a protein that contains 446 amino acids with a predicted 
molecular weight of 47 kDa. BCL-3 has seven ankyrin repeat domains (ARD) 
(Figure 1.3) as well as a proline-rich amino-terminal region and a proline and 
serine-rich carboxy-terminal region.  
Structurally the ARD of BCL-3 has homology with the ARDs of both NF-B1/p105 
and IB-α (177). However, in difference to the ARD of IB-, the BCL-3 ARD has 
an additional 2 residues in ANK1 leading to significantly different tertiary structures. 
Additionally, the BCL-3 protein has a seventh ARD, which replaces the PEST 
region (a 12 or more residue region rich in proline (P), glutamic acid (E),serine (S) 
and threonine (T) residues (178)) of IB- (179); PEST regions are regulatory 
regions controlling protein degradation and are commonly found in proteins with 
Figure 1.11 Map of BCL-3 DNA 
BCL-3 has a proline rich N-terminus which contains groups of basic amino acids that act 
as Nuclear Localisation Sequences. N-terminal domain contains lysine (K) residues K13 
and K26 that are sites of poly-ubiquitination (K48/K63 linked). BCL-3 has seven ankyrin 
repeat domains (ARD) which facilitate binding to NF-B homodimers. Both the N and C-
termini contain phosphorylation sites including the ones highlighted at serines 
394/398/419. Kinases known to be active on these sites are AKT, GSK3 and ERK1. 




short intracellular half-lives. Specifically, the PEST region of IB- is modulated by 
phosphorylation, which controls its rapid degradation by the 26S proteasome (180, 
181). Therefore, this structural difference of BCL-3 may lead BCL-3 to have a 
longer half-life than IB proteins due to lack of this sequence. 
BCL-3 has been reported to be predominantly nuclear because of two basic amino 
acid clusters near the N-terminus acting as weak nuclear localisation signals (NLS) 
(182). Additionally, the N-terminal proline-rich region of BCL-3 (amino acid 
residues 1-119) may also contain a binding site for proteins containing a SRC 
Homology 3 domain (SH3 domain) as it contains the amino acid motif X-P-p-X-P 
(X - aliphatic amino acid, P – proline). This domain is known to be an important 
mediator of protein-protein interactions and it may be that BCL-3 is able bind 
proteins such as STAT or PI3K through this motif (183, 184). The role of this 
domain has been corroborated by data analysing activated platelets where BCL-3 
binds to the SH3 domain of FYN (tyrosine kinase protein) (185). 
1.6.2 Translational control of BCL-3 
The BCL-3 gene is thought to be relatively unusual in that it contains two CpG 
islands (186). These CpG island sequences (rich in levels of C and G nucleotides) 
mark sites of transcriptional initiation. The 5’ CpG island was shown to be un-
methylated in BCL-3 in contrast to the 3’ island suggesting that the 5’ island is the 
primary promotor site of BCL-3 (186). BCL-3 is a target gene of several pro-
inflammatory transcription factors including canonical (187) and non-canonical NF-
B signalling (188), AP1 and STAT (signal transducer and activator of 
transcription). Induction of BCL-3 transcription, by these factors, occurs 
downstream of a number of cytokines such as TNF-α and interlukin-1α (IL-1α) 
(187), IL-2 (189), IL-4 (190), IL-6 (191), IL-9 (192), IL-10 (193) and IL-22 (194). 
Primarily, the upregulation of BCL-3 is mediated through the phosphorylation and 
activation of STAT3, which has been shown to bind to BCL-3 intronic enhancers 
 
 33 
(195). STAT3 is known to be a GSK3 target and inhibition of STAT3 
phosphorylation with a GSK3 inhibitor or in fact STAT3 inhibition itself, is shown to 
abrogate BCL-3 upregulation following STAT3 activation (196, 197). 
In addition to STAT signalling, NF-B signalling is thought to promote BCL-3 
expression. The BCL-3 gene promoter contains a number of NF-B consensus 
binding sites located -872 and -106 nucleotides upstream from the BCL-3 TSS. 
Transcription of BCL-3, by NF-B, can be driven by TNF, IL-1 and PMA (phorbol 
12-myristate 13-acetate/phorbol ester) (187). In mice, knockout of p50 diminished 
expression of BCL-3 (162). Moreover, there are NF-B consensus sites within 
intronic enhancer regions of the BCL-3 gene, suggesting that control of BCL-3 
transcription by NF-B not only relies on subunit binding to the BCL-3 promoter, 
but also to enhancers (198). Other work has identified that BCL-3 transcriptional 
control may require the atypical NF-B subunit p52, which represses BCL-3 
transcription, and that can be reversed by homodimer exchange on DNA by 
canonical NF-B heterodimers (p65-p50) (199).  
Unpicking the complexity surrounding BCL-3 transcription is challenging as it is 
clearly context and cell type dependent, but what is apparent is that BCL-3 is 
upregulated by a variety of cytokines, serving as a link between the STAT and NF-
B signalling pathways in response to cellular stress.  
1.6.3 Post-translational modification of BCL-3 
Post-translation modification (PTM) of proteins is a primary mechanism by which 
function, and abundance/degradation are controlled in the cell. BCL-3 is 
extensively phosphorylated predominantly at its C-terminal domain, in which there 
are 22 possible phosphorylation sites (serine, threonine and tyrosine). Binding of 
BCL-3 to p50 or p52 was thought to be prerequisite for its phosphorylation to take 
place (200, 201). However, more recent data has shown that phosphorylation of 
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BCL-3 is mediated by GSK-3 or ERK1 (202, 203), and occurs in both the cytoplasm 
and nucleus, leading to proteosomal degradation. 
Ubiquitination also plays an important role in BCL-3 sub-cellular localisation and 
degradation. The enzyme CYLD (homozygous loss of CYLD results in cylindroma) 
acts on BCL-3 in the cytoplasm to remove K63 (lysine 63) ubiquitin chains (204). 
This inhibits BCL-3 nuclear translocation and binding to NF-B homodimers. 
Degradation of BCL-3 also requires ubiquitination, although this appears to be via 
K48 ubiquitination as has been shown to occur predominantly in the nucleus via 
the PSMB1 subunit of the 20s proteasome (201). Ubiquitination also occurs on 
lysine residues 13 and 26 and is independent of phosphorylation by GSK3 when 
ubiquitination is performed by the E3 ligase, TBLR1 (201). 
In addition to these documented PTMs, it is likely that BCL-3 is a substrate for 
other unstudied kinases or is modified by not only phosphorylation or 
ubiquitination. For example, BCL-3 has 2 putative sites for ATM phosphorylation 
(Ser-Gln, SQ amino acid domain at positions 369 and 404) (205), linking its post-
translational modification to the DNA damage response. 
1.6.4 BCL-3 Function 
Functionally BCL-3 differs from the other IB proteins (IB-α, IB-β and IB-
epsilon) which bind to NF-B proteins in the cytoplasm inhibiting their nuclear 
translocation and subsequent transcriptional activity. Important to note are the 
contrasts in reported function of BCL-3, suggested to be a consequence of differing 
tissue models, cancer vs normal tissue, and differing experimental conditions.  
1.6.5 Control of NF-B sub-units 
First thought to inhibit nuclear translocation of p50 homodimers (206), binding of 
BCL-3 to p50 homodimers was later shown to unmask the NLS of p50 allowing 
translocation of the complex into the nucleus (182, 207). Furthermore, p50 protein 
 
 35 
with a mutated NLS was shown to be predominantly cytoplasmic even when bound 
to BCL-3 highlighting the importance of the p50 NLS following binding to BCL-3 
(207). Structural data suggests that BCL-3 may bind basic NLS residues less 
stably as the ankyrin repeats 1, 2 and 3 required for this interaction are less acidic, 
compared to IB- resulting in this alteration to BCL-3 function (179).  
1.6.6 Trans-activator or transrepressor 
Initial work, using in-vitro gel retardation assays, showed that bacterially derived 
BCL-3 inhibited p50 homodimer-DNA binding (177), but not p50-p65-DNA binding 
(208), in a manner dependent on the ARD of BCL-3 involving either repeats 1, 6 
or 7 (175); ARD binding was later corroborated by other groups (207, 209, 210). 
BCL-3 was later shown to directly bind with p50 homodimers to genes inducing 
repression (169). The ability of BCL-3 to act as a repressor is thought to be 
concentration dependant. While binding of p50 homodimers to B promotor sites 
competitively displaces transactivating p65:p50 heterodimers; when BCL-3 was 
co-transfected with p50, increasing concentrations of BCL-3 reversed the 
repressive nature of the p50 homodimers whilst still inhibiting p65:p50 heterodimer 
transactivation (162, 211). BCL-3 may mediate this function by selectively 
removing p50 homodimers from DNA allowing the binding of heterodimers and 
transactivation of the target gene (208). Controversially, the opposite effect was 
observed by another group examining the same cells and utilizing similar methods, 
suggesting perhaps multiple modes for BCL-3 transactivation depending on 
context (212). Additionally, data suggests BCL-3 is a transactivator when bound to 
p52 homodimers (212, 213). Critical to the role of BCL-3 as a transcriptional 
activator is the fact that BCL-3 has TADs (170), which given that both p50 and p52 




Therefore, in summary, it appears that BCL-3 has four primary mechanisms of 
gene interaction with p50/p52 homodimers; firstly through destabilisation of 
repressive p50/p52 homodimers bound to DNA (214, 215); secondly by forming a 
ternary activating/repressive complex on DNA (specificity of which is determined 
directly by the B sequence bound by the ternary complex (137) and by the binding 
of additional co-factors (216)) and thirdly by un-masking NLS domains on p50 that 
allows it to translocate and dissociate NF-B heterodimers from DNA. Fourthly, it 
is likely that BCL-3 alongside p50 or p52 homodimers, is part of the temporal NF-
B response to a stimulus, utilising the repressive nature of these complexes to 
control the expression of target genes following initial transcription by canonical 
NF-B proteins (217).  
1.6.7 BCL-3 protein interactions 
BCL-3 has been shown to form additional and alternative protein-protein 
interactions as well as the interaction with p50/p52. BCL-3 functions as a bridging 
factor between NF-B homodimers and other co-regulators, such as Tip60 (KAT5), 
Jab-1, Pirin and Bard-1 (216). This adds a further dimension to the regulation of 
transcription by BCL-3, with some co-regulators resulting in repression of target 
genes and others in transactivation. Further protein-protein interactions have been 
documented such as with Hsp70, HDAC1 and 3, CtBP1 and CtBP2 (218, 219).  
Acetylation is known to play an important role in other NF-B family subunits such 
as p65, where acetylation results in reduced binding of p65/p50 heterodimers to 
B sites on the DNA (220). It is unknown if the bridging role that BCL-3 plays, with 
proteins such as Tip60 and HDAC1/3, facilitates acetylation of p50 or p52 
homodimers, which would further define control of homodimer transactivation in 
the nucleus. Evidence exists to show that p50 can be acetylated and that this 
acetylation results in enhanced binding to B sites (221). 
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Thus BCL-3 has multiple functions ranging from activation of p50/p52 subunits in 
the cytoplasm, their nuclear import and modulation of homodimer transactivation 
through facilitating binding of different transcriptional co-regulators. It also is 
suggested that BCL-3 has contrasting functions depending on the pathological 
model used, in particular there is a significant reversal of function in inflammation 
models (222), which could be explained by investigation of co-factor binding and 
post translational modification of chromatin surrounding NF-B dimers (223).   
1.6.8 BCL-3 and the ‘Hallmarks of Cancer’ 
Cancer cells display certain hallmarks that are prerequisites for tumorigenesis and 
have been discussed in a series of landmark papers over the past 20 years and 
updated in 2011 (224). The multistep nature of colorectal carcinogenesis leads to 
tumours developing aberrations in these critical aspects of cell physiology that 
ultimately leads to cancer and its metastasis. BCL-3 has been implicated in a 
number of these ‘hallmarks of cancer’. 
1.6.8.1 Sustaining proliferative signalling 
Cancer cells can disregard the homeostatic cues that govern normal cells ability to 
grow and importantly stop growing. Cancers acquire the ability for self-sustaining 
proliferation through a number of different means, including dysregulation of 
cancer cell cell-cycle, increased growth factor production, stimulation of cells within 
the microenvironment resulting in increased pro-proliferative paracrine signalling 
and the deregulation of growth factor receptors leading to hypersensitivity to 
growth factors (224, 225). The effect of BCL-3 on tumour growth/proliferation has 
been observed in different tumour types. In colorectal cancer cells, BCL-3 induces 
the post-translational stabilisation of c-Myc, mediated by ERK1/2 increased tumour 
xenograft size (226); while BCL-3 over expression was shown to induce cell cycle 
progression, mediated by Cyclin-D1 in hepatocellular carcinoma (227, 228), 
malignant melanoma (229) and breast cancer (230). The converse was also true, 
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as suppression of Cyclin-D1 by p53 was shown to be dependent on BCL-3 
suppression (231). Furthermore, proliferation of skin cancer cells was shown to be 
abrogated when nuclear translocation of BCL-3 was blocked by its upstream 
regulator, CYLD (204). 
1.6.8.2 Activating invasion and metastasis 
Invasion into surrounding tissues is a defining feature of malignant cells followed 
by metastasis to distant organ sites, which is often the fatal event of solid 
malignancy (224). In breast cancer models, it has been demonstrated that BCL-3 
drives metastasis of tumour cells (232, 233). In HER2 positive breast tumour cells, 
BCL-3 KO resulted in an 80% reduction of metastatic burden in mice following tail-
vein injection of tumour cells (233). While in the MMTV-PyMT mouse model of 
mammary adenocarcinoma, BCL-3 suppression using Dox-inducible shRNA 
resulted in the reduction in lung metastasis, through targeting Smad3 stability in 
the TGF- signalling pathway (232). Additionally, a clinical study examined 
immunohistochemistry from paired normal and tumour tissue in hepatocellular 
carcinoma and showed BCL-3 expression results in advanced tumour node 
metastasis; this was shown to have contributed to the poorer prognosis observed 
in these patients (227).  
1.6.8.3 Evasion of Apoptosis 
BCL-3 has been shown to regulate cellular apoptosis through different 
mechanisms in different cell lines. Studies examining colorectal and cervical 
tumour cell lines has shown BCL-3 to be an important down-stream regulator of 
apoptosis by the AP1 complex, following UV-radiation (234). In HEK293 cells, 
BCL-3 stabilizes CtBP1 (an anti-apoptotic protein) leading to the repression of 
target pro-apoptotic genes, and was also shown to protect breast carcinoma cells 
from undergoing apoptosis after UV-radiation (235). 
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BCL-3 has been shown to prevent apoptosis by inhibiting proteins such as 
Smac/Diabolo and p53 activity (through upregulation of HDM2) (236-239). 
Although, even in p53-null backgrounds BCL-3 suppression was able to initiate 
apoptosis through targeting the expression of DNAPKcs, proteins critical for DNA 
damage repair (DDR) (236). 
Evidence from this and other groups showed BCL-3 to be a potent survival factor 
in colorectal cancer (2, 188), through activating the pro-survival AKT/PKB pathway 
(2). Given that BCL-3 is upregulated in a subset of colorectal malignancies (188, 
240, 241), it maybe that resistance to therapy is propagated through BCL-3 and its 
anti-apoptotic effects on tumour cells, thus making it an attractive target in cancer 
therapy. 
In hepatocellular carcinomas, BCL-3 is frequently overexpressed in tumour tissue, 
compared to normal tissue, in conjunction with p50 and p52 NF-B subunits (242). 
However, recently published data, using a hepatocyte specific BCL-3 over-
expression mouse model, showed that BCL-3 expression promoted hepatocyte 
death following an inflammatory insult and mice developed fewer hepatocellular 
carcinomas (243). This study also highlighted that BCL-3 overexpression reduced 
the influx of certain populations of immune cells into the liver (CD8+ t cells, B cells 
and leukocytes), protecting against induced inflammation. It may be that 
hepatocellular carcinomas are particularly sensitive to alterations in canonical NF-
B signalling and that repression of canonical NF-B occurs when BCL-3 is 
overexpressed in combination with atypical NF-B homodimers, leading to 
abrogation of apoptosis in this context. 
1.6.9 The role of BCL-3 in inflammation and immunity 
NF-B signalling is recognised to have contrasting function depending on the 
biological context (244), which appears to be consistent with the role of BCL-3 in 
cancer compared to its role in non-malignant, inflammatory models; the presence 
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of BCL-3 appears to ameliorate inflammation in these alternative non-malignant 
models. BCL-3 KO mice have defects in lymphoid organs, including displaying 
aberrant development of Peyer’s patches, which would affect intestinal immune 
surveillance and response to certain pathogens (245). 
BCL-3-/- has been studied in a variety of different inflammatory models, including 
pancreatitis, colitis, dermatitis and rheumatoid arthritis. In a mouse model of acute 
pancreatitis, where pancreatic inflammation is stimulated using cerulin or sodium 
taurocholate, results showed that BCL-3-/- mice had increased levels of oedema 
and necrosis in their pancreata (246). This finding, that BCL-3 KO increases the 
severity of inflammation, has been corroborated in an inflammatory bowel disease 
model (IBD; Crohn’s disease and ulcerative colitis) (222). In a contact 
hypersensitivity model of atopic dermatitis, BCL-3-/- mice had worsened 
inflammation following topical oxalazone treatment, which appeared to be 
mediated through increased cytokine production.(247). Earlier evidence, for this 
mechanism, comes from an important paper published in Science by Carmody et 
al. This paper examined the expression of pro-inflammatory cytokines in murine 
immune cells (macrophages and dendritic cells) devoid of BCL-3 (248). BCL-3 
acted to repress canonical NF-B transcription of target cytokines (such as TNF-
, CXCL1, CXCL2, IL-1 and IL-10) leading to significantly increased expression 
after inflammatory stimuli in the BCL-3 KO cells, corroborating earlier evidence 
(249). What was particularly interesting about this study was that not all cytokines 
responded in the same way to BCL-3 KO. In cytokines that showed an early spike 
in transcription following lipopolysaccharide (LPS), BCL-3 KO had a significant 
impact on their production; while cytokines such as IL-6 showed a slower increase 
in transcription that was unchanged in BCL-3-/- cells, compared to BCL-3 WT 
controls. This data suggests that BCL-3 KO affects different aspects (early and 
late) of the NF-κB driven response to inflammation. Interestingly, IKK KO in 
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intestinal epithelial cells worsens the histological severity of colonic inflammation 
and led to the animals loosing greater amounts of weight (145). If BCL-3 knockout 
leads to increased binding of canonical NF-B dimers (248), then it is unclear why 
the phenotype observed with BCL-3 knockout is similar to the phenotype observed 
when canonical NF-B has been inactivated by IKK deletion. 
In converse to the data above, another recent study showed that BCL-3 over-
expression, specifically in CD4+ T-cells (including T regulatory cells), results in a 
pancolitis of the large bowel of mice (250, 251). This cell-type specific effect was 
corroborated by work in CD4+ cells in a rheumatoid arthritis (RA) model, which 
showed over-expression of BCL-3 in these cells was implicated in the 
pathogenesis of RA (252). Interestingly, BCL-3-/- T cells failed to induce colitis 
when transferred into Rag1-/- mice (253), suggesting an inability of BCL-3-/- T cells 
to respond to the microbiota-derived and antigen-specific signals that drive colitis 
in this model. 
Following induction of inflammation there is a concomitant induction of BCL-3 in a 
variety of tissue types. This is likely to represent a feedback loop, in place to 
regulate pathways such as NF-B and modulate their function following a stimulus. 
Evidence for this comes from a number of sources; in respiratory syncytial virus 
(RSV) infection of airway epithelial cells, BCL-3 is initially upregulated leading to 
inhibition of NF-B and STAT transcription by acting as a bridging factor to HDAC1, 
which is transcriptionally repressive (219). Furthermore, BCL-3 represses STAT3 
regulating proteins (201); Repression of STAP2 by BCL-3 and p50 homodimers in 
conjunction with CtBP on the STAP2 promoter can diminish STAP2 dependent 
BRK kinase signalling that phosphorylates and activates STAT3 (254). BCL-3 is 
upregulated in tissue from patients with IBD (250). Although, further data from IBD 
patients has shown that in B cells isolated from diseased tissue, CpG sites in the 
BCL-3 gene are commonly methylated, and therefore repressed (255). 
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Despite these data showing the role of BCL-3 as both a pro-inflammatory and an 
anti-inflammatory mediator in non-cancer tissue, it does still appear that BCL-3 has 
similar control over regulation of apoptosis (discussed below in Results 3.1.1)  in 
non-malignant tissue compared to the role of BCL-3 in cancers.  
BCL-3-/- granulocytes, isolated following pulmonary transplant in mice, had higher 
levels of apoptosis, as measured by annexin V (256). This links to other data 
showing BCL-3 KO cells in mice colons had increased caspase-3 cleavage 
following dextran-sodium sulphate (DSS) induced colitis (222), suggesting these 
cells were undergoing more apoptosis.  
In summary, BCL-3 has alternative roles in inflammation depending on which cell 
type it is expressed in and whether all tissues have lost or gained expression. It is 
suggested, that KO of BCL-3 reduces the ability of cells to upregulate survival 
programmes following an inflammatory insult leading to concomitant rise in 
apoptosis; this results in a worse grade of histological inflammation and tissue 
damage propagating worse inflammation, suggesting it may be the pro-survival 
role of BCL-3, following stress/insult, which is critical to its function.
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1.7 Hypothesis and Aims 
BCL-3 is an atypical IκB protein that functions as a co-factor with atypical NF-κB 
homodimers, p52 and p50, to regulate atypical NF-κB driven transcriptional 
activation and repression depending on the cell type and context. There is clear 
evidence to show upregulation of BCL-3 in a subset of colorectal cancers, which 
correlates with poorer patient prognosis (240). Previous work, from this lab, shows 
BCL-3 promotes evasion of apoptosis in colon cancer cells but the role of BCL-3 
in promoting cell survival is not fully understood and to date nobody has 
investigated the function of BCL-3 in the difficult to treat rectal cancers (257).  
The management of LARC involves neo-adjuvant LCCRT to control the local 
spread of disease where the resection margins are compromised or threatened. It 
is essential to understand the response of LARC to neo-adjuvant LCCRT as poor 
response determines a significantly worse patient prognosis. Understanding the 
drivers of a poor response would enable patients to be stratified into those patients 
who should receive therapy, those patients who should receive therapy including 
additional adjunctive medication and those patients where response will always be 
poor, and therapy should be avoided by progressing straight to surgical resection. 
BCL-3 expression is upregulated in a IL-6/STAT3 dependent manner (195). The 
tumour stromal contains large numbers of activated fibroblasts known as cancer 
associated fibroblasts (CAFs) which secrete IL-6 as a principal cytokine. Fibrosis 
is a primary response following irradiation in rectal cancers but, as discussed 
earlier, response is often incomplete; leaving tumour cells surrounded by large 
amounts of activated fibroblasts.  
It is hypothesised that BCL-3 expression, upregulated by fibrosis in rectal cancers, 
promotes evasion of apoptosis and hence tumour survival. Additionally, it is 
hypothesised that BCL-3 expression would decrease the response to irradiation in 
rectal cancers, contributing to the poor prognosis reported in earlier studies. 
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1.7.1 Project aims 
Understand the role of BCL-3 in rectal cancers and analyse if BCL-3 protects cells 
from undergoing apoptosis in these cells. 
Identify the mechanism by which BCL-3 promotes evasion of apoptosis if observed 
in rectal cancer cells. 
Establish if BCL-3 plays a role in the response to irradiation in rectal cancer.  
Analyse rectal cancer tissue for BCL-3 expression and correlate to tumour 
response grade (TRG). 
Investigate the role of CAFs in promoting BCL-3 expression and growth or 
response to therapy of cancer cells in a 3D spheroid model system. 
Investigate, in-vitro, the role of BCL-3 in the DNA damage response and to 



















2.1 Tissue Culture 
2.1.1 Cultured Cells 
2.1.1.1 SW1463  
This cell line was obtained from the American Type Culture Collection (ATCC, VA, 
USA) and were checked for mycoplasma infection prior to use. SW1463 are 
derived from a 66 year old female patient with a Dukes’ C adenocarcinoma of the 
rectum (258). This cell line has homozygous mutations in KRAS (259), SMAD4 
(13), TP53, APC and SOX9 (260). SW1463 are MMR proficient.  
2.1.1.2 LS174T 
This cell line was established from a right sided Dukes’ B colonic tumour from a 58 
year old female patient (261). LS174T is MMR deficient cell line (hMSH6) (262) 
and concomitantly is wild-type for TP53 (263) and has a mutation in TGFβR2 (264). 
The cell line also has mutations in KRAS (259), PIK3CA (265), β-catenin (266) and 
E-cadherin (267) while being wild-type APC (260). Importantly, in the context of 
apoptosis, LS174T have mutant BAX, which results in the absence of the protein 
(264). 
2.1.1.3 HCA7/Parental 
The HCA7/Parental (herein known as HCA7/P) cell line was a kind gift from Susan 
Kirkland (Imperial College London, UK). HCA7/P were isolated from a Dukes’ B 
hepatic flexure adenocarcinoma of the colon in a 58 year old woman (268). 
HCA7/P is a MMR deficient cell line with a mutation in MSH3 and hypermethylation 
of MLH1 (269). This cell line has a heterozygous deletion at exon 8 codon 300 
leading to a frameshift mutation in p53 (270). Furthermore, HCA7/P has mutations 
in HER3 (ERBB3) and TGFβR2 (260). Interestingly, as well as being -catenin WT 
(266), HCA7/P have indeterminate APC status, previous studies thought APC was 




that result in a significantly truncated protein, which would likely result in loss of -
catenin regulatory activity (260, 266).  
2.1.1.4 SW837 
This rectal cancer cell line was isolated from a 53 year old male patient with a 
Dukes’ C adenocarcinoma of the rectum (258). This cell line has mutations in APC, 
KRAS and ATM (260), with a point mutation in exon 7 of TP53 (270). SW837 are 
MMR proficient. 
2.1.1.5 Fibroblast cell lines 
The fibroblast cell lines were isolated by members of the lab in the 1980s (Dr A 
Hague). They were obtained from patients with both FAP and sporadic tumours. 
FAP fibroblasts were JW and JD cells, while SC and CM were grown from sporadic 
adenocarcinomas. The SW cell line was obtained from normal tissue adjacent to 
a colorectal cancer.  
2.1.1.6 Adenoma/Carcinoma protein expression screen cell lines 
The following cell lines were only used in screens of protein expression amongst 
a selection of adenoma and carcinoma cells. The adenoma cell lines AA/C1, 
AN/C1, AA/C1/10C and RG/C2 cell lines were isolated and cultured originally by 
this group as described previously (272-274). The carcinoma lines HT29, HCT116, 
HCT15, SW480, SW620 and LOVO were all available from existing laboratory 
stocks, obtained from ATCC. 
2.1.2 2D Cell Culture 
All 2D carcinoma cell lines were cultured in Dulbecco’s Modified Eagles Medium 
((DMEM), Life Technologies, UK); 500 mL DMEM supplemented with 50 mL 
(10 %) Foetal Bovine Serum (FBS, Life Technologies, UK), 2mM glutamine (Life 
Technologies, UK) and penicillin/streptomycin solution (100 units/mL penicillin and 




DMEM was supplemented with 100 mL (20 %) FBS, penicillin/streptomycin 
solution (100 units/mL penicillin and 100 g/mL streptomycin), with the addition of 
insulin, 0.2 units/mL (Sigma–Aldrich, Dorset, UK) and hydrocortisone 1 g/mL 
(Sigma-Aldrich, Dorset, UK). 25 cm3 tissue culture flasks (T25 flasks, Corning, NY, 
USA) were used to maintain stock cells. Cells were maintained in incubators at 
37 ˚C in 5 % CO2 and medium was changed every 3-4 days. 
2.1.3 Cell passage 
Cells were passaged, and ratio split when cultures were sub-confluent. Firstly, 
medium was removed, and cells were washed with phosphate buffered saline 
(PBS). Next, cells were incubated with 2 mL Trypsin/EDTA (0.1 % w/v of trypsin 
(Dibco, Becton Dickinson, Oxford, UK) and 0.1 % w/v of ethylenediamine-
tetraacetic acid (EDTA) (Sigma–Aldrich, Dorset, UK) in PBS) at 37 ˚C until cell-cell 
and cell-flask contacts were disrupted. Trypsin/EDTA was neutralised by adding 
8 mL of 10 % DMEM to the flask and cell suspension was removed into a universal. 
Cell suspensions were centrifuged at 3000 rpm for 3 min. The supernatant was 
removed, and cells were suspended in further 10 % DMEM. Cells were syringed 
to provide single cells and were then diluted to ensure a ratio split of 1:6–1:20 
depending on cell line. Cells could also be counted at this point using a 
haemocytometer and used in downstream experiments.  
2.1.4 3D Cell Culture 
2.1.4.1 Human spheroid culture 
3D culturing of colorectal cancer cell lines from single cell suspensions embedded 
in Matrigel (BD Biosciences, California, USA) was adapted from methods 
published by Sato et al. 2009 (275). A single-cell suspension was produced from 
2D cell culture by trypsinisation (as described above 2.1.3), re-suspended in 5 mL 
PBS and syringed prior to being strained through a 40 μm nylon cell strainer 




haemocytometer and seeded into ice-cold Matrigel (200–500 cells/50 μL of 
Matrigel, around 2-5 L PBS/cell suspension in Matrigel). 50 L aliquots of 
Matrigel/cell suspension was then pipetted (using pre-chilled pipette tips (-20 ˚C) 
to ensure Matrigel does not polymerise inside pipette) into pre-warmed (37 ˚C), 24-
well tissue culture plates (24-well plate, Corning, NY, USA) (see Figure 6). 48-well 
plates (Corning, NY, USA) were also used with 20 L Matrigel/cell suspension per 
well. Polymerisation of Matrigel is achieved by incubating the plates at 37 ˚C for 
10-20 min until the gel has set. The gel is then bathed in 500 μL (24-well plate) or 
250 L (48-well plate) organoid medium per well. Medium for organoid culture has 
been adapted from Sato et al. 2009 (275) and consists of Advanced DMEM/F12 
((ADM/F12) Life Technologies, UK) supplemented with Bovine Serum Albumin 
0.1 % (BSA. Sigma–Aldrich, Dorset, UK), 2 mM glutamine, 100 units/mL penicillin, 
100 /mL streptomycin and 10 mM Hepes (Sigma–Aldrich, Dorset, UK). This 
medium was aliquoted into 48.5 mL units and stored at -20 ˚C. Prior to use the 
medium was defrosted and further supplemented with 1 mL of 1:50 B27 (Life 
Technologies, UK), 500 μL of 1:100 N2 (Life Technologies, UK) and 100 μL of 
1:500 N-acetyl cysteine (Sigma–Aldrich, Dorset, UK) (Appendix 1). Medium 
changes were performed one week following plating and thereafter every three-
four days. 
2.1.4.2 Mouse organoid culture 
Mouse small intestinal crypts were isolated from 6-week-old C57BL/6 BCL-3 null 
(BCL-3-/-) and control mice in triplicate by Dr. D Legge. Briefly, small intestines 
were excised from the mice after culling, washed with ice-cold PBS, the villi were 
scraped into a 50 mL falcon tube and incubated with 25 mM EDTA/PBS, for 
30 min. Crypts were collected and resuspended in Matrigel (50L with 75 L of 
crypt suspension) and polymerised as above (Methods 2.1.4.1). Crypts were 




0.5 μL/1000 μL ((stock 100 ng/μL) Peprotech, #AF-100-15), Noggin 
20 μL/1000 μL ((stock 5 μg/μL) Peprotech #250-38), mR-Spondin 5 μL/1000 μL 
((stock 100 μg/μL) R&D Systems #3474-RS). Medium was changed every three 
days. 
2.1.4.3 Passaging mouse organoid cultures 
Organoid cultures once they had reached a size where there was significant 
apoptotic debris within the lumen of each organoid (between 10-14 days after 
seeding). To passage Matrigel/crypt mixtures were mechanically broken up using 
cold PBS and a p1000 pipette. For each 100 μL Matrigel at least 2 mL PBS was 
used. PBS was supplemented with cold ADM/F12 1:4 ratio. This mixture was 
placed into a 15 mL falcon tube and centrifuged at 600 rpm for 3 min. After 
discarding the supernatant, the pellet was suspended in a further 4 mL of 
PBS/ADM/F12 and mechanically dissociated using a p200 pipette until organoids 
were hardly visible (around 5-10 cycles of pipetting up and down). The mixture was 
centrifuged at 600 rpm for 3 min and the supernatant discarded. A single further 
wash was performed and again the crypts spun down at 600 rpm for 3 min. The 
pellet was then suspended in the desired quantity of Matrigel on ice before being 
seeded into 24-well plates and supplemented with 500 μL of mouse organoid 
medium, as above. 
2.2 Genetic Transfection 
2.2.1 RNA Interference - siRNA 
Transient knockdown of target genes was performed using RNA interference 
(RNAi). RNAi will be achieved using small interfering RNA (siRNA) introduced into 
cells in suspension using Lipofectamine RNAiMAX (Life Technologies, UK). Sub-
confluent cells were medium changed onto 10 % DMEM free of penicillin and 
streptomycin antibiotics, to encourage exponential growth 12–24 hours prior to 




tissue culture flasks and transfected in suspension with human siRNA (as per 
manufacturer’s instructions). Sequences targeting BCL-3 siRNA (Sequence A: 
target sequence ‘AGACACGCCUCUCCAUAUU’; Sequence D: target sequence 
‘CCGUGCAGCUCUUGCUAGA’, Dharmacon, UK) or non-targeting siRNA (target 
sequence ‘UAAGGCUAUGAAGAGAUAC’, Dharmacon, UK), Bim siRNA 
(Sequence 2: target sequence Sense ‘UGACCGAGAAGGUAGACAA’, anti-sense 
‘UUGUCUACCUUCUCGGUCA’, Ambion, UK), NF-B1 siRNA (SMARTpool: 
target sequences #1 Sense ‘CCAAACAGUUCACCUAUUA’, Antisense 
‘UAAUAGGUGAACUGUUUGG’, #2 Sense ‘GGACGUGUCUGAUUCCAAA’, 
Antisense ‘UUUGGAAUCAGACA-CGUCC’, #3 Sense 
‘GGUGAUGGAUCUGAGUAUA’, Antisense ‘UAUACU-CAGAUCCAUCACC’, #4 
Sense ‘GUAGACACGUACCGACAGA’, Antisense 
‘UCUGUCGGUACGUGUCUAC’), NF-B2 siRNA (SMARTpool: target sequences 
#1 Sense ‘CCAAACAGUUCACCUAUUA’, Antisense ‘UAAUAGGUGAACUG-
UUUGG’; #2 Sense ‘GGACGUGUCUGAUUCCAAA’, Antisense ‘UUUGGAAUC-
AGACACGUCC’; #3 Sense ‘GGUGAUGGAUCUGAGUAUA’, Antisense 
‘UAUACUCAGAUCCGUCACC’; #4 Sense ‘GUAGACACGUACCGACAGA’, 
Antisense ‘UCUGUCGGUACGUGUCUAC’, Dharmacon, UK) were used 
compared to non-targeting control siRNA sequences. All sequences were 
prepared in nuclease-free water at 100 μM concentrations and stored at -20 C. 
For a 12.5 cm3 tissue culture flasks (T12.5 flask), initially, RNAiMAX 5 µL/flask is 
mixed with 250 µL/flask of Opti-MEM reduced serum medium (Life Technologies, 
UK) and concomitantly 1 L siRNA is mixed with 250 µL/flask Opti-MEM, for a final 
concentration of 50 nM siRNA/T12.5 flask. Mixtures were incubated at room 
temperature for 10 minutes. The RNAiMAX mixture is added dropwise to the siRNA 
while swirling gently, allowing the RNAiMAX and siRNA to form complexes at room 




1.5 mL of single-cell suspension of 1-2x106 cells in 10 % DMEM pen/strep free 
media in T12.5 flasks and allowed to incubate at 37 ˚C for 16 hr. After 16 hr, 
medium is aspirated and replaced with standard 10 % DMEM. Protein suppression 
is confirmed by western analysis at the time points of interest, taken from the 
introduction of siRNA to the cells. 
2.2.2 Stable overexpression of BCL-3 
The overexpression of BCL-3 was achieved by the transfection of a plasmid 
containing the human BCL-3 cDNA, under the control of a heterologous promoter. 
In order to over-express BCL-3, plasmids containing FLAG-tagged BCL-3WT and 
BCL-3ANK M123 (kind gift by Dr Alain Chariot (Liege, Belgium) (218)) or GFP-tagged 
BCL-3 (BCL-3GFP) (Origene, Rockville USA) were used. The mutant BCL-3 
construct (BCL-3ANK M123) contains three point mutations leucine>alanine at 
residues 168, 171 and isoleucine>alanine at residue 173, located between ankyrin 
repeats 1 and 2 leading to lack of binding of BCL-3 to p50 or p52 (201). SW837 
cells were used as they have low expression of BCL-3. SW837 initially underwent 
dose response to geneticin (G418 see methods 2.4.8) with doses ranging from 
100-500 μg/mL to ascertain the correct selection dose for these cells. A dose of 
400 μg/mL G418, with twice weekly medium changes, resulted in loss of any viable 
cells, and was selected. SW837 cells were transfected in T25 flasks as per 
manufacturer’s instructions. Initially, 250 μL of Opti-MEM with 10 μL Lipofectamine 
2000 (Life Technologies, UK) or 250 μL of Opti-MEM with 5 μg of pcDNA3.1 empty 
vector control plasmid or expression plasmid were incubated for 5 min, after which 




Following this, the complxes were added to cells and topped up with 2 mL of Opti-
MEM. Cells were incubated with transfection reagents overnight, after which 
medium was replaced with fresh DMEM 10 %. 72 hr later DMEM containing 
400 μg/mL G418 was introduced to the cells for selection. Two separate flasks of 
transfected cells per plasmid (flask A or B) were selected for 2 weeks before being 
passaged and analysed separately in downstream applications (western blot, 2D 
and 3D growth assays). Selected cells containing plasmids were maintained on 
200 μg/mL G418 long-term.  
 
2.3 Functional Assays 
2.3.1 Cell yield and survival assay 
To determine changes to cell yield and apoptosis after transfection colorectal 
adenoma/cancer cells were seeded in T12.5 or T25 flasks. Cells were incubated 
for 48 or 72 hr. At these time-points medium was collected for floating cell counting. 
 
 
Figure 2.1 BCL-3 plasmid maps 
A Map of pcDNA3.1 plasmid with inserted BCL-3 sequence (BCL-3WT, and BCL-3ANK M123). 
B Map of pCMV6-AC-GFP plasmid to produce BCL-3GFP. Plasmids contained genes for 






Medium containing the detached (floating cells) was removed and stored for 
counting; this apoptosis assay was validated in this laboratory as floating cells are 
known to be predominantly those that have undergone apoptosis in vitro (276).  
Remaining adherent cells were trypsinised (as above 2.1.3) and were counted to 
measure cell yield per flask. Cells were counted using a haemocytometer with at 
least four counts made per flask and an average taken of these. The proportion of 
apoptotic cells was determined by dividing the total number of floating cells 
counted by sum of number of floating cells and number of attached cells counted 
(276).  
2.3.2 Crystal violet cell viability assay 
A crystal violet cell viability assay was used to assess cell viability in 2D culture 
systems. Cells were grown in 6-well tissue culture plates (Corning, NY, USA) and 
transfected or treated with irradiation as described (Methods 2.2 & 2.4). At set time-
points (2 or 3 weeks) cells were washed twice with PBS (2 mL/well). Cells were 
then fixed with 2 mL/well of 4 % paraformaldehyde for 10 minutes. A further wash 
with 2 mL of PBS was carried out. A 0.5 % w/v solution of crystal violet (Sigma, 
UK) with distilled water was made and 2 mL/well placed on the cells for 10 minutes. 
Crystal violet solution was removed, and plates were washed in warm tap water to 
remove excess stain. Plates were allowed to dry briefly. 2 mL of 10 % v/v solution 
of acetic acid with distilled water was made and used to elute intracellular crystal 
violet from the cells with a 10 minute incubation on a rocker. A sample of 100 µL 
of the crystal violet/acetic acid solution was pipetted into each well of a 96-well 
plate (Corning, NY, USA) and read using a microplate reader (Bio-Rad, Hemel 
Hempsted, UK) at 595 nm absorbance. This assay was also a scaled down into a 





2.4.1 Pan-caspase inhibitor, QVD 
Drug treatment with quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl 
ketone (Q-VD-OPh or QVD, Calbiochem, USA), an irreversible broad-spectrum 
caspase inhibitor, was used to inhibit apoptosis. Cells were treated with 10uM QVD 
diluted in medium from 10 mM stock (DMSO) stored at -20 C. 24 hr after seeding 
cells were treated with QVD or DMSO and after a further 24 or 48 hours cells were 
processed for downstream applications.  
2.4.2 BCL-3 small molecule inhibitors 
BCL-3 inhibitors (BCL-3i) were a kind gift from Dr. Richard Clarkson (Cardiff 
University, Wales). Two inhibitors were obtained herein known as BCL-3iA and 
BCL-3iB. These drugs inhibit the interaction of BCL-3 with its NF-B subunit 
binding partners p50 and p52; the inhibitors do this by interacting with the ankyrin 
repeats of BCL-3, known to be critical for its interaction with either p50 or p52 (176). 
Established spheroid cultures were treated with medium containing BCL-3iA (stock 
concentration 100 mM in DMSO stored at -20 C and working concentration 
ranged from 0.01 to 100 M) or BCL-3iB (stock concentration 100 mM in DMSO 
and working concentration ranged from 0.01 to 100 M) every two days compared 
to vehicle control (DMSO) until the end of the experiment at two weeks from 
seeding spheroid cultures. 
2.4.3 Oxaliplatin 
Oxaliplatin (Sigma, UK) is a platinum-based compound (Figure 2.2) used as a first-
line agent in colorectal cancer (1). Platinum containing compounds cause a variety 
of Pt-DNA adducts that result in either inter-strand or intra-strand crosslinks 
resulting in inhibition of DNA replication, cell cycle arrest and apoptosis (277). 




particularly targeting the N7 position of guanosine (278). A stock solution of 10 mM 
oxaliplatin in DMSO was made up (stored at -4 C) and a range of concentration 
used experimentally (1-100 M in medium). Cells were treated with oxaliplatin or 
vehicle control for 72 hr prior to downstream applications. 
2.4.4 BCL2 Family inhibitor 
The BCL2 inhibitor ABT-737 (Selleckchem, USA) is an orally bioavailable BH3 
mimetic inhibitor of BCL2, BCLxl and BCLw but importantly not of MCL-1. BCL2 
and related multi-domain pro-survival proteins are anti apoptotic through their 
interaction with the multi-BH3 domain pro-apoptotic and BH3-only proteins. 
Inhibition of this interaction results in increased apoptosis. Stock solution of 20 mM 
ABT-737 in DMSO was made and stored at -20 C. Cells were treated (dose range 
0.001-50 M) at 72 hr after seeding for a period of 24 hr before returning cells to 
10 % DMEM or the cells were harvested for downstream applications.  
2.4.5 Poly ADP Ribose Polymerase inhibitor 
Veliparib (ABT-888, Selleckchem, USA) inhibits PARP1 and PARP2 function in the 
DNA damage response and leads to synthetic lethality in cells with homologous 
 Figure 2.2 Platinum-based chemotherapy compounds 
Oxaliplatin is a platinum containing compound that forms platinum (Pt) to DNA crosslinks, 





recombination DDR pathway deficiencies (such as BRCA1 mutations in breast 
cancer). Veliparib was dissolved at 10 mM in DMSO and stored at 10 mM at -
20 ˚C. Cells were treated with a range of doses (0.01-100 M) for 72 hr prior to use 
in downstream applications. 
2.4.6 Transforming Growth Factor-Beta 
Transforming Growth Factor-beta (TGF, R&D Systems, USA) was used to 
promote fibroblast activation and differentiation into a cancer associated fibroblast 
phenotype. TGF was dissolved in sterile water with 4 mM HCl and 1 % w/v BSA. 
TGF was stored at -20 C at 2 g/mL. Cells were treated with TGF at 10 ng/mL 
for 72 hr prior to being used in downstream applications 
2.4.7 Interleukin 6 
Interleukin 6 (IL-6, Life Technologies, UK) is a small 20 kDa cytokine produced 
early in a transient manner in response to infection and inflammation (279). IL-6 
was purchased from Sigma and dissolved in water. IL-6 was used at 25 ng/mL in 
all experiments. 
2.4.8 Geneticin 
Geneticin (G418, Sigma UK) is a aminoglycoside antibiotic that was origionally 
isolated as a product of Micromonospora rhodorangea (280). Cells containing the 
neo-gene from Tn5 encoding an aminoglycoside 3’-phosphotransferase are 
resistant to G418. Therefore, G418 is used for selection of cells that have been 
transfected with a plasmid containing this resistance gene. Typical doses are 
around 400 μg/mL for selection. 
2.4.9 Irradiation 
Cells were seeded and grown for 48 hours prior to irradiation. The radiation source 
is a Caesium-137 (Cs-137) irradiator. Prior to irradiation, cells were treated with 




alongside control cells to ensure identical environments throughout treatment. 
Cells were exposed to irradiation doses of 1, 2.5, 5, and 10 Gy (Table 2.1). 24 
hours following irradiation the medium was aspirated and refreshed with fresh 10% 
DMEM. Cells were incubated for two-three weeks and medium was changed twice 
a week. Cell viability was assessed using a crystal violet cell viability assay as 
above (2.3.2).  
Distance from 
Source 
1 Gy 2.5 Gy 5 Gy 10 Gy 
25cm 51 128 255 510 
40cm 130 325 650 1300 
60cm 292 731 1462 2924 
Table 2.1 -Irradiation dose 
Distance from Caesium-137 source and time required for dose of irradiation. Time in 




2.5 Molecular Biology 
2.5.1 RNA analysis 
2.5.1.1 RNA extraction 
Cells were placed on ice and washed twice with 2 mL ice-cold PBS. 1 mL of ice-
cold TRI Reagent® (Sigma–Aldrich, Dorset, UK), which contains guanidine 
thiocyanate and phenol, was placed onto the cells and incubated for a couple of 
minutes to allow dissolution of the cells, following which cells were scraped and 
put in Eppendorf tubes. Following this, a liquid phase separation step was 
performed using 200 L chloroform (BDH, UK), after vigorous shaking for 15 sec 
it was incubated for 10 minutes and then centrifuged at 11500 g for 10 min at 4 ˚C 
to split the liquid into three phases. RNA is then precipitated using 500 μL 
isopropanol shaken and left for 15 min, followed by pelleting at 11500 g for 10 min 
at 4 ˚C. The pellet is washed in 70 % v/v ethanol in ddH2O followed by 
centrifugation at 8500 g for 5 min at 4 ˚C. The RNA pellet is then suspended in 
100 μL ddH2O. 
RNA clean-up was performed as per manufacturers’ instructions using RNeasy 
Mini Kit (Qiagen, Germany) spin columns, including on-column treatment with 
DNase I for 15 min. Cleaned RNA was eluted from the spin-columns and RNA 
concentration and quality was measured using a NanoDrop (Thermo Scientific, 
Germany) spectrophotometer at 260-280 nm UV. RNA was considered free of 
contaminants and pure if 260:280 ration was >1.8. RNA was stored at -80 ˚C. 
2.5.1.2 Reverse Transcriptase Reaction 
Complementary DNA (cDNA) was synthesised by reverse transcriptase using the 
RNA dependent DNA polymerase moloney murine leukaemia virus (MMLV), to 
generate a single stranded DNA product from the mRNA template. RNA (2 μg) was 




was cooled quickly by placing directly onto ice to stop secondary structure 
reformation. To the RNA, MMLV buffer (5 μL), RNasin (RNase inhibitor, 25 units) 
and dNTPs (Deoxunucleotide mixture, 5 μL) was added to the reaction mixture. 
MMLV Reverse Transcriptase or ddH2O control were added to form duplicate 
tubes, to examine for evidence of contaminating DNA. These mixtures were then 
heated to 40 ˚C for 1 hr, before dilution with 175 L DNAase-free water and 
storage at -20 ˚C.  
2.5.1.3 qRT-PCR 
The quantitative real-time polymerase chain reaction (qRT-PCR) reaction was 
used to measure the relative abundance of the gene of interest compared to a 
housekeeping gene, such as the gene, TATA-binding protein (TBP). Reaction 
mixtures per sample were made in triplicate for each of the Reverse Transcriptase 
or singularly for ddH2O controls, which contained 6.25 μL SYBR Green (DNA 
reporter molecule. Qiagen, Germany), 1.25 μL primer set, 3 μL ddH2O and 2 μL 
cDNA. Fluorescence data was collected in real time and analysed using MxPro 
software to determine relative abundances of each primer in comparison to the 
housekeeping gene. Primers used were to BCL-3 (Cat number QT00008050), Bim 
(Cat number QT01013831) and TBP (Cat number QT00000721) (Quantitect 




2.5.2 Protein analysis 
2.5.2.1 Whole Cell Lysis 
Cells were transferred from the incubator to ice, where the medium was removed. 
Cells were washed twice with ice-cold PBS and aspirated, ensuring all liquid was 
full removed. 100 μL/flask ice-cold cell lysis buffer (Cell Signalling Technology, MA, 
USA) containing PIC (cOmpleteTM, Mini Protease Inhibitor Cocktail tablets, Roche 
Switzerland) (Table 2.2) was added to cells and cells placed on ice, on a rocker for 
10 min. Cells were scraped from the flask and transferred to a pre-chilled 
Eppendorf tube on ice. Samples were vortexed for 5 seconds and then transferred 
to a chilled centrifuge. Samples were centrifuged at 18500 g, 4 ˚C for 10 min. The 
supernatant was then transfer to a second, clean, chilled Eppendorf and stored at 
-80 ˚C until protein assay. 
Cell Lysis Buffer 
Tris-HCL (pH7.5) 20 nM 
NaCl 150 mM 
Na2EDTA 1 mM 
EGTA 1 mM 
Triton 1 % w/v 
Sodium pyrophosphate 2.5 mM 
Beta-glycerophosphate 1 mM 
Na3VO4 1 mM 
leupeptin 1 μg/mL 
Table 2.2 Cell Lysis Buffer 
10 mL of lysis buffer is made by adding 1 mL of 10xlysis buffer to 9 mL PBS and adding 
1xPIC tablet. Aliquoted into 1 mL and stored at -20 C. 
 
2.5.2.2 Whole Flask Lysis 
To determine differences in the expression of proteins known to be markers of 




prepared containing both the adherent and the floating cell population. The 
medium collected containing floating cells was collected; adherent cells were 
washed twice with ice-cold PBS, which was collected and collated with the original 
media. Media and PBS washes were then centrifuged at 3000 g for 3 minutes to 
pellet the floating cells. 100 l/flask of ice-cold cell lysis buffer (Table 5.1) was 
added to each flask. The cell pellet of floating cells and cellular debris was lysed 
with a 50 l portion of the lysis buffer already added to flasks. This was then 
removed and added back to the respective flask to create the WFL. Adherent cells 
were then scraped and the preparation of the cell lysate processed as above 
(Section 2.5.2.1). 
2.5.2.3 3D Spheroid Culture Whole Cell lysis 
To collect protein from 3D spheroid cultures a method was used (optimised from 
(281)) in order to remove traces of Matrigel which was found to contaminate protein 
concentration assays. Medium was aspirated and spheroids growing in Matrigel 
were dislodged and broken up using 4 mL/100 μL Matrigel of ice-cold 4 C PBS 
with 5 mM EDTA and a PIC tablet (1 tablet/20 mL) and transferred into 15 mL 
Falcon tubes (Thermo Fisher Scientific, MA, USA). The conical tubes were then 
rotated for 30 minutes at 4 C. Following this, the spheroid/PBS solution was 
centrifuged gently for 5 minutes at 1000 rpm. The supernatant was removed 
leaving a loose, spheroid pellet, which was suspended in a further 4 mL of cold 
PBS/EDTA 1 % and centrifuged as above. The PBS/EDTA was aspirated carefully 
by tilting the Falcon tube to ensure complete removal of PBS/EDTA while not 
disturbing the spheroid pellet. 50 L of cell lysis buffer was added to the pellet and 
incubated on ice for 10 minutes with vortexing 3 times. The cell lysis was 
transferred to new Eppendorf tubes and centrifuged at 15000 g, 4 ˚C for 10 
minutes. The supernatant was transfer to a clean, chilled Eppendorf tube and 




2.5.2.4 Protein Concentration Assay 
Protein concentration of cell lysates was determined using a Bio-Rad DC protein 
assay kit (Bio-Rad, Hemel Hempsted, UK), according to manufacturer’s 
instructions and is based upon the Lowry protein assay. Protein concentration were 
compared to a series of BSA standards and concentration was assessed using a 
microplate reader (Bio-Rad, Hemel Hempsted, UK) at 720 nm absorbance. 
Following elucidation of protein concentrations, concentrated samples of 100 g 
protein/25 L were made for western blotting by adding 25 μL of 5X Laemmli buffer 
(Table 2.3) to a 100 μL volume of distilled water/cell lysate mix (depending on 
protein concentration) and boiling for 5 minutes using a heat block, 100 ˚C. 
Samples were stored at -20 C.  
2.5.2.5 SDS-PAGE and Western Analysis 
This method of gel electrophoresis was originally described by Laemmli in 1970 
(282). Samples were run on either 9 % or 12.5 % acrylamide gels to ensure correct 
resolution of target proteins for subsequent analysis. Gels were cast (Appendix 5 
for gel constituents) and polymerisation of acrylamide catalysed chemically by the 
addition of tetramethylethylenediamine (TEMED) and ammonium persulphate 
(APS). Samples were run through the gel for 1 hour at 180 V. Proteins were then 
transferred to a membrane to enable further analysis (283). Transfer took place 
onto Immobilon-P polyvinylidene fluoride (PVDF) membrane (EMD Millipore, USA) 
using 100 V for 1 hour 30 minutes, while ‘transfer sandwich’ was immersed in 
transfer buffer (see Table 2.3 for buffers).  
Buffer Constituents 
Running 192 mM Glycine 
25 mM Tris 




Transfer 192 mM Glycine 
25 mM Tris 
20 %/v Methanol 
Blocking 10 mM Tris-HCl (pH 8) 
150 mM NaCl 
5 % low fat milk powder 
Washing (TBS-T) 10 mM Tris-HCl (pH 8) 
150 mM NaCl 
0.2 % Tween-20 
Laemmli 5x 312.5 mM Tris-HCl (ph6.8) 
50 % (v/v) Glycerol 
5 % (v/v) 2-mercaptoethanol 
10 % (w/v) SDS 
0.01 % Bromophenol blue 
Table 2.3 Buffers for Western Blot 
 
Membranes were then blocked for 1 hour in 5 % milk/TBS-T to eliminate non-
specific antibody binding. Primary antibodies (Table 2.4) were diluted in 0.05 % 
milk buffer (Table 2.3) before being added to membranes and incubated at 4 ˚C 
overnight on a rotator. Membranes were washed (3x10 minutes in TBS-T). 
Secondary antibody (specific for the species primary antibody was raised in) was 
diluted in 0.05 % milk buffer added and further incubation at room temperature 
occurred for 1 hour on a rotator. Membranes were washed again (3x10 minutes in 
TBS-T). Protein expression was determined by horseradish peroxidase (HRP) 
chemi-luminescence using a Luminol system (KPL, MD, USA) according to the 
manufacturer’s protocol. X-ray films (Kodak Diagnostic Film X-Omat, Kodak, UK) 
were used to detect chemi-luminescence with exposure times of 2 seconds to 45 
minutes depending on protein. Processing was completed using a Compact X4 
Film Processor (X-ograph Imaging Systems Ltd, UK).  
Primary 
antibody 




















1:1000 Mouse 05-361 EMD Millipore, 
Herts, UK 
RelA (p65) 1:10000 Rabbit  D14E12XP Cell Signalling 
Technology, 
MA, USA 
BCL2 1:1000 Rabbit  sc-492 Santa Cruz 
Biotechnology, 
CA, USA 
BCL-XL 1:1000 Mouse sc-509 Santa Cruz 
Biotechnology, 
CA, USA 
BCL-W 1:1000 Rabbit n/a Gift Ben Edde, 
UoB 
MCL-1 1:2000 Rabbit sc-819 Santa Cruz 
Biotechnology, 
CA, USA 
BAK 1:500 Mouse 556382 BD 
Transduction 
Laboratories 
BAX 1:1000 Rabbit sc-493 Santa Cruz 
Biotechnology, 
CA, USA 
Bim 1:1000 Rabbit 17003 Chemicon (now 
EMD Millipore, 
Herts, UK) 
Puma 1:1000 Rabbit 4976 Cell Signalling 
Technology, 
MA, USA 
BAD 1:1000 Rabbit 9292s Cell Signalling 
Technology, 
MA, USA 
Total AKT 1:1000 Rabbit 9272 Cell Signalling 
Technology, 
MA, USA 



















1:1000 Rabbit 19245 Cell Signalling 
Technology, 
MA, USA 




1:2000 Rabbit 2125s Cell Signalling 
Technology, 
MA, USA 
Table 2.4 Antibodies for Western Blot 
2.5.3 Immunofluorescent protein analysis 
2.5.3.1 Transfection and irradiation of cells on coverslips 
Cells were transfected in suspension (detailed above in section 2.2.1) with 50 nM 
BCL-3 siRNA or control siRNA and seeded onto 18 mm2 glass coverslips 
(coverslips were coated with poly-L-lysine, see below, (section 2.5.3.2)) placed into 
6-well plates (Corning, NY, USA). Cells were incubated for 72 hours from onset of 
transfection, at this point medium was spiked with 80 μL 1 M Hepes and cells were 
transferred to the irradiator and 2.5 Gy -irradiation delivered. Fixation of cells was 
started at exact 30 min, 6 hr, 12 hr or 24 hr post the end of the irradiation dose. 
2.5.3.2 Coating of coverslips 
Poly-L-lysine (Sigma-Aldrich, Dorset, UK) was used to coat glass coverslips prior 
to seeding cells; to promote cell adhesion to the glass for SW1463 cells. Coverslips 
were immersed in 0.001 % Poly-L-Lysine solution for 1 hr after which they were 
washed twice in sterile filtered water and then dried ready for use. 
2.5.3.3 Fixation and slide preparation 
Medium was aspirated, and coverslips washed twice with ice-cold PBS. Cells were 




X-100 (Sigma-Aldrich, Dorset, UK) for 15 min. Paraformaldehyde/Triton X-100 was 
removed within a fume-hood and coverslips were washed three times with PBS for 
5 min/wash. Any residual formadehyde was quenched using 0.1375 M glycine for 
5 min at room temperature, followed by a further PBS wash for 5 min. A solution 
of 1 % w/v bovine serum albumin (BSA) in PBS was used to block the coverslips 
for 15 min. Coverslips were then removed from wells and inverted cell-side down 
onto a 70 L drop of primary antibody (Table 2.5), including separately an isotype 
control, diluted in 1 % BSA in PBS, which were placed on a length of Parafilm 
(Sigma-Aldrich, Dorset, UK). Coverslips were incubated with primary antibody for 
1 hr at room temperature, following this, coverslips were placed back into wells 
and three washes of 5 min with PBS completed. The coverslips were removed from 
the wells and inverted onto a 70 L drop of secondary antibody (Table 2.5). 
Incubation with secondary antibody was for 1 hr at room temperature with 
coverslips by foil to limit bleaching by light. After incubation, coverslips were placed 
once again within the wells and a further three 5 min washes with PBS performed. 
On the second wash, DAPI (4’,6-diamidino-2-phenylindole, Sigma-Aldrich, Dorset, 
UK) at 1:10000 was added to the wash and incubated with the coverslips for the 
duration of the wash. Coverslips remained covered from light throughout wash 
periods. To mount coverslips, 15 L of Mowiol (Sigma-Aldrich, Dorset, UK) with 
2.5 % 1,4diazabicyclo-[2,2,2]-octane (DABCO, Sigma-Aldrich, Dorset, UK) was 
placed onto a glass slide and coverslips inverted onto this. Mowiol was left to 
harden overnight in the dark before imaging. 
Primary 
antibody 
Dilution Species Catalogue 
Number 
Manufacturer  
BCL-3 1:200 Rabbit sc-185 Santa Cruz, 
Biotechnology, 
CA, USA 






H2AX 1:500 Mouse 05-636 EMD Millipore, 
Herts, UK 
Isotype 































Table 2.5 Immunofluorescence antibodies 
2.5.3.4 Confocal imaging of slides 
A Leica confocal microscope (Leica DMI 6000, Inverted confocal microscope, 
Wolfson Imaging Suite, University of Bristol) was used to obtain images at 40x and 
63x magnification. Care was taken to ensure that observed fluorescence was a 
true reading and not background signal. IgG isotype control primary antibodies 
were used that lacked specificity to the target but matched the class, species and 
concentration of the target. Furthermore, BCL-3 suppression using siRNA was 
used to determine the correct signal for BCL-3, following optimisation of the lazar 
intensity with IgG control fluorescence. By ensuring that there was no significant 
fluorescence within the IgG controls, calibration of the laser intensity for the BCL-
3 signal was possible. H2AX foci were counted manually and an average number 
of foci/nucleus for each condition was obtained. 
2.5.4 Chromatin Immunoprecipitation (ChIP) 
2.5.4.1 Chromatin crosslinking, fixation, lysis and sonication 
Cells were medium changed 24 hr prior to being fixed when between 60-80 % 
confluent. If transfected, cells were fixed at 72 hr post initiation of transfection. To 




PBS. Cells were then incubated at room temperature for 10 min with fresh 1 % 
formaldehyde (CH2O) (PierceTM 16 % formaldehyde (w/v), 1 mL in 15 mL PBS. 
Thermo Fisher Scientific, MA, USA). CH2O was removed into a waste jar and the 
unreacted CH2O was quenched with glycine to stop further cross-linking. 
Quenching was performed with 5 mL of 0.1375 M glycine per flask and cells 
incubated at room temperature for 5 min. Flasks were then placed on ice and the 
cells washed twice with 5 mL/flask of ice-cold PBS. All residual PBS was removed 
and 500 μL of cold cytoplasmic lysis buffer (Table 2.6) was added to each flask. 
Cells were scrapped and recovered into a 1.5 mL Eppendorf tube and incubated 
on ice for 10 min with brief vortexing twice. Lysates were centrifuged at 700 g for 
5 min at 4 C and the supernatant (cytoplasmic fraction) aspirated and discarded 
into a waste pot. The pellet was suspended in a further 500 μL of cold cytoplasmic 
lysis buffer and then centrifuged again at 700 g for 5 min at 4 C. Following 
aspiration and discarding of the supernatant (residual cytoplasmic fraction) without 
disturbing the nuclear fraction pellet, the pellet was suspended in 500 μL of room 
temperature nuclear lysis buffer (Table 2.6) and incubated on ice for 10 min. 
Lysates were transferred to a sonicator (Diagenode Bioruptor, Belgium) and 
sonicated for 30 sec for between 15-20 cycles in iced-water. Sheared chromatin 
was checked to ensure sonication had resulted in a smear around a DNA 500bp 
marker (Promega, USA) as visualised on a 1.5 % agarose gel.  
2 μL per condition of sheared chromatin was added to 45 μL CSTLB (Table 2.6) 
and incubated with 1 μL RNase A (10 mg/mL) (EMD Millipore, Herts, UK) at 37 C 
for 30 min. Following this 1 μL Proteinase K (10 mg/mL) (Sigma-Aldrich, Dorset, 
UK) was added and a further incubation for 2 hr at 62 C completed. 5x Orange G 
(Sigma-Aldrich, Dorset, UK) was added to samples at a 1:5 ratio and the sonicated 




unsonicated samples on a 1.5 % agarose gel. After confirmation of chromatin 
shearing efficiency samples could be stored at -80 C. 
ChIP Buffers Constituents 
Cytoplasmic Lysis Buffer 10 % Glycerol 
10 mM Tris-HCl pH8 
1.5 mM MgCl2 
0.5 % NP-40 
1xProtease Inhibitor Cocktail 
Tablet/10 mL 
Nuclear Lysis Buffer 1 % SDS 
50 mM Tris- HCl pH8 
10 mM EDTA 
1xProtease Inhibitor Cocktail 
Tablet/10 mL 
CST Lysis Buffer (CSTLB) 
used as Dilution Buffer 
1xCell Signalling Technology lysis 
buffer (see above) 
20mM  Tris-HCl pH7.5 
150 mM NaCl 
1 mM Na2EDTA 
1 mM EGTA 
1 %Triton 
1xProtease Inhibitor Cocktail 
Tablet/10 mL 
Elution Buffer 1 % SDS 
50 mM Tris- HCl pH8 
10 mM EDTA 
Wash Buffer 1 0.1 % SDS 
0.1 % deoxycholate 
1 % Triton X-100 
0.15 M NaCl 
1 mM EDTA 
0.5 mM EGTA 
20 mM HEPES 
pH 7.6 
Wash Buffer 2 0.1 % SDS 
0.1 % deoxycholate 




0.5 M NaCl 
1 mM EDTA 
0.5 mM EGTA 
20 mM HEPES 
pH 7.6 
Wash Buffer 3 0.25 M LiCl 
0.5 % sodium deoxycholate 
0.5 % NP-40 
1 mM EDTA 
0.5 mM EGTA 
20 mM HEPES 
pH 7.6 
Wash Buffer 4 1 mM EDTA 
0.5 mM EGTA 
20 mM HEPES 
pH 7.6 
TAEx50 2 M Tris acetate 
100 mM Na2EDTA 
Mixed 1:50 with ddH2O before use 
Table 2.6 ChIP buffers 
2.5.4.2 Immunoprecipitation of chromatin 
Samples were, thawed on ice, then centrifuged at 14000 g for 15 min to pellet any 
insoluble material and precipitated SDS. Supernatant was transferred to a fresh 
Eppendorf tube. Using a NanoDrop (Thermo Fisher Scientific, MA, USA) 
spectrophotometer, DNA concentration was measured (A260) against the nuclear 
lysis buffer devoid of SDS as a blank. DNA is thought to be ‘pure’ if the A260:A280 
ratio was above 1.6.  Sample concentrations were equalised by diluting the more 
concentrated sample to the concentration of the weaker sample using nuclear lysis 











BCL-3 3 μg 
(200 μg/mL) 
Rabbit sc-185 Santa Cruz, 
Biotechnology, 
CA, USA 
BCL-3 3 μg 
(48 μg/150 μL) 
Rabbit 23959-1-AP Proteintech, 
Manchester, UK 















Rabbit  AB5131 Abcam, 
Cambridgeshire, 
UK 
NF-B2/p52 3 μg (1 μg/μL) Mouse 05-361 EMD Millipore, 
MA, USA 
Table 2.7 ChIP antibodies 
25 g of chromatin for each antibody to be used for ChIP was transferred to a fresh 
Eppendorf tube and diluted to a total volume of 500 μL with CSTLB (Table 2.6). 
Each sample was pre-cleared with 1 g species specific IgG antibody (EMD 
Millipore, Herts, UK) and 5 L of Protein A or G beads (A – Rabbit, G - Mouse) 
(Dynabeads, Thermo Fisher Scientific, MA, USA) and incubated for 3 hr on a 
rotator at 4 C. After this time, the samples were briefly centrifuged and placed 
onto a magnetic rack on ice (Dynamag-2 magnetic particle concentrator, Thermo 
Fisher Scientific, MA, USA). After 30 sec, the chromatin was retrieved into a new 
Eppendorf tube. 5 L of chromatin was salvaged from each experimental condition 
to be processed later as the input sample. 1-5 μg of primary antibody (Table 2.7) 
was added to the chromatin and rotated in the cold room at 4 C overnight. The 
following day, 20 μL of Protein A or G beads were added to each Eppendorf tube 
and incubated on a rotator for 3 hr. Samples were retrieved and briefly centrifuged 
before being placed on the magnetic rack on ice. After 30 sec, the liquid was 
removed from each Eppendorf tube and discarded. Sequential washes of the 




wash was followed by a 5 min rotation at 4 C before Eppendorf tubes were placed 
back onto the magnetic rack on ice. Washes were 2x Buffer 1, 1x Buffer 2, 1x 
Buffer 3 and 2x Buffer 4. After the final incubation of 5 min, samples were 
transferred to new Eppendorf tubes and the liquid was discarded. At room 
temperature, 100 μL of elution buffer was added to each Eppendorf tube 
containing beads and incubated at 65 C for no longer than 16 hr (typically around 
12-14 hr) to reverse CH2O cross-linking. This was followed by a treatment with 
1 μL RNase A at 37 C for 30 min and then with 1 μL proteinase K at 55 C for 
2 hr. Both incubations were performed on a shaking heated incubator 
(Accutherm™, Labnet International, NJ, USA) at 1200 rpm, which maintained the 
Dynabeads in solution. Samples were then cooled to room temperature before a 
DNA clean-up step. 
2.5.4.3 DNA clean-up 
The QIAquick PCR purification kit (Qiagen, Germany) was used to clean DNA 
ready for PCR as per manufacturer’s instructions. Samples were placed onto spin 
columns after pH had been corrected using 3 μL of 3 M sodium acetate, to a 
pH<7.5. Samples were centrifuged for 1 min at 13000 rpm and the flow-through 
discarded. A further wash was performed, and samples centrifuged again for 1 min 
at 13000 rpm. DNA was eluted from membranes and stored at -20 C.  
2.5.4.4 PCR and agarose gel electrophoresis 
Immunoprecipitated chromatin was analysed using end-point PCR, as well as qRT-
PCR. PCR was carried out using primers ( 
Primer set 
name 
Forward  Reverse  








 Table 2.8 ChIP primers 
 
help from Dr. A Greenhough), to genomic DNA, using online software, the UCSC 
genome browser and Primer3 (284, 285). For end-point PCR, a 50 μL reaction mix 
was made per ChIP sample; consisting of 25 μL Promega Master Mix (Promega, 
WI, USA), 2 μL primer pair, 1 μL ChIP sample or ddH2O control, 21 μL ddH2O and 
0.5 μL DMSO (additive to reduce primer dimerization) (Sigma-Aldrich, Dorset, UK). 
BCL2L11(1b) GAGCGGGAGGCTAGGGTA AGGCTCGGACAGGTAAAGG 
BCL2L11(2) CGGGTTGGGGTAGGTGAG TGGCGTGTTTACCGGAGTA 
BCL-3 GGGAGAGAACCAGAGAGACG GTTGAGTCCGGGTCACTGAG 
GAPDH TCGAACAGGAGGAGCAGAGAGCGA TACTAGCGGTTTTACGGGCG 
Bimoff GAGGTGGTGGGGAGAAATGA TTCCAGCCCCTTTCCCTAAG 
Primer set 
name 
Forward  Reverse  
BCL2L11(1) GGGAGGCTAGGGTACACTTC CAGGCTCGGACAGGTAAAGG 
BCL2L11(1b) GAGCGGGAGGCTAGGGTA AGGCTCGGACAGGTAAAGG 
BCL2L11(2) CGGGTTGGGGTAGGTGAG TGGCGTGTTTACCGGAGTA 
BCL-3 GGGAGAGAACCAGAGAGACG GTTGAGTCCGGGTCACTGAG 
GAPDH TCGAACAGGAGGAGCAGAGAGCGA TACTAGCGGTTTTACGGGCG 




The touchdown PCR (TD-PCR, Table 2.9 (286)) programme was used to amplify 
DNA templates, after which 5x Orange G (Sigma, UK) was added in a 1:4 ratio. 
Samples were run alongside DNA markers on an 1-2 % ethidium bromide (Bio-
rad, UK) agarose (Geneflow, National Diagnostics, UK) gel (1-2 % in 1xTAE) for 
40 min at 200 V and imaged using a UV light box. For qRT-PCR, a standard 
protocol (Methods 2.5.1.3) was used but immunoprecipitated chromatin used, in 
place of cDNA with the primers designed for use with genomic DNA ( 
 Table 2.8). For one reaction mix 12.5 μL SYBR Green (Qiagen, Germany), 10 μL 
ddH2O, 1 μL primer pair and 1.5 μL ChIP sample was used. Results were 
compared to IgG control to ascertain fold-change in DNA abundance between 
conditions. Additionally, as with end-point, PCR samples were mixed 4:1 with 
Orange G and run on an agarose gel, as above, to check for primer-dimerisation. 
Gels were visualised on a UV light- 
Primer set 
name 
Forward  Reverse  
BCL2L11(1) GGGAGGCTAGGGTACACTTC CAGGCTCGGACAGGTAAAGG 
BCL2L11(1b) GAGCGGGAGGCTAGGGTA AGGCTCGGACAGGTAAAGG 
BCL2L11(2) CGGGTTGGGGTAGGTGAG TGGCGTGTTTACCGGAGTA 
BCL-3 GGGAGAGAACCAGAGAGACG GTTGAGTCCGGGTCACTGAG 
GAPDH TCGAACAGGAGGAGCAGAGAGCGA TACTAGCGGTTTTACGGGCG 
Bimoff GAGGTGGTGGGGAGAAATGA TTCCAGCCCCTTTCCCTAAG 
Step Time  Temperature (C) Cycles 





Denaturation 25 sec 94 










2.6 Data Analysis 
Data including statistical analysis was performed in the Graphpad Prism 7 
software. Parametric data was represented as means and standard deviations 
(SD) analysed with either a Student’s t-test or for multiple means an ANOVA. Non-
parametric data represented as medians and interquartile range (IQR) and was 
analysed with a Wilcoxon Signed Rank test or for multiple conditions a Kruskall 
Wallis test. Spheroid population data was noted to be log normally distributed and 
was summarised as medians (IQR) and analysed with Kruskall Wallis. The number 
of H2AX foci/nuclei are known to be Poisson distributed (287) and summarised 
as mean (SD).  
Leica Application Suite Lite (Leica, USA) software was used to analyse image data 
alongside the MATLAB software for automated image analysis.  
Adobe Photoshop 6 (Adobe, USA) was used to create all figures.  
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3 Results 1: BCL-3 promotes cell-survival in 
colorectal tumour cells through supressing the 






Elimination of old or damaged cells is a critical component of development, 
homeostasis and disease (288). Cellular elimination is controlled principally by a 
process known as apoptosis, or programmed cell death (289). Initially described 
as individual cell separation, condensation, fragmentation and phagocytosis (289), 
apoptosis was subsequently found to be a highly regulated process (290); whilst 
also having a basic mechanism that is evolutionarily conserved (291). Apoptosis 
is split into two main pathways, the intrinsic and extrinsic apoptotic pathways (292). 
Evasion of apoptosis is well recognised as a major component of tumour 
development and therapy resistance in cancer; and is one of the original ‘hallmarks 
of cancer’ (224). 
3.1.1 Apoptosis 
The intrinsic pathway is mediated by mitochondria and is initiated by diverse 
cytotoxic stimuli such as DNA damage, growth-factor deprivation or viral infection 
(293). Activation of this pathway leads to mitochondrial outer membrane 
permeability (MOMP), which allows release of factors such as cytochrome c, but 
also Smac/DIABLO, apoptosis-inducing factor (AIF) and procaspases from the 
intermembrane space (294, 295). On release from mitochondria, cytochrome c 
binds to Apaf-1 leading to activation of the caspase cascade and cell death. 
Caspases are proteolytic, cysteinyl aspartate enzymes, stored in the cytoplasm as 
zymogens (inactive pro-forms of the enzyme). The release of cytochrome c, in the 
intrinsic pathway, allows the dATP/ATP dependent binding of procaspase-9 to the 
Caspase Recruitment Domain (CARD) of apoptotic protease-activating factor-1 
(Apaf-1) to form the apoptosome (296). Binding of procaspase-9 to Apaf-1 cleaves 
caspase-9 which in turn cleaves other members of the caspase family (caspase-3 
and caspase-8) setting off the cleavage cascade. Initially, cleaved caspase-9 




cleavage products which are subsequently auto-cleaved at the Asp25 residue, by 
active caspase-3. This auto-cleavage results in a powerful amplification of the 
apoptotic signal and means the cell is unable to escape from the apoptotic 
cascade. As an effector caspase, cleaved caspase-3 then proteolytically degrades 
numerous proteins (such as poly ADP ribose polymerase (PARP), inhibitor of 
caspase-activated DNase (ICAD) and structural proteins) within the cell resulting 
in the apoptotic phenotype observed by Kerr et al published in 1972. These events 
are tightly controlled by the balance of pro-survival and pro-apoptotic members of 
the BCL-2 family. This family of proteins consists of over 20 related members that 
share BCL-2 Homology (BH) domains (288) and have been classically subdivided 
into 3 classes. 
3.1.2 The BCL-2 protein family 
BCL-2 with its related members, are critically important in apoptosis as upstream, 
negative regulators of cytochrome c release and its downstream effects of 
caspase-3 cleavage (297). The pro-survival members BCL-2, BCL-w, BCL-xL, 
MCL-1 and A1, share three or four BH domains (293). Of these, the BH1, BH2 and 
BH3 domains form a hydrophobic groove on the surface of pro-survival BCL-2 
members that is able to bind the BH3 domain of Bax and Bak, preventing their 
activation; furthermore, the groove can bind the BH3-only domains of the BH3-only 
class (298). The Bax family (Bax/Bak) of multi-BH domain proteins (1-3 BH 
domains) (299) reside on mitochondrial membrane or in the cytoplasm and upon 
activation, form pores that enable permeabilisation of the mitochondrial outer 
membrane, which allows the release of cytochrome c (discussed above) (300).  
There is controversy about how BCL-2 family of proteins function to inhibit 
apoptosis, with two main models; the direct (301) and the indirect (302) activation 
models. In the direct activation model BH3-only proteins (Bim, Bid (301) and 




oligomerisation and MOMP. Other BH3-only proteins do bind Bax/Bak directly but 
this results in abrogation of binding with pro-survival BCL-2-like proteins. The 
indirect model suggests that BH3-only members act to antagonise pro-survival 
BCL-2-like proteins and inhibit their function; in the case of ‘sensitizer’ BH3-only 
proteins this allows the release of ‘activator’ BH3-only members like Bim and Bid 
from BCL-2-like members enabling them to bind directly to Bax/Bak (304). 
Importantly, work has shown that both models are necessary for full apoptotic 
activity of the BH3-only proteins, in particular Bim (305). Binding results in 
neutralisation of the BCL-2-like family and activation of Bax or Bak. In addition to 
this, the BH3-only proteins are recognised to have specific binding affinities for 
each of the pro-survival BCL-2 members, highlighting some degree of context 
dependency (300, 302, 304). 
3.1.3 BCL2 interacting mediator of cell death (Bim) 
The pro-apoptotic BH3-only family of proteins are united by the solitary inclusion 
of a BH3 domain in the protein and include the members Bim, Bid, Puma, Noxa, 
Bad and Bik. The BH3-only protein Bim is thought to be one of the more important 
and potent of the family members (306). Bim, or BCL-2 interacting mediator of cell 
death, has three commonly recognised isoforms (BimEL, BimL and BimS). Bim is a 
promiscuous binding partner for all the BCL-2-like anti-apoptotic family members; 
highlighting the important functional role Bim plays in apoptosis from many different 
signals, as well as the potency of Bim (302, 305).  
Critical to Bim function is the BH3 domain. Bim indirectly activates Bax by binding 
to and inhibiting the pro-survival BCL2 proteins (BCL-2, BCL-w or BCL-XL). It does 
this by utilising the BH3 domain, present in all three Bim isoforms to interact with 
the hydrophobic groove that is central to the pro-survival proteins’ function (306), 
as Bim with mutated BH3 domains were unable to bind this groove (307). Alongside 




enables crosstalk between the extrinsic and intrinsic mitochondrial apoptosis 
pathways (290)) it functions as a direct activator of Bax (299, 305), inducing 
conformational change in Bax and its oligomerisation.  
Bim expression and function is regulated by a number of different mechanisms 
including transcriptionally, post-translational modification and protein 
sequestration. Early studies of Bim showed it to be predominantly localised to 
intracytoplasmic membranes, independent of Bim association with BCL2 (306). 
Later data, highlighted that it is BimEL and BimL which bind to dynein light chain 1 
(DLC1), leading to the suppression of Bim apoptotic activity (308). Furthermore, 
the sequestration of Bim, with DLC1, is dependent on phosphorylation of Bim, as 
phosphorylation by JNK on threonine 56 counteracts this interaction, leading to 
release of Bim from DLC1 and its functional activation (309).  
Additional phosphorylation events also control Bim degradation and therefore 
apoptotic function (310). Bim is principally a target of activated ERK, but also AKT 
kinases, both of which lead to Bim phosphorylation, subsequent ubiquitination and 
proteosomal degradation. In colorectal tumours with BRAF mutations, Bim is 
repressed through phosphorylation by constitutively active ERK1/2 and is 
subsequently degraded (311). Moreover, suppression of Bim by PGE2 in early 
colorectal tumours (a subset have upregulated by COX2) is also thought to be 
through ERK1/2 signalling (312). Moreover, inactivation of ERK1/2 by upstream 
action of a protein phosphatase on MAPK, induces Bim leading to apoptosis (313). 
BimEL is also phosphorylated on serine 87 by AKT leading to its degradation (314). 
Importantly, de-phosphorylation of these sites by protein phosphatase 2A is a 
potent apoptotic mechanism in endoplasmic reticulum (ER) stress (315) but, 
additionally, could play a role in general protein regulation.  
Bim is also tightly controlled at the transcriptional level and is primarily regulated 




this pathway, phosphorylated AKT (activated) phosphorylates FoxO1 or FoxO3a 
leading to their nuclear to cytoplasmic translocation and silencing of the 
transcriptional function of these proteins. Other transcription factors that are 
thought to regulate Bim include E2F1 as part of the Rb pathway (321) and CHOP-
C/EBP following ER stress (315). 
3.1.4 Aims 
BCL-3 nuclear expression in colorectal tumours has been shown to confer a worse 
prognosis for patients (240). Additionally, in-vitro data from this group has identified 
BCL-3 to be a survival factor in colon cancer cells (257) as discussed in the 
introduction (Section 1.6.8). There is however limited data on if and how BCL-3 
regulates the apoptosis pathway directly in rectal cancer cells. The aim of this work 
was to establish whether BCL-3 protected rectal cancer cells from undergoing 






3.2.1 BCL-3 expression in rectal cancer cell lines 
To establish the validity of the BCL-3 antibody and expression of BCL-3 in rectal 
cancer cells compared to colon cancer cells and adenoma cells, BCL-3 expression 
was analysed in a panel of cells (Methods 2.1.1). It was important to determine 
expression of BCL-3 in rectal cancer cells compared to adenoma or colon cells 
firstly to identify if BCL-3 is expressed in rectal cancer cells and to identify which 
cell lines to use for future experiments. BCL-3 was detected using western blotting, 
which identified the characteristic smear of BCL-3 protein, at around 55 kDa, that 
results from its multiple post-translational modifications, particularly 
phosphorylation (203). Western blot identified that SW837 were a low expressing 









Figure 3.1 Expression of BCL-3 in rectal cancer derived cell lines in comparison to 
a panel of colon carcinoma and adenoma derived cell lines. 
Western blot analysis was used to compare BCL-3 expression in two rectal cancer cell 
lines SW837 and SW1463 to a panel of colon adenoma and carcinoma cell lines. 





3.2.2 BCL-3 suppression increases levels of floating cells in 
colorectal tumour cells with high expression of BCL-3 
Previous work from this group supports the published view that BCL-3 is a pro-
survival, oncogene in colon cancer and other solid malignancies (257, 322). 
Additionally, previous work by this group has shown that the shed or floating cell 
fraction is predominantly apoptotic in colorectal cancer cell lines (Methods 2.3.1). 
BCL-3 was suppressed to determine whether altered cell survival in rectal cancer 
cells (SW837 and SW1463) compared to control high BCL-3 expressing cells 
(HCA7/P and LS174T). To suppress BCL-3 cells were transfected with siRNA 
(50nM, Sequence A) (257). Cell counts of adherent and floating cells were 
performed (Figure 3.2) and the percentage of floating cells calculated as a 
percentage of the total adherent cells per flask. Results showed that numbers of 
floating cells increased at 48 and 72 hours in three out of four of the cell lines, with 
statistical significance achieved in the SW1463, HCA7/Par and LS174T cell lines 
at 72 hr and at 48 hr in the HCA7/Par and LS174T cell lines. In the low BCL-3 
expressing SW837 cell line, BCL-3 suppression failed to increase floating cell 
numbers at either time point. Protein was harvested to analyse the efficiency of 
BCL-3 knockdown with siRNA for each experiment. Western analysis confirmed 
BCL-3 knockdown in all cell lines at 48 and 72 hr. These data confirmed that in 
high BCL-3 expressing rectal cancer cells and colon cancer cells, suppression of 






Figure 3.2 Suppression of BCL-3 increases cell death in rectal and colon cancer 
cells 
BCL-3 was suppressed in colon (LS174T (A), HCA7/P (B)) and rectal cancer cells 
(SW1463 (C), and SW837 (D)) with siRNA. At 48 and 72 hours following transfection 
adherent and floating cells were counted. Results showed there was significant increases 
in floating cell numbers, predominantly at the 72 hour time-point, following BCL-3 
knockdown except in the SW837 cell line (D), which are a low BCL-3 expressing cell line.  
BCL-3 knockdown was verified using western blot (E-H). Graphs show combined data 
from 3 independent experiments (mean and standard deviation (SD)). Statistical analysis 
was performed on GraphPad Prism 7 software using a Student’s T-Test (* :P<0.05, ** : 










3.2.3 BCL-3 suppression increases expression of the markers of 
intrinsic apoptosis 
Dying cells undergo a undergo a cascade of events leading to cell death via a 
number of mechanisms including apoptosis (programmed cell death). Molecular 
markers can be utilised to determine the mechanism of apoptotic death. To validate 
that the increase in floating cells was as a result of increased apoptosis in cells 
with suppressed BCL-3. Whole flask lysates (WFL; the combined population of 
adherent and floating cells, methods 2.5.2.2) were harvested and western analysis 
used to probe for molecular markers of apoptosis, cleaved caspase-3 (Intrinsic 
apoptosis (296)) and cleaved PARP (specific cleavage product of apoptosis (323) 
(Figure 3.3). BCL-3 was knocked down using siRNA in LS174T, SW1463 and 
HCA7/P cells, which had shown statistically significant fold increases in floating 
cells previously. WFL was collected at 48 hr following transfection. Results showed 
that BCL-3 suppression increased levels of cleaved caspase-3 and cleaved PARP 
suggesting induction of intrinsic apoptosis. Interestingly, LS174T (Figure 3.3 C) 
carcinoma cells have very low levels of basal apoptosis and this was mirrored with 
relatively lower levels of cleaved-PARP and cleaved caspase-3 compared to the 
other cell lines analysed. Cleaved-PARP was chosen as a more robust marker of 
apoptosis induction in these colon and rectal cancer cell lines for future 
experiments. These results suggest that suppression of BCL-3 increases 







Figure 3.3 BCL-3 suppression using siRNA induces increased cleavage of markers 
of intrinsic apoptosis: cleaved caspase-3 and cleaved PARP. 
SW1463 (A), HCA7/P (B) and LS174T (C) colorectal cancer cells were transfected with 
BCL-3 siRNA or Control siRNA. At 48 hours from transfection attached and floating cells 
were pooled to create WFL. Markers of apoptosis (Cleaved Caspase-3 and Cleaved 
PARP) were detected using western blot. Results showed BCL-3 suppression increased 
the induction of cleaved caspase-3 and cleaved PARP suggesting the induction of intrinsic 







3.2.4 Apoptosis induced by BCL-3 suppression can be blocked using 
QVD (pan caspase inhibitor) 
The pan-caspase inhibitor quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-
methyl ketone (Q-VD-OPh or QVD) blocks the cleavage of caspases, which blocks 
the downstream effects of MOMP and inhibits apoptosis (324). To confirm that 
increases in floating cells and expression of markers of apoptosis following BCL-3 
suppression was through induction of apoptosis, QVD was used to inhibit this 
process. Colorectal cancer cells, SW1463, HCA7/P and LS174T were transfected 
with BCL-3 siRNA or control siRNA (50 nM). 24 hr following transfection QVD 
(10 μM) was added to inhibit apoptosis induced by BCL-3 knockdown (Methods 
2.4.1). Cell counts were performed 72 hr following transfection, to measure 
adherent and floating cells. It was observed, that while the number of floating cells 
increased following BCL-3 knockdown, this was abrogated by treatment with QVD 
(Figure 3.4). Furthermore, western blots of whole flask lysates showed 
upregulation of cleaved caspase-3 and cleaved PARP, which was almost 
completely abrogated with QVD treatment. Taken together, these data show that 
BCL-3 suppression increases levels of apoptosis in both colon and rectal tumour 
cells with high basal levels of BCL-3 expression. 
Interestingly it was noted that when samples were treated with QVD a further band, 
recognised by cleaved caspase-3 antibody, appeared on the immunoblot. This 
band was at the 20kDa marker, which could be an intermediate caspase-3 
cleavage product (Figure 3.4). When caspase-3 is cleaved initially by the 
apoptosome, this is carried out by caspase-9 leading to a p20 product that is further 
cleaved to the final fully active caspase-3 by auto-cleavage (303). This observation 
suggests that QVD blocks this auto-cleavage leading to a build-up of the 20 kDa 






Figure 3.4 The pan-caspase inhibitor QVD blocks BCL-3 suppression induced 
apoptosis. 
LS174T (A), SW1463 (B) and HCA7/Par (C) cells were transfected with BCL-3 or control 
siRNA and treated with QVD (10 μM) or vehicle control at 24 hr. Adherent and floating cells 
were counted. Protein lysates were collected for adherent cells (Whole Cell Lysate, WCL) 
and pooled adherent and floating cells (Whole Flask Lysate, WFL). BCL-3 suppression   
increased proportions of floating cells, which was abrogated by treating cells with QVD (A-
C). Western analysis confirmed induction of molecular markers of apoptosis, which was 
blocked by treatment with QVD. Counting experiments shown are the combined data from 
3 independent experiments (mean and SD) (A-C). Western blots shown are exemplar blots 
from n=3 experiments (D-F). Statistical analysis was performed on GraphPad Prism 7 











3.2.5 BCL-3 regulates Bim a pro-apoptotic member of the BCL2 family  
The BCL2 protein family are important regulators of apoptosis (325). The canonical 
NF-B pathway regulates BCL-xL a pro-survival member of the BCL2 family of 
proteins (326). Although, the role of BCL-3 as a regulator of the BCL2 protein family 
is unknown in colorectal tumour cells. Therefore, to determine whether apoptosis 
seen with BCL-3 knockdown a panel of BCL-2 proteins was analysed. (Figure 3.5). 
These included members from all three classes of the BCL-2 family of proteins. 
The three colorectal cell lines LS174T, SW1463 and HCA7/P, where apoptosis 
induction had been observed, were transfected in suspension with BCL-3 siRNA 
(50nM Sequence A, Methods 2.2.1). Whole cell lysates were obtained at 48 and 
72 hours following transfection. Results showed that the pro-apoptotic, BH3-only 
protein Bim was regulated, with BCL-3 suppression inducing Bim levels in all three 
carcinoma cell lines at both time-points (Figure 3.5 A-C). Moreover, it appeared 
that all three isoforms (BimEL, BimL and BimS, formed by alternative splicing (327)) 
were upregulated by BCL-3 suppression, suggesting that BCL-3 may be regulating 
Bim at the transcriptional level. Interestingly, the protein panel also revealed that 
in two of the cell lines (SW1463 and LS174T (Figure 3.5 A&B)) there was 
downregulation of BCL-w, a pro-survival member of the BCL-2-like family, with no 
clear regulation in HCA7/P (Figure 3.5 C). Other noted protein regulation, was of 
the pro-survival BCL-2-like protein MCL-1. It appeared that MCL-1 was up-
regulated at the 48 hr time-point with BCL-3 suppression. Furthermore, it was 
confirmed that the LS174T cell line did not have Bax expression as a result of 
mutation (Figure 3.5 B). The Bax gene is known to contain microsatellite repeats 
which leave it susceptible to mutation in tumours with deficient mismatch repair 




These data suggest that BCL-3 suppression may be leading to apoptosis through 
upregulation of the pro-apoptotic BH3-only protein, Bim rather than through other 
members of the BCL2 family. Bim can sequester and inhibit the majority of the pro-
survival members of BCL2 proteins as well as binding directly to activate the pro-
apoptotic proteins BAX and BAK, making Bim a critical regulator of apoptosis.  
Figure 3.5 BCL-3 knockdown primarily 
alters Bim out of a panel of proteins 
critical for mitochondrial apoptosis. 
BCL-3 was suppressed using siRNA as 
described in methods. Cell lysates were 
collected from SW1463 (A), LS174T (B) and 
HCA7/P (C) colorectal cancer cells at 48 
and 72 hours following transfection. 
Proteins were probed for using western 
blotting. Each cell line shows representative 






3.2.6 Validation that Bim is regulated by BCL-3 
It was important to ensure that the observed effect of BCL-3 suppression on Bim 
protein expression was not as a result of off-target effects from a single siRNA 
sequence (sequence A). Gene suppression using short interfering RNA or siRNA 
takes advantage of conserved mechanisms of gene regulation and defence 
against external RNA (329). siRNA functions to degrade target mRNA following 
transcript specific sequence identification; however, despite being highly 
reproducible, it is recognised that off-target effects may occur even with minimal 
sequence homology, resulting in hybridisation of siRNA and other transcripts (330). 
Therefore, BCL-3 was suppressed using a second sequence (50nM sequence D) 
and compared to control siRNA or standard target sequence (sequence A) (Figure 
3.6 A-C); both these two target sequences have been previously validated and 
shown to induce efficient knockdown of BCL-3 (257). Cell lysates were analysed 
with western analysis and despite only partial suppression, results confirmed 
increased expression of Bim with each sequence of siRNA targeting BCL-3. 
Interestingly, in SW1463 cells, Bim upregulation was more pronounced following 
BCL-3 suppression with sequence D (Figure 3.6 C), although BCL-3 siRNA 
sequence A did clearly result in Bim upregulation too. These data suggest that the 
observed effect on Bim from BCL-3 suppression was not an off-target effect of a 







Figure 3.6 Suppression of BCL-3 using differing siRNA sequences results in 
induction of Bim protein expression. 
To ensure that regulation of Bim by BCL-3 suppression was not sequence specific, 
colorectal cancer cell lines (LS174T, HCA7/P and SW1463) were transfected according to 
described methodology (see methods). Cells were transfected in suspension with two 
alternative sequences of siRNA targeting BCL-3 (sequence A and D), which had been 
previously validated by our group as the optimal sequences for BCL-3 protein suppression 
(2). Cells were lysed at 48 and 72 hours post-transfection and BCL-3 and Bim protein 








3.2.7 Knockdown of Bim abrogates BCL-3 suppression-induced 
apoptosis 
To determine if the increase in apoptosis of colorectal cancer cells observed 
following suppression of BCL-3 was dependent on regulation of Bim expression, a 
co-transfection experiment was performed. SW1463, HCA7/P and LS174T 
colorectal carcinoma cells were transfected in suspension with BCL-3, Bim or a 
combination of both siRNA sequences. Total siRNA was controlled for by adjusting 
the amount of control siRNA in the single transfected conditions (BCL-3 or Bim) to 
ensure maximum siRNA was no more than 100 nM (Methods 2.2.1). At 72 hr 
following transfection adherent and floating cells were collected and counted. The 
percentage of floating cells was then determined. Results show the increase in 
apoptosis induced by BCL-3 suppression was abrogated by Bim knockdown in all 
the cell lines tested (Figure 3.7). Western blot was used to confirm protein 
knockdown of BCL-3 and Bim in the WCL. Furthermore, abrogation of apoptosis 
was confirmed by cleaved PARP at the molecular level in WFL in co-transfected 
cells (Figure 3.7). These observations suggest that the increase in floating cells 
and therefore apoptosis is dependent on Bim expression as when Bim expression 







Figure 3.7 BCL-3 knockdown induced apoptosis is dependent on Bim. 
SW1463 (A), HCA7/P (B) and LS174T (C) colorectal cancer cells were transfected with BCL-3, 
Bim, control siRNA or co-transfected with both siRNA sequences. Total siRNA as well as 
concentration of each manufacturer siRNA (BCL-3: Ambion, Bim: Dharmacon, Methods 2.2.1). 
Cells were counted 48 hours after transfection. BCL-3 suppression significantly induced 
apoptosis, which was abrogated by co-suppression of Bim (A-C). WCL and WFL were harvested 
and western blot performed to analyse expression of BCL-3, Bim and cleaved-PARP (D-F). -
Tubulin expression was used as a loading control. Counting experiments are combined data 
from n=3 independent experiments (mean and SD) and western blots are exemplary from n=3 
experiments.  Statistical analysis was performed on GraphPad Prism 7 software using a 









3.2.8 BCL-3 knockdown does not alter pAKT expression or pERK 
expression 
AKT is known to have anti-apoptotic functions which are partially mediated through 
phosphorylation of the Forkhead Box O (FoxO) transcription factor (318). A 
principle target of FoxO transcription is Bim (317, 331). When FoxO is 
phosphorylated this results in its nuclear exclusion and eventual degradation, 
resulting in reduced Bim transcription (332). Previous work from this group has 
shown that BCL-3 expression modulated levels of phosphorylated AKT (pAKT) in 
the cell lines SW480 and HCT116 (257). It was hypothesised that BCL-3 
suppression may negatively regulate pAKT expression, thereby reducing FoxO 
phosphorylation and activating Bim gene transcription, western analysis was 
performed to probe for pAKT (serine 473). Colorectal cancer cells SW1463, 
HCA7/P and LS174T were transfected in suspension with BCL-3 siRNA compared 
to control siRNA as described in methods. Protein was harvested 48 and 72 hr 
following transfection and western blot performed. Results showed that there was 
no consistent regulation of pAKT by BCL-3 suppression at either 48 or 72 hr from 
transfection (Figure 3.8). These data suggest that, in the colorectal cancer cell lines 
SW1463, HCA7/P and LS174T, the effects of BCL-3 suppression, on Bim 
upregulation, are not mediated through the AKT-FoxO-Bim axis.  
  
Figure 3.8 BCL-3 suppression does not alter pAKTS473 levels in the colorectal cancer 
cell lines SW1463, HCA7/P and LS174T 
HCA/P (A), SW1463 (B) and LS174T (C) cells were transfected in suspension with BCL-3 
or control siRNA (50 nM). Whole cell lysates were collected at 48 and 72 hr from 
transfection initiation. Western analysis was performed and showed that after suppression 
of BCL-3, Bim expression was indeed induced; however, pAKTS473 expression was 
unchanged in all three cell lines analysed. Equal loading confirmed with -Tubulin 
expression. Westerns are exemplary images from n>3 independent experiments. Note 
SW1463 BCL-3 and Bim blot used in Figure 3.5. 




3.2.9 Bim expression increases with BCL-3 and p52 suppression in 
HCA7 and SW1463 but not LS174T colorectal cancer cells 
BCL-3 is an important co-factor in atypical NF-κB signalling where it regulates 
transcription by the atypical NF-κB homodimers p50 and p52. Previous 
observations showed that BCL-3 was not altering pAKT levels in SW1463, HCA7/P 
and LS174T colorectal cancer cells. It was hypothesised that the effect of BCL-3 
suppression on Bim up-regulation may be through regulation of the atypical NF-κB 
homodimers. To examine if NF-B1 or NF-B2 suppression had similar effects on 
Bim expression compared to BCL-3 suppression siRNA was used to all three 
genes. Therefore, SW1463, LS174T and HCA7/P cells were transfected with BCL-
3, NF-B1 and NF-B2 siRNA and compared to control siRNA. Protein lysates 
were collected at 72 hr following transfection. Western blot was used to examine 
protein expression. Results showed that Bim expression was induced by both BCL-
3 and NF-B2 knockdown but not NF-B1 suppression in HCA7/P and SW1463 
cells (Figure 3.9 A&B). Interestingly, this was not the case in LS174T carcinoma 
cells, where NF-B2 suppression reduced Bim levels in comparison to both control 
and BCL-3 transfected cells. These observations suggest that, in HCA7/P and 
SW1463 cells, BCL-3 and p52 both repress Bim expression. In LS174T cells it may 
be that BCL-3 suppression induces Bim by an alternative mechanism.  
Further analysis highlighted that NF-B2 knockdown resulted in the induction of 
BCL-3 in all the cell lines analysed but NF-B1 suppression did not have the same 
effect on BCL-3 (Figure 3.9 A-C). 
These data suggest that BCL-3 and p52 suppression have mirrored effects in 
HCA7/P and SW1463 carcinoma cells resulting in upregulation of Bim. To analyse 






Figure 3.9 Bim upregulation results from NF-B2 suppression as well as BCL-3 
suppression but not NF-B1 
HCA7/P, SW1463 and LS174T cells were transfected in suspension as described 
(Methods 2.2.1). 50 nM siRNA of each siRNA was used to supress BCL-3, NF-B1 and 
NF-B2, 72 hr following transfection initiation whole cell lysates were harvested and 
western analysis performed. Results showed that NF-B2 suppression as well as BCL-3 
suppression increased Bim expression, while NF-B1 knockdown failed to induce Bim 
expression in SW1463 and HCA7/P cells but not in LS174T cells. Western blots are 
exemplar data representative of n=3 independent experiments.  




3.2.10 BCL-3 suppression increases levels of Bim mRNA 
BCL-3, when acting as an NF-B co-regulator, is known to have repressive roles 
on gene transcription (199), which would corroborate the effect observed. The 
results obtained so far indicate that BCL-3 suppression results in upregulation of 
all Bim isoforms in those colorectal cell lines analysed with high basal BCL-3 
expression. SW1463 and HCA7/P cells were used as previous experiments had 
shown apoptotic response and Bim upregulation was greatest in these cell lines. 
Additionally, Bim was regulated by both BCL-3 and p52 in these cells. To 
determine if the regulation of Bim protein expression by BCL-3 suppression was at 
the transcriptional level, qRT-PCR was performed to measure levels of Bim mRNA. 
HCA7/P and SW1463 were transfected with 50 nM siRNA (BCL-3 vs control) and 
left for 48 and 72 hours to achieve maximal knockdown of BCL-3. The early time-
point of 48 hr was utilised to capture changes in mRNA level, which would be 
expected to occur prior to protein alterations. mRNA was purified using a Qiagen 
PCR kit after which cDNA was synthesised before being incubated with the qRT-
PCR reaction mixture (primers used BCL-3, Bim and TBP as the housekeeping 
gene). Primers used for qRT-PCR were designed to identify all three of the main 
Bim isoforms created by alternative splicing. It was observed that BCL-3 
suppression significantly induced expression of Bim mRNA at both 48 and 72 hr 
after transfection in HCA7/P (1.80 fold increase at 48 hr and 1.83 fold increase at 
72 hr) and SW1463 cells (1.67 fold increase at 48 hr and 1.43 fold increase at 
72 hr) (Figure 3.10). BCL-3 mRNA was confirmed to be significantly reduced by 
transfection (data not shown). These data suggest that upregulation of Bim is 
through denovo gene transcription in these colorectal cancer cells. Further 
experiments would be performed to assess if BCL-3 was found at regulatory 








Figure 3.10 BCL-3 suppression leads to increased levels of Bim mRNA. 
SW1463 and HCA7/P cells were transfected in suspension with BCL-3 siRNA. Total cellular 
RNA was extracted from cells at 48 and 72 hours post transfection. qRT-PCR was 
performed using primers to Bim and TBP (housekeeping primer). Results showed that BCL-
3 suppression significantly increased Bim mRNA levels in SW1463 and HCA7/P cells at 
both time-points. Data is mean and SD of 3 biological replicates with Relative Quantity 
(dRn) normalised to the housekeeping gene. Statistical analysis was performed on 
GraphPad Prism 7 software using a Student’s T-Test (* :P<0.05, ** : P<0.01, *** : P<0.001, 




3.2.11 BCL-3 binds to the Bim promoter at NF-B consensus sites 
3.2.11.1 ChIP primer Design 
BCL-3 is well recognised to repress transcription when bound to atypical NF-B 
homodimers in the nucleus (Introduction 1.6.6). Bim is known to be regulated by 
non-canonical NF-B signalling with RelB-p52 complexes identified at putative NF-
B consensus sequences present at the BCL2L11 promoter (153). Data shown 
previously identified that BCL-3 and p52 regulated Bim expression in SW1463 and 
HCA7/P cells (Figure 3.6). Additionally, BCL-3 suppression regulated Bim mRNA 
levels suggesting modulation of transcription (Figure 3.10). Chromatin 
immunoprecipitation (ChIP) was used to determine whether BCL-3 regulated Bim 
transcription by binding to the BCL2L11 gene. BCL-3 binds to DNA through its 
association with NF-B homodimers (see introduction 1.6.4 for references). NF-B 
dimers bind to DNA on B consensus sites, which can vary in their sequence. It 
was unclear if specific consensus sequences (such as those site in the Bim 
promoter shown to bind non-canonical dimers (153)) enable atypical/homodimer 
binding as NF-B DNA binding sequences are distinct for each subunit. As p52 
suppression had induced Bim expression mirroring the effect of BCL-3 suppression 
but p50 knockdown had not induced Bim, an NF-B consensus site on the 




The genomic DNA sequence of BCL2L11 was downloaded from the UCSC 
Genome browser (http://genome.ucsc.edu/ using Human Genome December 
2013 GRCh38/hg38 Assembly) (Appendix 4). To identify possible p52 homodimer 
binding sequences, the online program JASPAR (http://jaspar.genereg.net/ 
database containing transcription factor DNA-binding preferences, modelled as 
position weight matrices (PWM), under a creative commons attribution) was mined 
to identify the DNA-binding PWM. The p52 PWM was identified (Figure 3.11). 
These sequences were then used to analyse the BCL2L11 gene promoter region. 
Results identified a number of putative NF-B DNA-binding sites within 5000 bases 
(5 kb) that matched the p52 homodimer PWM obtained from JASPAR. Primers 
were designed using Primer3 software (http://primer3.ut.ee/) with optimum primer 
size of 150 bp and choosing primers with minimal predicted self-complementarity 
to minimise primer dimer and secondary structure formation. Primers were chosen 
for PCR to include those NF-B regions closest to the BCL2L11 transcription start 
Figure 3.11 The BCL2L11 promoter contains two putative NF-B DNA binding sites 
Analysis of the BCL2L11 gene using NF-B p52 homodimer consensus sequences 
identified a number of possible DNA-binding sites within the BCL2L11 promoter. Online 
software JASPAR was used to identify p52 consensus binding sequences. These 






site (TSS). Additionally, primers were designed to NF-B consensus sites in the 
BCL-3 promoter region as BCL-3 is recognised to be a target of transcriptional 
repression by p52 (199) and therefore, would act as a positive control; furthermore, 
primers were designed to a region close to the BCL2L11 gene with no identified 
NF-B consensus sites, which would act as a negative control.  
3.2.11.2 Sonication Efficiency 
Initial experiments were performed in HCA7/P and SW1463 cells growing, 
exponentially, in basal conditions (10 % DMEM, T25 flasks). Chromatin was 
sonicated (15-20 cycles, 30 sec/cycle) into fragments of between 100-500 bp 
lengths (Figure 3.12), as these are considered optimal for the downstream PCR 
steps following IP; too large fragments may result in false positive detection, while 
over-sonication may result in too smaller fragment size and false negative results.  
Chromatin sonication was checked to ensure optimal fragment size by running 
samples on a 1.5 % agarose gel (Figure 3.12). 
  
Figure 3.12 Validation of sonication efficiency 
using HCA7 carcinoma cells. 
HCA7/P carcinoma cells were grown in 2xT25 flasks 
until 60-80 % confluent. Cells were fixed using 4 % 
paraformaldehyde for 10 min. The nuclear 
compartment was isolated and lysed, following 
which nuclear lysates were sonicated for 16 cycles. 
Sonicated DNA was then resolved on an 1.5 % 
agarose gel for 40 min at 200 V. Results showed 
that 16 cycles of sonication was sufficient to 
fractionate DNA into fragments of between 100-




3.2.11.3 Primer dimerisation 
It was noted that there was significant primer-dimer formation, likely as a result of 
too high 3’ self-complementarity of the primers. This can be an issue in PCR due 
to a number of reasons including template that is found at very low levels leading 
exponential amplification of small fragments resulting in utilisation of PCR reagents 
and reduction in PCR of the true template. 
As significant primer dimer had been observed, in the primers of interest, it was 
necessary to try and reduce this by optimising the PCR reaction conditions. 
Additives to PCR reactions can minimise primer dimer by optimising the reaction 
conditions. DMSO works by disrupting base pairing in primers with high GC content 
(333). Using the ChIP samples prepared from HCA7/P cells it was possible to test 
if the addition of DMSO would improve the reaction efficiency and abrogate primer 
dimer formation of the primers of interest. 1 % or 3 % v/v DMSO was added in to 
the reaction mixtures (Methods 2.5.4.4). It was observed, that the addition of the 
PCR additive DMSO 1 % v/v resulted in improved PCR efficiency and reduced 
primer dimer formation for primers designed to the BCL2L11 and BCL-3 promoter 
(Figure 3.13 A&D). Additionally, it was clear that the addition of 3 % v/v DMSO 
resulted in worse PCR efficiency and significant primer dimer formation again 
(Figure 3.13 B&E). A further primer to the BCL2L11 promoter was designed, as 
described above, with increased stringency on Primer3 software 
(http://primer3.ut.ee/) to ensure that there was reduced self-complementarity of the 
designed primers (complimentary 3’ bases (1-2) and any complimentary bases (3-
4)) (Figure 3.13 C). This primer, BCL2L11 (1b), was used in PCR with the same 
optimised reaction mixture and led to further reduction in primer-dimer formation. 
Additionally, primers to a putative B site in a non-promoter region of Bim (Bimoff) 
and GAPDH (Figure 3.13 F&G) acted as controls with results showing no binding 




optimised primer to the Bim promoter (BCL2L11 (1b)) and reaction mixture with 






Figure 3.13 1% DMSO reduces primer dimer formation for primers with high GC 
content. 
HCA7/P carcinoma cells were grown and fixed as before. End-point PCR was performed 
with ChIP samples. 1 or 3 % v/v DMSO was added to the reaction mixtures and PCR was 
run as in methods 2.5.4.4. PCR products were analysed on a 2 % agarose gel. It was 
observed that 1 % v/v DMSO resulted in more efficient PCR reaction with reduced primer 
dimer formation for both primers tested (A&D compared to B&E). Interestingly, increasing 
DMSO to 3 % resulted in a less efficient reaction and much greater primer dimer formation 
(B&E). Furthermore, a second primer (BCL2L11b) to the same BCL2L11 promoter region 
was designed, with significantly lower 3’ or any self-complementarity resulting in less 
primer dimer formation compared to the original BCL2L11 primer (A&C). p52 bound to 
the positive control region in the BCL2L11 gene (F) but not to GAPDH, while BCL-3 bound 








3.2.11.4 BCL-3 and p52 bind to the BCL2L11 promoter in colon 
and rectal cancer cell lines 
Further experiments were performed to investigate if BCL-3 was found at the Bim 
promoter in rectal cancer cells. To do this, the optimised primer to NF-B p52 
consensus site in the Bim promoter (BCL2L11 (1b)) was compared to a GAPDH 
primer in a second cell line (SW1463). ChIP was performed as before on HCA7/P 
and SW1463 cells and end-point PCR (Methods 2.5.4.4) to analyse the 
immunoprecipitated chromatin. Products were run on a 2 % agarose gel for 40 min. 
It was observed that BCL-3 and p52 were identified at the BCL2L11 promoter 
(BCL2L11 (1b)) in both SW1463 and HCA7/P CRC cells (Figure 3.14 A and B). 
Importantly, BCL-3 or p52 were not found at the GAPDH promoter, which acted as 
a negative control (Figure 3.14 C). Additionally, there was no signal observed in 
IgG control immunoprecipitates, suggesting that the results from the BCL-3 and 
p52 pulldown is specific. These results confirm that BCL-3 and p52 are found at 
the Bim promoter in both colon and rectal cancer cell lines. 
  
Figure 3.14 BCL-3 and p52 are found at the BCL2L11 promoter. 
HCA7/P and SW1463 carcinoma cells were grown in exponential phase. Cells were fixed 
with 4 %paraformaldehyde for 10 min. Sonicated chromatin was immunoprecipitated with 
IgG, acH3, BCL-3 and p52 antibodies overnight and collected on Dynabeads. Input and 
ChIP samples underwent PCR in comparison to H2O control. Products were run on a 2 % 
agarose gel at 200 V for 40 min. These preliminary results identified that BCL-3 and p52 
were both found bound to the BCL2L11 promoter (SW1463 A and HCA7/P B) but not to 







3.2.11.5 BCL-3 suppression increases levels of active histone 
marks (acH3) at the BCL2L11 promoter 
BCL-3 is known to interact with the histone modifying enzymes TIP60/KAT5 (216) 
and HDAC1 (219). Having identified that BCL-3 binds to the promoter region of 
BCL2L11, it was necessary to understand if BCL-3 modulated chromatin marks 
that signify active gene transcription. It is recognised that acetylated histone 3 
(acH3) is an important histone modification that signifies active transcription (334). 
Additionally, phosphorylated Pol2 at serine 5 is found at promoters and marks 
Figure 3.15 Preliminary ChIP data suggests BCL-3 knockdown reduces abundance 
of acetylated Histone 3 at the BCL2L11 promoter. 
BCL-3 was suppressed in HCA7/P cells using siRNA and compared to cells treated with 
control siRNA (50 nM). At 72 hr following transfection, cells were processed for 
downstream applications; whole cell lysates were taken for western blot and 2xT25 flasks 
were fixed with 4 % paraformaldehyde for chromatin immunoprecipitation. Western blot 
was used to confirm BCL-3 knockdown and Bim induction, -Tubulin was used as a loading 
control. Chromatin immunoprecipitation was performed on fixed and sonicated samples 
using antibodies to acH3, Pol2S5 and IgG. After ChIP, end-point PCR and qRT-PCR were 
performed. End-point PCR products were run on an 2 % agarose gel. qRT-PCR data was 






transcriptional initiation (335). Therefore, ChIP was performed to ascertain if BCL-
3 knockdown effected levels of acH3, with IP also performed to assess for 
alterations in Pol2S5. In HCA7/P carcinoma cells, BCL-3 siRNA (50 nM) was 
transfected in suspension and compared to control siRNA. BCL-3 knockdown was 
confirmed at 72 hr with western blot (Figure 3.15 A). The results show that BCL-3 
knockdown increased levels of acetylated histone 3 at the BCL2L11 promoter 
consistent with the transcriptional activation observed previously (Figure 3.15 B 
and C). Although, there was no significant alteration to Pol2S5 at the Bim promoter 
with BCL-3 suppression. These data suggest that BCL-3 could play a direct role in 






3.2.12 Response of a panel of colorectal cancer cell lines to ABT-737 
Targeting evasion of apoptosis by colorectal tumour cells is an attractive 
therapeutic prospect, as it would enable sensitisation of tumour cells to currently 
used chemo-radiation or enable novel targeted therapies. Moreover, colorectal 
cancers are known to have increased levels of BCL2 and BCL-xL, which may limit 
the effectiveness of BCL-3 suppression on cancer cell apoptosis (336-338). 
Mechanistic studies of drugs targeting BCL2 dependent apoptosis, such as ABT-
737, have suggested that they do not directly induce apoptosis in target cells but 
help to sensitise these cells to apoptotic stimuli, by tipping the balance towards the 
pro-apoptotic proteins, thereby allowing increased MOMP and apoptosis (339). 
Therefore, as BCL-3 suppression was shown to induce Bim expression, a 
hypothesis was considered; by blocking the effect of the pro-survival BCL2 proteins 
there would be sensitisation of colorectal cancer cells to BCL-3 knockdown 
resulting in reduced survival compared to BCL-3 suppression alone. To test this 
hypothesis, it was important to understand the IC50 values for the colorectal cell 
lines being used, so as to enable correct dosing throughout the BCL-3 knockdown 
experiments. Colorectal tumour cells SW1463, SW837, HCA7/P and LS174T were 
seeded into 48 well plates and allowed to grow for 48 hr before being treated with 
ABT-737 at logarithmically varying doses, based on micromolar concentrations 
described in the literature (339). Following 24 hr of treatment standard media was 
placed onto cells and cells allowed to grow until a week had passed since seeding. 
Cells were then fixed and stained with crystal violet as per methods. 
Concentrations of eluted crystal violet in acetic acid were analysed to ascertain 
changes to total proportion of viable cells per condition. Results showed that IC50 




ascertain if BCL-3 would be sensitised by ABT-737 it was decided to use sub-IC50 
concentrations in the following experiments.  
  
Figure 3.16 Treatment of colorectal tumour cells with the BCL2 inhibitor ABT-737 
SW1463, SW837, HCA7/P and LS174T cells were seeded into 48 well plates for 48 hr 
prior to being treated with ABT-737 or vehicle control (DMSO). ABT-737 treatment was for 
24 hr following which cell media was changed to standard 10% DMEM and cells incubated 
until seven days following seeding. A crystal violet cell viability assay was then performed 
and absorbance of crystal violet in solution measured using a microplate reader. Data 
shown is the mean fold change of cell viability, following treatment normalised to the vehicle 
control, of two independent experiments, for each cell line, plotted on a semi-log graph. 
Dashed line indicates the IC50 line. Observed IC50 values calculated using non-linear 
regression for cell lines analysed were SW1463 10.55 μM (95 % CI 10.73-12.35), , SW837 
10.19 μM (95 % CI 7.38-14.34 μM), HCA7/P 14.59 μM (95 % CI 10.74-19.52), LS174T 
18.5 μM (95 % CI 11-50.98). Analysis of IC50 values performed using Graphpad Prism 




3.2.13 BCL-3 knockdown does not sensitise to treatment with ABT-737 
Having analysed the general effect of ABT-737 on the viability of colorectal cancer 
cells, the aim was to translate these data into those cells where BCL-3 had been 
suppressed to ascertain if there was any benefit to concurrent treatment with a 
BCL2 inhibitor following BCL-3 suppression. As the effect on Bim expression 
following BCL-3 knockdown was greatest in SW1463 and HCA7/P cells (Figure 
3.17), these cell lines were chosen for the ongoing experiments. Cells were 
transfected as before in suspension and seeded into 24 well plates, or T12.5 flasks 
(for protein lysate collection). At 48 hr following transfection cells were treated with 
sub-IC50 values of ABT737 or vehicle control. Cells were fixed at seven days 
following transfection and stained with crystal violet. It was observed that there was 
no significant additive effect of ABT-737 treatment on reduction in cell viability in 
either cell line tested (SW1463 or HCA7/P) following BCL-3 suppression. Western 
analysis of lysates taken following BCL-3 suppression and ABT-737 treatment 
showed BCL-3 suppression induced Bim (Figure 3.17). Interestingly, in the 
SW1463 cell line, ABT-737 treatment resulted in Bim protein induction, particularly 
BimEL, this was not the case in HCA7/Par cells.  
Taken together, these data suggest that BCL2 inhibitors combined with BCL-3 
suppression may not be therapeutically efficacious in colorectal cancers with high 







Figure 3.17 ABT-737 treatment does not increase levels of apoptosis observed 
following BCL-3 suppression in colorectal tumour cells. 
Colorectal cancer cells SW1463 and HCA7/P were seeded into 48 well plates and BCL-3 
was suppressed using siRNA in suspension as described in methods. Following 48 hr of 
transfection medium was replaced with 10 % DMEM containing either ABT-737 (0.1, 1 or 
5 μM) or vehicle control (DMSO) for 24 hr treatment. At this time point medium was again 
removed and replaced with standard 10% DMEM, cells seeded in T12.5 flasks concurrently 
were lysed at this point also. Cells seeded for western analysis were treated with ABT-737 
at 5 μM. Statistical analysis of cell viability data showed non-significance at all doses of 
ABT-737 compared to control, in both cell lines. Western blots are exemplary from n=3 
experiments.  Statistical analysis was performed on GraphPad Prism 7 software using a 




3.3 Discussion  
It is recognised that BCL-3 expression promotes evasion from apoptosis in several 
different cell types and under different conditions (discussed in introduction 
1.6.8.3). However, although BCL-3 has been previously shown to promote tumour 
cell survival in colon cancer cells (257), its role in promoting cell survival in rectal 
cancer cells was unknown. In addition, there is limited data on the mechanism 
underpinning the regulation of apoptosis by BCL-3. Therefore, initially BCL-3 
expression in two rectal cancer cells was compared to a panel of colon and 
adenoma cell lines and the high BCL-3 expressing cell line was taken forward for 
further experiments. It is shown that loss of BCL-3 promotes apoptosis in rectal 
cancer cells (confirmed as apoptosis by blocking caspase cleavage using QVD). 
This is potentially important as it suggests targeting BCL-3 in those cancers with 
higher expression could increase that rate of cell death of tumour cells, leading to 
tumour regression. A possible limitation of this study was the number of rectal 
cancer cell lines included and it would also be interesting to examine further rectal 
cancer cell lines for BCL-3 expression and assess if other high BCL-3 expressing 
lines exhibit the same response to BCL-3 suppression. 
The BCL2 family proteins are critical regulators of apoptosis. Much work has 
shown that Bim expression and function is controlled through PTM (309, 311, 312). 
Interestingly, using RNAi results showed that BCL-3 suppression consistently 
increased Bim protein and mRNA expression, suggesting loss of BCL-3 was 
increasing Bim transcription. Importantly, apoptosis following loss of BCL-3 was 
dependent on the increase in Bim expression. Bim is a BH3-only protein that 
functions as a critical and potent pro-apoptotic regulator by binding to pro-survival 
BCL2 family members (reviewed in section 3.1.3). Bim has been shown to be an 
important regulator of apoptosis in colorectal tumour cells (311) although this study 




have BRAF mutations, implicating Bim as a critical regulator of apoptosis in a wider 
range of CRC cells, not only BRAF mutant CRC cells. Further investigation could 
be performed to assess whether KRAS WT, mutant or BRAF mutations alter the 
response to BCL-3 suppression in cancer cells. Given that BCL-3 functions as a 
co-regulator with atypical NF-B homodimers, investigations were performed to 
assess if suppression of NF-B1 and NF-B2 resulted in regulation of Bim. The 
results identified that Bim expression was increased following NF-B2 knockdown 
but not NF-B1. These data should be interpreted with the understanding that the 
siRNA targets the full-length NF-B1 or NF-B2 transcripts. Therefore, it may be 
that the effect of NF-B2 knockdown on Bim is driven by suppression of the full-
length NF-B2 rather than the processed p52 protein itself. Full length NF-B2 is 
known to have bona fide IB functions and the siRNA would target these functions 
(340).  
Given that Bim protein expression was increased by both BCL-3 and NF-B2 
suppression experiments, qRT-PCR was performed following BCL-3 suppression 
and showed upregulation of Bim mRNA. Therefore, in-silico analysis was 
performed to analyse the BCL2L11 gene for NF-B consensus sites, this was to 
enable primer design for ChIP analysis. The B consensus sites found on DNA are 
known to be specific to particular NF-B dimers (133, 135); although, it is unknown 
if BCL-3 alters which B consensus site the homodimers can bind to (whether 
interaction with BCL-3 can change the specificity of hetero- or homodimer binding). 
ChIP was performed to assess if BCL-3 and/or p52 bound to the regulatory regions 
of Bim previously implicated as important for its expression (153). Results indicated 
that BCL-3 was found at the Bim promoter alongside p52 in basal conditions. This 
led me to propose that BCL-3 may be repressing Bim transcription by binding to 




The findings suggest that supressing BCL-3 led to release of transcription 
repression and Bim transcription. The data presented above suggests that BCL-3 
suppression reduces cell viability despite expression levels of other BCL2 family 
proteins.  
This is the first data to show that apoptosis induced by BCL-3 suppression is Bim 
dependent in rectal cancer. Moreover, this is the first data to show that BCL-3 and 
p52 are found at the same NF-κB consensus site within the BCL2L11 gene 
promoter. Previous studies have shown that Bim transcription is repressed by non-
canonical NF-κB heterodimers through association with HDAC4, leading to 
resistance to apoptosis and therapy resistance (153). Results showed that histone 
3 acetylation increases following BCL-3 loss and it may be that BCL-3 is promoting 
repressive chromatin through facilitating histone modification (discussed in final 
discussion 5). Clinically, it is known that a proportion of tumours have upregulated 
BCL-3 expression which would be contributing to evasion of apoptosis and therapy 
resistance through Bim suppression and it may be that targeting BCL-3 in rectal 
tumours is attractive therapeutically. 
The data shown above have shown that BCL-3 suppression directly upregulates 
the pro-apoptotic BCL2 family protein Bim. Bim leads to apoptosis through binding 
to pro-survival members of the BCL2 family. The pro-survival BCL2 family 
members, such as BCL2 and BCL-xL, are drivers of colorectal tumorigenesis, 
progression and therapy resistance, highlighting these proteins as attractive 
therapeutic targets (341, 342). Inhibition of the pro-survival members of the BCL2 
family is possible using small molecule inhibitors (ABT-737, ABT-263 and ABT-
199) that occupy the hydrophobic pocket of BCL-2, BCL-xL and BCL-w, 
competitively inhibiting binding of the BH3 -helix and inducing apoptosis (339). It 
was hypothesised that the effect of Bim upregulation on apoptosis could be 




However, the data showed no additional effect of BCL2 inhibition when combined 
with BCL-3 knockdown. Though the mechanism is not determined, this could be 
because MCL-1 is highly expressed in these cell lines and it could be that MCL-1 
is driving the resistance to ABT-737 in these cells (345). The BCL2 inhibitors have 
similar efficacies for inhibiting BCL-2 members, except MCL-1, with later inhibitors 
(ABT-199) being more protein specific (346). Additionally, it may be that un-
sequestering Bim from BCL2 or BCL-xL, by using the ABT-737 (343), has no 
additional effect when Bim has been significantly upregulated by BCL-3 
suppression. Further work could assess if specific MCL-1 inhibition or use of a 
BCL2 inhibitor that also targeted MCL-1, resulted in increased sensitivity to 
apoptosis in cells following Bim upregulation by BCL-3 suppression.  
In summary, BCL-3 regulates Bim expression in colorectal cancer cells leading to 
increased apoptosis. It was shown that BCL-3 binds to the Bim promoter, alongside 
p52, where it appears to have a repressive effect on Bim transcription. 
Interestingly, there was no synergy or added effect of ABT-737 treatment in these 
colorectal cancer cell lines. As stated above there is preliminary evidence that 
BCL-3 suppression may increase chromatin accessibility. Chromatin remodelling 
drugs have been used to increase the efficacy of conventional drugs in cancer 
treatment (data for HDAC inhibitors for example has shown increased 
radiosensitivity in colorectal cancer cells) (347). This led to the investigation as to 
whether inhibition of BCL-3 function could alter the response of colorectal cancer 
cells to conventional therapy. Targeting BCL-3 in colorectal cancers would be an 






















In rectal cancer, patients are typically treated with DNA damaging agents such as 
irradiation and platinum-based drugs (oxaliplatin or cisplatin) (18). In locally 
advanced rectal cancer, the DNA damaging treatment is neo-adjuvant long course 
chemo-radiation. However, there are a significant proportion of patients who fail to 
respond to neoadjuvant therapy and as a result have significantly poorer prognosis 
(Introduction 1.2.1.2). Understanding what drives the response to DNA damaging 
therapy in tumour cells is critical to improving the efficacy of therapy and, with the 
utilisation of biomarkers, could lead to the stratification of patients into those who 
will benefit and should receive therapy and those who are poor responders and 
could progress straight to surgery. 
As well as its use as a therapeutic agent, cells are exposed to DNA damage 
through three main mechanisms, environmental agents (UV-radiation, ionising 
radiation and genotoxic chemicals), cellular metabolism and its associated 
products (ROS, hydroxyl radicals and H2O2) and the occasional spontaneous 
disintegration of some chemical bonds in DNA (hydrolysis of nucleotide residues 
and deamination of bases) (348). The outcomes of DNA damage are significant, 
including cell-cycle arrest (required to prevent replication of damaged DNA and 
propagation of the DNA damage to daughter cells through mitosis (349)), cell fate 
decisions (apoptosis if DNA damage is too severe and un-repairable) and 
alterations to gene transcription (350). Upstream of these cellular effects is a 
cascade of processes initiated by the DNA damage known as the DNA damage 
response (DDR). 
Critically, no single repair process can facilitate the repair of all the different types 
of damage and all pathways are highly conserved due to the existence of DNA 
damage from the very origin of DNA itself (348). There are four main DDR 




(NER, encompassing global genome NER (GG-NER) and transcription coupled 
NER (TCR)), error-free homologous recombination (HR) and error-prone non-
homologous end joining (NHEJ, encompassing canonical and alternative NHEJ). 
An additional DDR pathway is mismatch repair (MMR) which repairs incorrectly 
matched bases following replication and is important pathway when deranged in a 
number of cancers including CRC (351). These repair mechanisms can be broadly 
divided into repair pathways for single strand break (SSB) or double strand break 
(DSB), although there is significant overlap. DSB are significant lesions to 
overcome for the cellular DDR machinery and are highly toxic (352). 
DSBs are induced by irradiation, free-radicals, chemicals, replication fork collapse 
with SSB and during repair of inter-strand DNA crosslinks. Irradiation results in the 
formation of both simple and complex DSBs. Additionally, irradiation also results 
in large numbers of SSB and base abnormalities, which also necessitate repair via 
appropriate DDR pathways (353). Repair pathway choice is highly regulated 
following DNA damage. It is highly dependent on cell cycle phase (354), which 
controls which proteins are recruited to DSB to perform end resection or initiate 
end joining (355). HR requires template DNA to repair DNA with high-fidelity, 
restricting HR to S/G2 phases of the cell cycle. NHEJ operates throughout the cell 
cycle but is particularly dominant in G0/1. Additionally, the regulation of repair 
pathway choice is made through alterations in NHEJ and HR protein expression 
and protein PTM by cyclin dependent kinases (CDKs). CDKs mediate the 
phosphorylation of target genes (for example CtIP, EXO1), which results in the 
increased resection of DNA ends in cycling cells favouring the resection dependent 
pathways (HR, SSA and alt-NHEJ) (356). 
Pathway choice is also regulated by proteins such as 53BP1 and BRCA1; for 
example, 53BP1 is capable of blocking resection of DNA ends by preventing CtIP 




pathway choice and execution are isolated, actually, it should also be recognised, 
that repair pathways are intricately interlinked with many of the proteins performing 
roles in either repair pathway (ATM, MRN complex and BRCA1), providing cross-
talk between the two pathways to ensure that DNA is repaired if one fails or 
compete with each other for DSB sites (350, 357, 358). For example it is thought 
that alternative-NHEJ (alt-NHEJ) takes over from the HR pathway in HR-deficient 
tumours (359).  
Briefly, the DDR process involves the sensing of DNA damage, transduction of this 
signal and activation of effector proteins to alter cellular function (350). Initially, 
DSB sensing involves a number of different complexes depending on mechanism 
and type of damage (MRN complex, RPA complex, sirtuins, Ku complex and 
PARP1) (360). Activation of each complex results in alternate downstream 
signalling cascades and alternative mechanisms of repair (HR, c-NHEJ and alt-
NHEJ). Additionally, the kinetics of complex recruitment to DNA damage 
determines mechanism of repair (361). NHEJ proteins PARP1 and Ku70/80 are 
quickly and independently recruited to DSB sites (360), whilst recruitment of HR 
dependent proteins occurs over a slower timescale. 
Following lesion sensing, the PI3K-like protein kinases (PIKK) are activated 
creating a signal-transduction cascade. Proteins such as ATM (Ataxia 
telangiectasia mutated), ATR (ATM and Rad3-related) and DNA-PKcs (DNA-
dependent protein kinase)) are activated by DNA damage sensors. ATM, for 
example, is activated following binding to the MRN complex, where it is acetylated 
(by a co-factor, Tip60 (362)) and auto-phosphorylated (363). Activated PIKK 
proceed to phosphorylate a large number of substrate proteins including 
checkpoint control proteins and histones such as H2AX. 
H2AX is one of the core histones (H2B, H3 and H4 being the other members) 




has a S-Q-E motif, which is recognised by activated PIKK following DNA damage, 
leading to phosphorylation on serine 139 (then known as H2AX) (364-366). 
Inhibition of PIKK results in absent H2AX foci formation and absent irradiation 
induced foci (IRIF) downstream of H2AX (367); highlighting that H2AX 
phosphorylation is a critical early event that coordinates the DDR. H2AX formation 
is proportional to the quantity of radiation and maximal concentrations are seen at 
30 minutes following irradiation dose (368).  
 H2AX has several roles at DSB, including de-compaction of chromatin and 
recruitment of additional repair factors. Firstly, H2AX interacts with proteins, such 
as the SNF2/SWI2 family member, INO80 that remodel chromatin in the region of 
the DSB, in an ATP-dependent manner, to make it more accessible to the DDR 
machinery (369, 370).  Secondly, recruitment of MDC1 to H2AX is mediated 
through the BRCT domain in MDC1 (371). MDC1 is phosphorylated by ATM (372) 
and then coordinates the additional recruitment of large numbers of effector 
proteins such as RNF8 (373, 374), 53BP1 (375), RAD50 or Rad51 and BRCA1 
(367) into IRIF facilitating repair of the lesion. Measurement of H2AX foci and the 
IRIF associated with H2AX is a valuable tool in radiation biology research.  
4.1.1 BCL-3 and NF-κB in therapy response 
The role of BCL-3 in response to therapy is yet to be fully elucidated. As discussed 
previously (Introduction 1.6.4), BCL-3 is an important cell survival factor in 
colorectal tumours (240, 257). There is limited evidence on the role of BCL-3 in the 
response of cancers to DNA damaging agents. Studies in breast cancer cells 
showed BCL-3 over-expression was protective against DNA damage induced 
apoptosis following cisplatin and UV-C irradiation (239). Additionally, an RNAi 
study in C.elegans revealed that the BCL-3 orthologue, C04F12.3, played a role in 




proteins important in DDR such as BARD1, TIP60 (216) or HDAC1 (219), although 
how this interaction effects the DNA damage response has not been studied. 
These data highlight that if BCL-3 does play a role in the DNA damage response 
it may be well-conserved through different species. There is also evidence in a 
keratinocyte model of skin carcinogenesis that UV radiation induces the activation 
of BCL-3:p52 or BCL-3:p50 complexes within the nucleus of exposed cells; 
suggesting that BCL-3 may be part of an atypical NF-B dependent response to 
this DNA damaging agent (377). However, the impact of NF-B signalling is still 
being elucidated.  
Understanding of the NF-B signalling pathway in response to DNA is best 
understood in canonical signalling and poorly understood in non-canonical or 
atypical signalling. Genotoxic stress, such as the DSBs caused by irradiation 
(amongst other DNA damaging agents), results in activation of NF-B signalling 
(120, 378). The canonical NF-B pathway has been shown to be the principle 
pathway activated, which is consistent with the evidence that NF-B prevents 
apoptosis, promoting cell survival after cell stress. It appears that there are several 
different mechanisms by which canonical NF-B activation exerts its effects 
following irradiation. In response to DNA damage, canonical NF-B pathway 
subunits are directly activated in a mechanism dependent on ATM (Ataxia 
Telangiectasia Mutated) (379, 380). Additionally, it has been shown that canonical 
NFB pathway activation occurs as a result of mutations to DDR pathways within 
tumours, such as BRCA1 deficiency (124). The mechanism behind this is complex. 
It was initially examined in cells lacking functional ATM protein (AT cells), which 
failed to activate NF-B following treatment with DNA damage inducing agents 
such as IR, camptothecin or etoposide. This complemented work showing IB 
degradation was unchanged in AT cells, unlike control cells which showed early 




members involved include the IB kinase (IKK) complex, p50 and NEMO. The IKK 
complex is central to the activation of canonical NF-B signalling. Data from breast 
carcinoma cells has shown that DNA damage induced activation of ATM results in 
the NEMO dependent activation of p65 (381). This appears specific to ATM, as 
ATR and DNA-PKcs do not cause the same activation of NF-B. Further work 
showed that SUMOylated NEMO is phosphorylated by ATM at serine 85 (159), 
leading to its non-degradative ubiquitination, nuclear export (along with a 
proportion of ATM) and the subsequent activation of IKK and IKK; thereby, 
leading to activation of canonical NF-B signalling (159, 382). Moreover, PARP1 
plays a critical role in this model, acting as a scaffold to assemble ATM, PIASy and 
NEMO, leading to the signalling cascade as described (383). p50 is known to be 
phosphorylated on serine 329 leading to fine tuning of genes undergoing 
transcription by activated canonical heterodimers, although this may only occur in 
response to certain types of DNA damage (384, 385). Therefore, canonical NF-B 
activation, with subsequent upregulation of targets such as BCL2, CIAP2 and IL-8 
(386), is a critical and conserved response to DNA damage, particularly DSBs. 
What is the translation of these studies clinically? Data is contradictory from 
different cell types. Some studies suggest that levels of activated p65 do not predict 
response to radiation in rectal cancer patients (387). Whilst others have shown 
increased expression of canonical subunits, such as p65, in pre-therapy biopsy 
specimens correlated with shortened overall patient survival; although, p65 
expression again did not correlate with the clinical/pathological response to 
radiation (TRG) (386, 388). In other malignancies, such as glioblastoma, in patients 
with higher expression of activated canonical signalling proteins (phosphorylated 
p65) the response to radiation is reduced (389). Therefore, while p65 expression 
predicts overall survival and is upregulated by radiation, p65 expression does not 




survival independent of radiation response (itself a predictor of survival). Given the 
different outcome in different cancers, it is likely the effect is context specific. 
Other NF-B subunits have been implicated in radiation response in rectal cancer. 
In a small retrospective study, patients carrying a nucleotide polymorphism of the 
NF-B1 (p105/p50) gene promoter, rs28362491 (DEL/DEL) had an increased 
sensitivity to chemo-radiation (390). This polymorphism occurs 94bp upstream of 
the NF-B1 TSS and results in reduced expression of NF-B1 on stimulation by 
LPS (391). This suggests that reduced expression of NF-B1 following 
inflammatory stimuli may result in increased sensitivity to radiation in rectal cancer.  
There is clearly an exciting opportunity in understanding what role BCL-3 and the 
atypical NF-B signalling pathway play in response to radiation in colorectal 
cancer, given the paucity of data currently published. 
4.1.2 The tumour microenvironment and response to therapy 
The TM is a major component of malignancy, as mutated epithelial cells alone do 
not constitute a tumour (392). The TM represents the complex interaction between 
the malignant cells and other non-malignant cells (for example endothelial, immune 
and stromal cells) and proteins (393). Importantly there is a reciprocal relationship 
between these two populations (malignant and non-malignant) of cells with bi-
directional pro-tumour signalling contributing to therapeutic resistance of the 
malignant population (394). Large proportions of fibroblasts within cancers are 
thought to be cancer-associated fibroblasts (CAFs; also known as tumour-
associated fibroblasts, reactive stromal fibroblasts or peritumoral fibroblasts) which 
are perpetually activated by cancer cells through a paracrine mechanism (for 
example secretion of bFGF (basic fibroblast growth factor), PDGF (platelet derived 




cancers then become addicted to the CAF-derived signals within the TM leading 
to a positive feedback loop.  
CAFs are recognised to initiate and promote cancer progression, drive metastasis 
(396), epithelial-mesenchymal transition (EMT) of tumour cells and promote 
resistance to therapy, utilising cell-cell contact as well as the secretion of signalling 
molecules (397-399). The origin of CAFs is still controversial but they are thought 
to be derived from a number of different cell populations, from different tissues, 
including differentiation of resident fibroblasts or the recruitment of mesenchymal 
stem cells (MSC) but also may include adipocytes, stellate cells, pericytes and 
other circulating stem cells (400). CAFs can be identified by upregulation of 
markers such as -smooth muscle actin (SMA) (401), as well as S100A4, 
vimentin and fibroblast activation protein (FAP) (398). Morphologically, CAFs are 
distinct cells that have large spindle shapes with abundant stress fibres and well 
organised transmembrane associated fibronectin containing fibres connected to 
actin microfilaments (known as the fibronexus) (401). 
CAFs are thought to promote or be indicative of poorer outcomes or more 
aggressive tumour biology. Clinically, the expression of markers suggestive of a 
CAF phenotype in advanced CRC have been associated with higher rates of 
vascular invasion (402). Additionally, high expression of CAF markers such as -
SMA in CRC resulted in patients having a poorer OS (403) and high ratios of 
stromal cells to carcinoma cells is also associated with poorer prognosis and 
tumour recurrence in CRC (394). In rectal tumours the TM is thought to be 
important in the development of local recurrence following neoadjuvant therapy 
(404). Stroma with high expression of CAF markers (SMA, FAP, CD26 and 
SDF1) predicted tumour regrowth and therefore local recurrence in LARC following 
LCRT (405, 406). Neo-adjuvant therapy itself also leads to fibroblast activation 




Following irradiation fibroblasts secrete higher levels of growth factors such as 
HGF and FGF (408). Neo-adjuvant therapy also results is the significant formation 
of stroma or fibrosis within the TM, a feature that is measured using TRG (409).  
CAFs also directly propagate persistent inflammation within the tumour. CAFs are 
recognised to facilitate tumour-promoting inflammation through several 
mechanisms including direct production of pro-inflammatory chemokines/cytokines 
and the secretion of factors that attract multiple immune cell types into the tumour. 
This signalling results in direct upregulation a number of signalling pathways in 
tumour cells including NF-B (410, 411), PI3K/AKT and JAK/STAT3, which 
contributes to a variety hallmark capabilities (392). CAFs promote activation of 
these signalling pathways through secretion of a multitude of proteins; results from 
microarray data from pancreatic, skin, cervical and breast tumours showed 
significant upregulation of pro-inflammatory genes such as COX-2, IL-1, IL-6 and 
members of the CXCL family of chemokines, by the respective tissue specific CAF 
(410). IL-6 is a principal cytokine secreted by CAFs. IL-6 is a pleotropic cytokine 
that regulates cells by binding to the IL-6R leading to the recruitment and homo-
dimerisation of glycoprotein 130 (gp130) (412). This leads to phosphorylation and 
dimerisation of STAT3 and its translocation to the nucleus where it activates 
transcription of target genes. IL-6 signalling has effects on inflammation, immune 
cell coordination and haematopoiesis (413). In breast cancer it has been shown 
that IL6 is a key cytokine secreted from CAFs (414) while in colorectal cancer, 
CAF-derived IL6 stimulates proliferation of tumour xenografts (415). BCL-3 is 
known to be upregulated in a subset of colorectal cancers (240). However, the 
mechanisms driving BCL-3 upregulation in these tumours is not clear. BCL-3 is a 
STAT3 target and is therefore likely to be downstream of cytokines such as IL-6. 
IL-6 has been shown to consistently upregulate BCL3 in a bank of myeloma cell 




hypothesised that BCL-3 expression in CRC may be related to CAFs and to tumour 
response to radiation. 
4.1.3 Aims 
The aims of this chapter are to elucidate the role BCL-3 plays in the response of 
colorectal tumour cells to DNA damaging agents, such as irradiation or oxaliplatin, 
and understanding what role CAFs play in BCL-3 regulation of therapeutic 





4.2.1 BCL-3 expression may confer resistance to LCRT in rectal 
tumours 
BCL-3 has been shown to be upregulated in a subset of colorectal tumours but its 
effect on the response of tumours to therapy is unknown. To examine whether 
BCL-3 expression related to response to LCRT in rectal cancer, samples from the 
ASPIRE cohort study (IRAS 141548) (Appendix 1 for protocol) were used. Biopsy 
samples were obtained at diagnosis and tumour samples were obtained following 
surgical resection after neo-adjuvant LCRT. Patients were followed to assess 
response to therapy. Therapy response was analysed using the American Joint 
Committee on Cancer/College of American Pathologists (AJCC/CAP) tumour 
regression grade (TRG) by gastro-intestinal pathologists at each of the sites 
recruiting patients. The AJCC TRG (TRG 0-3, Appendix 3) classifies tumour 
response according to the ratio of remaining tumour cells and fibrosis in tumour 
samples (62). Biopsy and tumour samples were fixed in formalin and processed 
by Southmead Histology Department (Claire Blunt MSc). Immunohistochemical 
analysis was performed using antibodies to BCL-3 (Table 2.5). Preliminary results 
of a small initial group of patients (n=13) showed that BCL-3 staining appeared to 
correlate with response to LCRT (Figure 4.1), with minimal BCL-3 staining relating 
to a good response to irradiation (TRG1) while strong BCL-3 staining correlated 
with poor therapeutic response (TRG3). Despite these interesting results it is 
important to note that further analysis of the full cohort is ongoing and results will 
be analysed and published in full when available. However, these preliminary 
findings suggest that BCL-3 high expression may correlate with response to 
therapy and therefore may play a role in protecting tumour cells from LCRT in rectal 







Figure 4.1 BCL-3 expression in rectal cancers may predict response to neo-
adjuvant radiation  
To ascertain if expression of BCL-3 in rectal tumours correlated with TRG following 
neoadjuvant radiation in rectal cancers, samples were used from the ASPIRE cohort 
study. Biopsy and tumour samples were stained with antibody to BCL-3 and imaged using 
widefield light microscopy. BCL-3 staining was scored as none – 0, minimal – 1, moderate 
– 2 and strong – 3. TRG was assessed by pathologists at each participating centre of the 
ASPIRE cohort study. Preliminary results showed that in some patients BCL-3 expression 
correlated with TRG, high BCL-3 expression with high TRG. Results are exemplary data 




4.2.2 Optimisation of seeding densities for cell lines to be used in -
irradiation cell viability experiments 
The aim of the following experiments was to determine the impact of BCL-3 
expression on the radiation sensitivity of colorectal cancer cells. Leading on from 
earlier work, a high (SW1463) and low (SW837) BCL-3 expressing rectal cancer 
cell line was compared to colon carcinoma cells (HCA7/P and LS174T). I used an 
in-vitro model to assess cell viability following irradiation in combination with BCL-
3 knockdown as it had been identified that BCL-3 may play a role in response to 
irradiation in rectal tumours, from the ASPIRE study (Figure 4.1). To maintain cells 
in an actively growing phase the seeding density of cells into plates was critical. 
Therefore, optimisation of seeding densities in 6 well plates was performed. 
Figure 4.2 Seeding densities for crystal violet cell viability assay in colorectal tumour 
cells 
Colorectal cancer cells SW1463, HCA7/P, LS174T and SW837 were seeded into 6-well 
plates at two weeks from seeding cells were fixed with 4 % paraformaldehyde and stained 
with crystal violet. Cell density was picked so that cells were not over or under confluent at 




Colorectal tumour cells SW1463, HCA7/P, LS174T and SW837 were seeded out 
in a series of increasing seeding densities into 6-well plates. Cells were grown for 
two weeks as I wanted to be able to analyse both the early and late effects of 
radiation on cell viability, following this growth phase cells were fixed with 4 % 
paraformaldehyde and stained with crystal violet (0.5 % w/v). Plates were scanned 
and assessed for confluence. It was observed that the seeding density required for 
each cell line would be cell line dependent. For future experiments cell lines were 
seeded at a density of between 0.5x104 or 2x104. 




4.2.3 Radiation dose response rates in 4 colorectal cancer cell lines  
As future experiments would combine BCL-3 suppression and irradiation, further 
experiments would determine the radiation dose that reduced the cell yield 
between 20-50 %. This would ensure a dose of radiation that did not result in too 
greater cell viability reduction and would facilitate measurement of the effect of 
BCL-3 suppression in conjunction with the effect of the radiation. Using the seeding 
densities obtained from previous experiments (Figure 4.2) further crystal violet cell 
viability assays were performed with a broad range of radiation doses (1, 2.5, 5 
and 10 Gy). Cells were seeded into 6-well plates and grown for 2 days before being 
exposed to the specified doses of --irradiation from a Cs137 source. After two 
further weeks of growth, cells were fixed with 4 % paraformaldehyde and stained 
with crystal violet (0.5 % v/v), crystal violet was eluted with acetic acid (10 % v/v) 
and absorbance measured with a microplate reader set at 594 nm. Results are 
summarised in Figure 4.3. Typically, 1 or 2.5 Gy resulted in between 20-50 % 
reduction in cell viability as measured by crystal violet. Interestingly, it was noted 
that the LS174T cell line were more radio-resistant than the other cell lines as 5 Gy 
resulted in a 10-50 % reduction in cell viability (depending on seeding 
concentration of cells) compared to SW1463, HCA7/P and SW837 cells where 
5 Gy resulted in a >50 % reduction in cell viability. Additionally, it was noted that 
seeding density affected viable cells at the same radiation dose. LS174T cells 
treated with 5 Gy had a range of around 10 % reduction in cell viability when cells 
were seeded at 2x104/well, but a 40-50 % reduction in cell viability when seeded 
at 0.5x104/well. HCA7/P cells also showed a similar effect at both 2.5 and 5 Gy. 
These data show that irradiation response is both cell line and seeding 






Figure 4.3 Sensitivity of colorectal cancer cells to -irradiation 
To ascertain the sensitivity of colon and rectal cancer cells to -irradiation at different 
seeding doses, cells were seeded into 6-well plates and after 48 hours exposed to radiation 
from a Cs137 source. After 2 weeks cells were fixed with 4 % paraformaldehyde and a crystal 
violet cell viability assay was performed. Measurement of crystal violet absorbance was 
made at 594 nm using a microplate reader and normalised to the un-irradiated controls. It 
was noted that LS174T cells were consistently more resistant to irradiation that the other 
colorectal cancer cells. HCA7/P cells were relatively radiosensitive and therefore a higher 
seeding density was utilised. Results are means of n = 2 biological replicates with errors 





4.2.4 BCL-3 knockdown sensitises colorectal cells to -irradiation 
BCL-3 has been shown to promote tumour cell survival in-vitro and over-
expression, in the tumour, is known to confer worse survival in patients with 
colorectal cancer (240, 257). Previous work has identified that BCL-3 promotes 
survival in rectal cancer cells (Results 3.2). Patients with rectal cancers that are at 
high risk of local recurrence (Introduction 1.2.1) are typically treated with pre-
operative chemo-radiation. The question remained as to whether BCL-3 
expression protected colorectal cancer cells from the effects of irradiation. Using 
optimised conditions of seeding density and radiation dose from previous 
experiments (Figure 4.2 & Figure 4.3), colorectal tumour cells, with high BCL-3 
expression (LS174T, HCA7/P and SW1463), were transfected with BCL-3 siRNA 
(50 nM) and 48 hours following transfection were exposed to -irradiation (1 and 
2.5 Gy). Cells were then fixed with 4 % paraformaldehyde and a crystal violet cell 
viability assay performed. Protein lysates were collected at 48 hr from pairs of 
transfected cells to confirm efficiency of knockdown. 
Results are summarised in Figure 4.4. It was observed that BCL-3 knockdown 
decreased cell viability, as shown previously. When colon and rectal cancer cells 
were subjected to combined  -irradiation and BCL-3 suppression there was a 
significant additional reduction in cell viability compared to non-targeting siRNA 
controls (Figure 4.4). Data for LS174T and HCA7/P colon carcinoma cells showed 
the increase in radio-sensitivity was significant at both 1 and 2.5Gy (Figure 4.4 A 
&B); however, SW1463 rectal cancer cells showed significant increase in radio-
sensitivity at 1 Gy but a non-significant increase in radio-sensitivity at 2.5 Gy 
(Figure 4.4 C). This may be due to the high sensitivity of SW1463 cells to BCL-3 
knockdown. Western blot showed that BCL-3 expression was significantly reduced 




Importantly, these data suggest that BCL-3 suppression may result in increased 
radio-sensitivity, at low doses of radiation (1 and 2.5 Gy). These data suggest that 
BCL-3 could play an important role in radioprotection of colorectal tumour cells 





Figure 4.4 BCL-3 knockdown increases radio-sensitivity in colorectal cancer cells 
Colorectal cancer cells LS174T, HCA7/P and SW1463 were transfected with BCL-3 siRNA 
(50 nM) and at 48 hours following transfection exposed to -irradiation from a Cs137 source. 
Cells were fixed at 2 weeks following transfection and a crystal violet cell viability assay 
was performed. Additionally, protein lysates were collected at 48 hours following 
transfection to assess for knockdown efficiency at the time of irradiation exposure. Results 
showed that BCL-3 siRNA reduced cell viability compared to control siRNA following -
irradiation at two clinically relevant doses. Knockdown was confirmed using western blot. 
Graphs show means and SD of combined data from three independent experiments. 
Statistical analysis was performed on Graphpad Prism 7 software using ANOVA (*:P<0.05, 







4.2.5 BCL-3 suppression sensitises to oxaliplatin, a DNA damage 
inducing agent used in the management of rectal cancer 
Clinically, oxaliplatin has been shown to be efficacious in the management of 
colorectal cancers (417). Oxaliplatin is a platinum-containing drug (other platinum-
containing drugs include cis-platin or carboplatin, see Figure 2.2 Platinum-based 
chemotherapy compounds) that induces DNA inter and intra-strand crosslinks that 
lead to SSB or DSB if these SSB are encountered by replication forks (277). To 
examine if BCL-3 suppression decreased cell viability in combination with this 
alternative DNA damaging agent, rectal cancer cells (SW1463) were transfected 
with BCL-3 siRNA (50 nM) or non-targeting siRNA and then treated with oxaliplatin 
(1-100 M) at 48 hr following transfection, for a duration of 24 hr after which 
medium was replaced with DMEM. At 1 week from transfection cells were fixed 
with 4 % paraformaldehyde and stained with 0.5 % v/v crystal violet (Methods 
2.3.2). Measurements of absorbance were made at 594 nm and summarised in 
Figure 4.5. Results showed that BCL-3 knockdown reduced cell viability of 
SW1463 rectal cancer cells following low doses of oxaliplatin (1 μM) but not at 
higher doses of oxaliplatin (10-100 μM) (Figure 4.5 A). Western analysis was used 
to confirm suppression of BCL-3 protein at 48 hours following transfection (Figure 
4.5 B). 
These results in a single cell line suggest that the effect of BCL-3 suppression on 
cell viability following DNA damage may not be limited to -irradiation. This 
suggests that BCL-3 expression is important in DDR and understanding this role 
is important as it may have implications for patient response to therapy. To 
examine if radio-resistance could be induced by increasing BCL-3 expression, 






Figure 4.5 BCL-3 knockdown sensitises rectal cancer cells to an alternative DNA 
damaging agent, oxaliplatin. 
SW1463 rectal cancer cells were treated, 48 hours following transfection (50 nM BCL-3 
siRNA), with oxaliplatin for 24 hours total. Cells were fixed and stained with crystal violet 
at 72 hours following oxaliplatin treatment. Results identified that BCL-3 suppression 
sensitised to oxaliplatin at low doses (1 μM) but not at higher doses, where the effect of 
oxaliplatin on cell viability was more pronounced (A). Protein lysates were obtained at 48 
hours following transfection and analysed using western blot to assess for knockdown 
efficiency (B). Graphs represent combined mean fold change in cell viability from 4 




4.2.6 BCL-3 stable overexpression in a low basal expressing BCL-3 
rectal cancer cell line 
SW837 rectal cancer cells have low basal expression of BCL-3 (Results 3.2.1) and 
so were used to determine if over-expression of BCL-3 resulted in resistance to 
radiation. Plasmids used were BCL-3WT, BCL-3ANK M123 (kind gift from Alain Chariot, 
Liege Belgium) and BCL-3GFP in a pcDNA 3.1 plasmid (Origene, USA). 
Additionally, BCL-3WT and BCL-3ANK M123 constructs were FLAG tagged to enable 
efficient pulldown if IP experiments were to be performed. BCL-3ANK M123 is a full 
length BCL-3 gene with 3 point mutations in the region of the 1st and 2nd ankyrin 
repeats, which inhibits binding of BCL-3 to p50 or p52 (218). BCL-3GFP is a full 
length BCL-3 gene tagged with c-terminal turbo-GFP. 
Plasmids were transfected into SW837 cells and cultured for three days (Methods 
2.2.2). Thereafter, DMEM with 10 % FCS medium was supplemented with G418 
400 μg/mL to select transfected cells followed by 200 μg/mL G418 to maintain cells 
long-term. Populations were grown up from an A flask and a B flask to create 
individual cell lines before being split and expanded. To assess expression of 
endogenous and exogenous protein, cell lysates were collected from each cell line 
generated, for each plasmid and western blot used to analyse BCL-3 expression. 
It was observed that BCL-3 was over-expressed in SW837 cells as shown in Figure 
4.6. BCL-3WT was expressed as a characteristic multi-band protein, at a 
significantly higher amount compared to endogenous expression in the empty 
vector cells. In comparison to BCL-3WT, BCL-3GFP was detected at a significantly 
slower migrating band, highlighting the GFP tagged protein was retarded in the 
gel. Expression of BCL-3ANK M123 protein was shown to result in a faster migrating 
single band, which did not appear to undergo post-translational modification as 




Importantly, there was no observed differences in BCL-3 expression levels 
between clone A or B suggesting these cell lines could be considered as biological 
replicates for each other when validating future experimental results. In preliminary 
work it was observed that the BCL-3GFP and the BCL-3ANK M123 did not grow any 
differently to the BCL-3WT cells and so it was decided that only the BCL-3WT stable 
over-expression cells would be taken forward into future experiments.  
 
  
Figure 4.6 BCL-3 over-expression in the SW837 rectal cancer cell line 
BCL-3 was stably over-expressed in the SW837 rectal cancer cell line, which has low basal 
levels of BCL-3. To achieve this, SW837 cells were transfected with a pcDNA3 plasmid 
with an empty vector, WT BCL-3, WT BCL-3 with GFP or mutant BCL-3. Plasmids 
contained a geneticin/neomycin (G418) selection vector and cell lines that had taken up 
the plasmid were selected with 400 μg/mL G418. Protein lysates were collected following 




4.2.7 BCL-3 stable over-expression in rectal cancer cells does not 
alter cell viability following -irradiation  
Using the SW837 BCL-3WT cell line generated (Figure 4.6), it was possible to 
examine if BCL-3 over-expression had a radio-protective effect in rectal cancer 
cells. SW837 cells with either stably expressed control pcDNA3.1 plasmid or WT 
BCL-3 plasmid, were grown in 6-well plates at a seeding density of 1x104 per well. 
Plates were then exposed to -irradiation (Cs137 source, 1 and 2.5 Gy) and medium 
was changed every 3-4 days. After 2 weeks of culture (mirroring previous 
experimental conditions Figure 4.4), plates were fixed with 4 % v/v 
paraformaldehyde and stained with crystal violet (0.5 %v/v). Absorbance was 
measured at 595 nm. Protein lysates were collected from parallel T25 flasks and 
western blot performed to confirm over-expression. Results showed that over-
expression of BCL-3 did not confer statistically significant increase in radio-
resistance to SW837 rectal cancer cells (Figure 4.7). Therefore, further 
experiments were not performed. It maybe that despite the over-expression of 







Figure 4.7 SW837 stably over-expressing BCL-3 does not protect cells against -
irradiation induced cell death 
Rectal cancer cells SW837 were stably transfected with WT BCL-3 pcDNA plasmid or 
control plasmid. Stably over-expressing SW837 cells were seeded into plates and 48 hours 
after seeding irradiated using a Cs137 source (1 and 2.5 Gy). Cells were cultured for 2 
weeks following irradiation before being fixed with paraformaldehyde (4 % v/v) and stained 
with crystal violet (0.5 % v/v). Results show no statistical difference in sensitivity to either 
radiation dose, in SW837 cells over-expressing BCL-3. Protein lysates were collected from 
parallel flasks of BCL-3 WT and control plasmid cells and over-expression confirmed with 
western analysis. Data shown is mean and SD of n = 2 independent experiments. Statistical 
analysis was performed on GraphPad Prism 7 software using ANOVA (* :P<0.05, ** : 




4.2.8 Automated spheroid area analysis accurately measures 
colorectal cancer spheroids embedded in Matrigel and is 
comparable to manual spheroid diameter measurement 
To test cellular response to irradiation in a model that better recapitulated aspects 
of the 3D tumour microenvironment by enabling cell polarisation (apical and basal 
cell polarity), cell-cell contact and cell-ECM contact, a 3D tumour spheroid model 
was utilised. These models are suggested to bridge the gap between 2D in-vitro 
models and in-vivo animal models (418). 3D spheroid models are commonly used 
to culture ex-vivo intestinal crypt cells as initially described by Sato et al (275). 
However, these models do not allow for quantification aside from rudimental 
analysis of spheroid diameter or a subjective assessment of size/number of 
spheroids. To facilitate these experiments, initially automation of the spheroid size 
assessment was developed; this would enable accurate, high throughput analysis 
of experimental data. Single cell suspensions of cancer cell lines were seeded into 
50 μL Matrigel domes, in 24 well plates. Cells were allowed to form early organised 
spheroids before being imaged on a widefield microscope (schematic shown in 
Figure 4.8 A with an exemplary SW1463 spheroid shown in B). Z-stack images 
were obtained that ensured each spheroid within the microscope field was imaged 
with its widest diameter in focus. Images were then processed either manually to 
measure individual spheroid diameter or through a MATLAB script (Appendix 6) 
that measured each individual spheroid area. Optimisation of seeding density was 
performed for SW1463 cell lines, to enable analysis of individual spheroids, rather 
than spheroids clumped together. Results showed that spheroids seeded at a 
lower seeding density (200 cells/50 μL of Matrigel) were easier to analyse using 
the automated area analysis tool; it was also observed that spheroids at 200 




at 400 cells/50 μL (Figure 4.8 C), which was likely to be due to media utilisation by 
the higher number of spheroids at the end of the experiment. 
 
  
Figure 4.8 Automated spheroid area analysis in the rectal cancer cell line SW1463 
SW1463 rectal cancer cells were grown as 3D spheroids in Matrigel. Single cell suspension 
was mixed with Matrigel to achieve a seeding density of either 200 or 400 cells per 50μL 
or Matrigel. Cells will form spheroids in Matrigel through a process of cell division combined 
with polarisation (A) (adapted from Pampaloni et al), leading to early organised SW1463 
spheroids with a hollow lumen (B). To ascertain if the automated spheroid area analysis 
was comparable to the manual diameter measurement SW1463 rectal cancer cells were 
seeded into Matrigel (400 or 200 cells per 50 μL). Spheroids were measured using a digital 
ruler on the Leica Application Suite Lite software or a custom MATLAB script (Appendix 6) 
at day 4, 8, 13, 19 and 21. Results showed that there was no difference in relative size 
between the two seeding densities. Interestingly it was noted that the lower seeding density 
grew faster later in the experiment (day 19 and 21) (C). Data shown is the dual analysis of 
a single experiment with manual diameter measurement and automated area 









4.2.9 BCL-3 expression in cells grown in 3D culture conditions 
Following optimisation of the 3D culture conditions necessary for high throughput 
image analysis, I sought to determine if endogenous BCL-3 expression was altered 
when grown in 3D culture conditions and with 3D culture medium (275, 419). 
SW1463 and LS174T cells were grown initially in 2D culture but grown with either 
standard 2D medium of DMEM with 10 % FCS or 3D medium, Advanced DMEM 
(ADM/F12) supplemented with N2, B27 and N-acetylcysteine (NAC). Western 
analysis was performed on protein lysates collected form sub-confluent cells after 
48 hr of growth in either medium. The results showed that growing cells in 3D 
culture medium (while in 2D culture flasks) did not change the expression of BCL-
3 (Figure 4.9 A). Having observed that the 3D medium did not alter expression of 
BCL-3 in cells grown in flasks, investigations were performed to identify if BCL-3 
expression in spheroid culture was altered. A panel of colon and rectal cancer cell 
lines (HCA7, HT29, HCT116, HCT15, SW480, SW620, LOVO, LS174T, SW837 
and SW1463) were seeded from a single cell suspension into Matrigel (density of 
500 cells per 50 μL) and allowed to grow for 14 days. Cells were harvested from 
the Matrigel (Methods 2.5.2.3) and lysed in cell lysis buffer as per 2D culture 
lysates. Western analysis was performed, where it was observed that relative BCL-
3 expression between cell lines was comparable to the expression of BCL-3 
observed in the 2D western blots (Figure 4.9 B). In 3D, high BCL-3 expressing 
cells were HCT116, LOVO, LS174T and SW1463; low BCL-3 expressing cells 
were HT29, HCT15, SW480, SW620 and SW837. These data suggest that relative 
expression between cancer cells lines in 3D is comparable to 2D cultures. As 
previous experiments showed that exogenous over-expression of BCL-3 failed to 
induce radio-resistance in rectal cancer cells; the aim was to analyse if stimulation 




physiologically relevant stimulation of BCL-3 expression was considered important 





Figure 4.9 BCL-3 expression in 3D culture conditions in a panel of colon and rectal 
cancer cell lines 
BCL-3 expression was initially examined in 2D flasks but using the 3D culture medium 
(ADM/F12 with N2, B27 and N-acetylcysteine) compared to standard medium (10% 
DMEM). Protein lysates were analysed by western blot and results showed that BCL-3 
expression was not affected in SW1463 or LS174T colorectal cancer cells grown in either 
medium in 2D (NB both bands are BCL-3) (A). BCL-3 expression was then examined in 
colorectal cancer cells grown for 14 days in 3D culture. Cells were separated from the 
Matrigel extracellular matrix and protein lysates produced. Western analysis was 
performed, where it was observed that BCL-3 expression could be detected and that 
relative protein expression between cell lines was comparable to the 2D BCL-3 screen 
(Figure 3.1) (B). It should be noted that it was not possible to collect a protein lysate from 





4.2.10 Fibrosis is a principal component of response to radiation in 
rectal cancer  
Fibrosis is a principal response to neoadjuvant radiation utilised in LARC (409). 
The assessment of proportion of fibrosis as a ratio to remaining tumour volume 
determines the regression grade of a tumour (TRG). Current guidance advocates 
the use of the AJCC/CAP (American Joint Committee on Cancer/College of 
American Pathologists) TRG for assessment of rectal cancers, where it has been 
shown to predict prognosis with tumours showing a good response (65, 420). The 
hypothesis was that radiation induces fibrosis in tumours which may lead to 
upregulation of BCL-3. To assess the proportion of rectal cancers that exhibited 
fibrosis following irradiation, tissue samples were used form the ASPIRE cohort 
study (IRAS 141548, REC 08/H0107/74, NIHR CRN portfolio ID16024). This study 
collected tissue from patients undergoing neo-adjuvant chemo-radiotherapy for 
locally advanced rectal cancers. Tumour response grade (TRG) is a 
histopathological grading system that measures the proportion of tumour replaced 
by fibrosis following neoadjuvant LCCRT. 92 specimens from the ASPIRE cohort 
study were assessed for their response to radiation by local pathologist and graded 
using the AJCC TRG system (TRG 0 no viable tumour cells, TRG 1 moderate 
response - single or small groups of tumour cells, TRG 2 minimal response - 
residual cancer outgrown by fibrosis, TRG 3 poor response – minimal or no tumour 
cells killed). Formalin-fixed paraffin-embedded (FFPE) samples were sectioned to 
5 m and stained with haematoxylin and eosin (H+E). A total of 92 patients were 
enrolled in the ASPIRE study. Results showed that TRG status correlated with 
Dukes stage (classification of tumours based on T, N and M-stage combined), T-
stage and N-stage of resected tumours (Figure 4.10). Those tumours with a lower 
TRG had a much higher likelihood of being node negative and of a lower T-stage, 




infiltrates were clearly seen in the majority of specimens examined. These results 
also highlight that residual tumour (TRG2 and TRG3, that has undergone 
incomplete regression) becomes incarcerated within fibrosis or fibro-inflammatory 
tissue (Figure 4.10). Previously shown data (Figure 4.1) identified that BCL-3 
expression in tumour biopsies may predict response to LCCRT. Following 
irradiation, the role of the fibrotic stroma in promoting BCL-3 expression is 
unknown. In the 6-8 weeks of interval between LCRT and surgery it is highly likely 
that the ongoing interaction between tumour cells and the surrounding stromal cells 
is deleterious, but the biological result of this incarceration is incompletely 
understood. Remaining tumour cells are surrounded by fibrosis which may 
promote BCL-3 expression worsening patient prognosis. Therefore, the aim was 
to model this interaction in-vivo to understand the possible role of CAFs in BCL-3 






Figure 4.10 Fibrosis is a major component of the response to radiation in rectal 
cancer and closely related to pathological tumour stage 
Samples and data from the ASPIRE prospective observational cohort study (IRAS 141548, 
REC 08/H0107/74, NIHR CRN portfolio ID16024) was analysed. 92 patients were enrolled 
and TRG, T-stage, N-stage and Dukes stage was determined in surgical resection 
specimens following LCRT. Results showed that TRG was closely related to pathological 
staging (A-C). As TRG increased there were Dukes stage increased with more C1 and C2 
tumours in the TRG2 and TRG3 specimens (A), as well as more advanced T-stage (B) and 
fewer node negative specimens (C). H+E staining was performed on tumour specimens 
and exemplary slides shown for each grade with areas enlarged for comparison. Results 
of the staining highlight that with increasing response tumour tissue is replaced by fibrosis 
or fibroinflammatory tissue. TRG0 specimens show tumour completely replaced by fibrosis. 
TRG1 and TRG2 specimens show tumour surrounded by fibrosis. TRG3 are tumours with 








4.2.11 BCL-3 expression is upregulated by IL-6 in rectal cancer cells  
BCL-3 is a target of STAT3 signalling and is therefore downstream of cytokines 
such as IL-6. IL-6 is considered to be one of the principle cytokines released by 
activated fibroblasts. The hypothesis was that BCL-3 expression is upregulated by 
IL-6 secretion by fibroblasts into the media. To analyse if BCL-3 expression was 
responsive to IL-6 cytokine treatment, rectal cancer cells were treated with IL-6 
(25ng/mL). Cells were seeded in 2D and treated with IL-6 while still sub-confluent; 
cells were harvested for analysis 2, 4, 6, 8 and 24 hr following treatment and 
analysed for mRNA abundance and protein expression using qRT-PCR and 
western blot respectively. Results showed that there was a significant induction of 
BCL-3 mRNA following IL-6 treatment and increased protein expression of BCL-3. 
STAT3 phosphorylation was confirmed following IL-6 treatment. These results 
suggest that the rectal cancer cell line SW1463 is responsive to IL-6 treatment 
leading to upregulation of BCL-3, which is potentially due to STAT3 activation. 
CAFs present in irradiated tissue secrete IL-6, upregulating BCL-3; in spheroid 
cultures, it was hypothesised that CAFs may increase the growth of CRC spheroids 






Figure 4.11 Rectal cancer cells upregulate BCL-3 in response to IL-6  
SW1463 rectal cancer cells were treated with IL-6 (25ng/mL). mRNA and protein were 
analysed for upregulation at 2, 4, 6, 8 and 24 hr following IL-6 treatment. Results show that 
IL-6 induces BCL-3 expression at both the mRNA level and protein level particularly at the 
8 and 24 hr post-treatment timepoints, n of 1. pSTAT3 was used to show activation of the 





4.2.12 Investigating the role of CAFs on 3D growth and sensitivity to 
irradiation 
Fibroblasts are a principle component of the TM. Predominantly, fibroblasts are 
found in the TM as the more aggressive CAF phenotype, which promotes tumour 
progression, growth and metastasis. Evidence suggests that CAFs modulate NF-
B signalling but with no investigation into the regulation of BCL-3 (410). To 
examine the effect of fibroblasts on BCL-3 expression in 3D culture, a co-culture 
model of colorectal cancer cells and fibroblasts is described. Co-culture of 
fibroblasts with colorectal cancer spheroids in collagen scaffolds is reported to 
mimic expression and morphology observed in in-vivo tissue (411). However, it 
was unknown if introducing colonic fibroblasts into the 3D CRC model, in Matrigel, 
would result in viable fibroblast cells and/or change in spheroid growth. There was 
scarce previous data regarding fibroblasts seeding density, therefore, low numbers 
of fibroblasts were seeded with the standard CRC 3D protocol (described 
previously) and spheroid growth was measured over time. Fibroblasts that had 
previously been isolated, by previous members of the group, from human 
colorectal cancers were grown until 50-60% confluent in T75 flasks before being 
made into a single-cell suspension. Fibroblasts were seeded into Matrigel at 
different densities (none, 25, 50, 100 and 200 fibroblasts per 50 L) while CRC 
cells were seeded at the standard 200 cells per 50 L Matrigel. Spheroids were 
measured at 7 and 11 days following seeding into Matrigel using widefield 
microscopy, as before, and analysed with an in-house spheroid area assessment 
programme. Results showed that spheroids from CRC cells (SW1463) grew no 
differently when co-cultured with and without fibroblasts (morphological images 
shown are exemplary images from day 11 spheroids). Spheroid growth was 
unaffected by the low numbers of fibroblasts seeded into co-culture as shown at 




remained as single cells or becoming doublets whilst remaining embedded within 
the Matrigel. These data suggest it is possible to combine colonic fibroblasts within 
the current 3D CRC spheroid model and measure growth of the CRC spheroids as 
previously described. Further experiments were required to assess if increasing 





Figure 4.12 Colorectal cancer spheroids grow normally when co-cultured with low 
numbers of colon fibroblasts 
Colorectal cancer cells SW1463 were co-cultured with colorectal fibroblasts JW. Cancer 
cells (200 cells/50 μL) and fibroblasts (0, 25, 50, 100 and 200 cells/50 μL) were suspended 
as a single cell suspension in Matrigel and supplemented with ADM/F12 media. Growth 
was assessed at 7, 11 and 14 days after seeding using widefield microscopy and an in-
house automated spheroid assessment protocol. Data showed that low numbers of 
fibroblasts co-cultured with colorectal cancer cells did not alter the growth or formation of 
the cancer spheroids. Data shown here is from a single independent experiment with all 
data points shown. Data was log normally distributed and median and interquartile ranges 




4.2.13 Growth of SW1463 colorectal cancer spheroids is increased in 
co-culture with fibroblasts 
Having shown already that the addition of small numbers fibroblasts into a 3D 
spheroid model did not alter growth of spheroids, experiments were conducted to 
examine if increasing the number of fibroblasts in co-culture increased growth. 
SW1463 colorectal cancer cells (200 cells per 50 μL) were seeded with JW 
fibroblasts (500 cells per 50 μL) and spheroid growth was assessed at 7-, 11- and 
14-days following seeding using widefield microscopy and an in-house automated 
imaging programme. Results showed that there was a small but consistent 
increase in spheroid size over the experimental time-period (Figure 4.13 A+B). It 
was observed that at the day 7 timepoint spheroids in co-culture with JW fibroblasts 
were significantly larger with a 40 % increase in growth compared to control (Figure 
4.13 B). Growth of SW1463 spheroids increased when co-cultured with fibroblasts 
at day 11 and day 14 from seeding, which was not statistically significant, 
suggesting that fibroblasts may be able to enhance growth. However, as the 
number of epithelial cells increases the fibroblasts are overwhelmed, exhausting 
the growth effect. Given the small increases in growth observed in these 
experiments I wanted to know the effect of activating the fibroblasts (to a cancer-






Figure 4.13 Colorectal cancer spheroids require higher numbers of fibroblasts in co-
culture to initiate increases in spheroid growth 
SW1463 colorectal cancer cells were seeded into 3D culture in Matrigel in conjunction with 
JW fibroblasts. Fibroblasts were seeded as single cells at 500 cells per 50 μL and SW1463 
at 200 cells per 50 μL of Matrigel and supplemented with ADM/F12 media. Growth was 
assessed at 7, 11 and 14 days after seeding using widefield microscopy and an in-house 
automated spheroid assessment protocol. Data showed that there were small increases in 
spheroid size over the 2 weeks of culture which was significant at 7 days following seeding. 
Data shown here is the combined medians/ IQR from 2 independent experiments with >30 
spheroids measured per experiment. Statistical analysis was performed on GraphPad 






4.2.14 Growth of rectal cancer spheroids (SW1463 and SW837) is 
increased with activated fibroblasts 
Cancer associated fibroblasts are activated through paracrine TGF- signalling 
within the tumour microenvironment (421). This leads to upregulation of proteins 
that act as biomarkers for this activation, particularly SMA. It is recognised that 
CAFs are the predominant phenotype of fibroblasts found within the TM. Previous 
experiments have shown that co-culture of fibroblasts with CRC spheroids resulted 
in a small, but statistically non-significant, increase in spheroid growth. To examine 
if activating fibroblasts increased growth of CRC spheroids co-culture experiments 
were designed with fibroblasts treated with TGF (10 ng/mL). Fibroblasts were pre-
treated with TGF in T75 flasks for 72 hr prior to being trypsinised, counted and 
seeded (500 cells/50 μL) with SW1463 or SW837 (200 cells/50 μL) in co-culture 
(Methods 2.1.4). Co-cultures were supplemented with ADM/F12 media 
supplemented with N2, B27 and NAC (see methods) and changed three times a 
week. Additionally, fibroblasts treated with either TGF or vehicle control were 
collected for protein extraction and analysed using western blot to investigate 
fibroblast activation. Western blot confirmed that expression of SMA was 
increased in fibroblasts treated with TGF compared to control fibroblasts. CRC 
spheroid growth was assessed using an in-house spheroid area assessment 
programme. Results showed that spheroid growth increased when co-cultured with 
TGF activated fibroblasts and compared to vehicle control treated fibroblasts. 
Results are summarised in (Figure 4.14). Statistical analysis of the data showed in 
SW1463 spheroids significantly increased growth with TGF treated fibroblasts 
compared to control at 14 days growth (Figure 4.14 A). SW837 spheroids also 
grew faster with TGF treated spheroids and showed significantly increased 
growth at day 11 (Figure 4.14 B). These data suggest that activated fibroblasts 




conditions. Further experiments were performed to assess if this was a single 
fibroblast cell line effect.  
 
  
Figure 4.14 Rectal cancer cells co-cultured with activated fibroblasts have increased 
growth 
Rectal cancer cells were co-cultured in Matrigel with activated fibroblasts or un-treated 
fibroblasts. JW fibroblasts were transformed into an activated phenotype using TGF 
(10 ng/mL) for 72hr prior to seeding into co-culture with colorectal cancer cells. CRC cells and 
fibroblasts were seeded as single cells in Matrigel and medium (ADM/F12 + supplements) was 
changed every 2 days to ensure that nutrients were not depleted by the co-culture conditions. 
Spheroids formed from rectal cancer cells and spheroid area was measured at days 7, 11 and 
14 from seeding into Matrigel using an in-house automated spheroid area assessment tool. 
Data shown is from n=3 independent experiments (individual experiments measured >30 
spheroids per condition per time-point). Median spheroid area was combined and fold change 
in spheroid area (TGF compared to control treated fibroblasts) at each time-point was 
analysed. Statistical analysis was performed on GraphPad Prism 7 software using students t-






4.2.15 Activated fibroblasts from normal and sporadic cancers 
potentially promote growth of SW1463 rectal spheroids 
JW fibroblasts were isolated from a patient with a germline APC mutation, leading 
to FAP syndrome. To determine if activated fibroblasts from normal colon (SW 
fibroblasts) and from a sporadic colon carcinoma (SC and CM fibroblasts) also 
promoted spheroid growth further co-culture experiments were performed. 
Fibroblasts were seeded into T75 flasks and grown to 50-60 % confluence at which 
point the fibroblasts were supplemented with TGF or vehicle control. Fibroblasts 
were cultured for 72 hr in these media. For co-culture experiments in Matrigel, 
fibroblasts were trypsinised and counted prior to being seeded with SW1463. 
Fibroblasts were seeded at 500 cells per 50 μL Matrigel alongside cancer cells at 
200 cells per 50 μL Matrigel. Co-cultures were supplemented with ADM/F12 media 
supplemented with N2, B27 and NAC (Methods 2.1.4) and changed three times a 
week. Spheroids were measured at day 7, 11 and 14 from seeding of the co-
cultures and images analysed using the spheroid area assessment programme. 
As before, the results showed that the SW fibroblasts induced increased growth of 
SW1463 spheroids, particularly at the day 14 time-point following seeding (Figure 
4.15). Co-culture with CM and SC fibroblasts resulted in a reduced effect. It should 
be noted that this data is the median values from single biological replicates and 
statistical analysis was not performed. These preliminary results suggest that the 
effect on spheroid growth from fibroblasts in 3D co-culture was not limited to JW 
fibroblasts and is likely to be independent of the germline mutation in APC that the 





Figure 4.15 Co-culture of SW1463 rectal cancer spheroids with alternative 
fibroblasts results in increases in spheroid sizes. 
Further fibroblast lines were assessed for their effect on spheroid growth when embedded 
in co-culture with SW1463 rectal cancer spheroids. CM (sporadic) and SW (normal) colonic 
fibroblasts were treated as previously with TGF or VC for 72 hr prior to being seeded at 
500 cells per 50L in Matrigel with SW1463 cells. Results showed that these alternative 
fibroblasts from non-FAP backgrounds induced increased growth of rectal cancer 
spheroids, particularly at day 14 from seeding. Data shown is preliminary data showing 
median values with interquartile range and all data points, from single experiments with 
>60 spheroids measured per condition at each time-point. Data was analysed in Graphpad 





4.2.16 Co-culture of colorectal cancer spheroids with fibroblasts does 
not alter radiation sensitivity of the cancer spheroids 
In irradiated tumours, fibroblasts undergo activation and secrete growth factors and 
cytokines that contribute to tumour proliferation and invasiveness (408). 
Additionally, previous data showed remaining tumour cells are surrounded by 
fibroblasts in rectal cancers, that have not had a pCR (Figure 4.10). Given that co-
culture of fibroblasts increased tumour spheroid size, investigations were 
performed to determine if co-culture with fibroblasts altered the radiosensitivity of 
colorectal cancer cells in this 3D spheroid culture system. To test this, the rectal 
cancer cell line SW1463 was co-cultured with SW or SC fibroblasts in Matrigel. 
SW1463 cells were seeded at 200 cells per 50 L alongside fibroblasts at 500 cells 
per 50 L. ADM/F12 medium (supplemented with B12, N2 and NAC) was changed 
every two days throughout the course of the experiment. Spheroids were irradiated 
on day 7 of culture following initial imaging. Spheroids were then imaged on day 
11 and day 14 (4 and 7 days following irradiation) to assess spheroid growth. 
Spheroid area was assessed using an in-house automated programme. Data 
showed conflicting results for each fibroblast cell line used. When SW1463 
spheroids were co-cultured with SW fibroblasts, spheroids were more resistant to 
radiation when not activated by TGF (Figure 4.16). Whereas, spheroids co-
cultured with SC fibroblasts showed greater resistance to radiation when 
fibroblasts had been activated by TGFβ, although both were non-significantly 
different to their un-irradiated controls. Firstly, this suggests that the role of 
activated fibroblasts depends on the origin of the fibroblast but also suggests that 
different fibroblasts may respond differently to irradiation itself leading to alterations 
in effect on the cancer cells. It may also suggest that TGF activation of fibroblasts 
is variable. Therefore, despite activation of fibroblasts in this co-culture system 




continued without co-culture of fibroblast, but with conditioned media, to increase 






Figure 4.16 Rectal cancer spheroids co-cultured with fibroblasts have increased 
radioresistance  
SW1463 rectal cancer cells were co-cultured as before with SW fibroblasts in Matrigel. 
Spheroid size was measured on days 7, 11 and 14 from seeding and analysed with an in-
house spheroid assessment programme. Media was changed every 2 days through-out 
the experiment. Results showed that after 2 weeks growth in co-culture SW1463 spheroids 
grown with fibroblasts were more resistant to 2.5Gy radiation (Day 14 A+B+D). Co-culture 
with TGF treated fibroblasts resulted in Data shown is three independent experiments 
with each experiment containing two technical replicates (n=>30 spheroids measured per 
condition per time point). To determine fold change for each condition per time-point, 
values were compared to control spheroids at day 7. Statistical analysis was performed on 





4.2.17 Conditioned media from activated fibroblasts results in a small 
increase in growth of rectal cancer spheroids 
Fibroblasts secrete a variety of factors that mediate epithelial tumour cell function 
in a paracrine mechanism (397). Due the limits of co-culture in Matrigel (Matrigel 
lost significant structure with high fibroblast numbers) conditioned media was used 
to increase the concentration of soluble factors in the media that could potentially 
regulate spheroid growth. Previous experiments showed around an 20% increase 
in spheroid growth when spheroids were co-cultured with fibroblasts after 2 weeks 
of growth. Data from other groups that has shown that fibroblasts embedded within 
100% Matrigel signal in a predominantly paracrine manner to other cell types 
embedded within the Matrigel, as the fibroblasts have limited mobility in this ECM. 
To examine if the effect on spheroid growth was due to paracrine signalling within 
this 3D system conditioned medium was used. Conditioned media (CM) was 
collected from activated JW fibroblasts following treatment for 72 hr with TGF 
(creating TGF CM) or collected from non-activated fibroblasts treated with vehicle 
control only (VC CM). Fibroblasts were seeded into T75 flasks and grown to 50-
60 % confluence (approx. 1x106-1x107 cells) at which point the fibroblasts were 
supplemented with TGF or VC media. Fibroblasts were cultured for 72 hr in these 
media before being washed with 12 mL PBS (wash off media components and 
TGF not found in 3D media). Activated fibroblasts were then supplemented with 
3D spheroid media (ADM/F12 and supplements) for 24 hr. Media was collected 
and centrifuged at 3000 rpm for 3 min to remove any cellular debris. Media was 
syringe filtered with a 20 μm filter to sterilise and stored at 4C. SW1463 rectal 
cancer cells were seeded at 200 cells per 50 μL Matrigel and supplemented with 
TGF CM or VC CM. Results showed that there were increases in SW1463 
spheroid area at all time points (7, 11- and 14-days following seeding) (Figure 




significant increases in relative spheroid size at day 11 (TGF CM spheroids larger 
by 45 % SD +/-6 %, p=0.006 compared to VC CM) and day 14 (TGF CM 
spheroids larger by 20 % SD +/-4 %, p=0.016 compared to VC CM). Using CM 
allows for increased concentration of soluble factors from fibroblasts rather than 
the low levels produced from 500 fibroblast cells in co-culture, which resulted in 
increased spheroid growth. These results suggest that fibroblasts signal to tumour 





Figure 4.17 Conditioned media from activated fibroblasts increases growth of 
SW1463 rectal cancer spheroids 
SW1463 were seeded into Matrigel at 200 cells per 50 μL and supplemented with 
conditioned media (CM) every 2 days for the duration of the experiment. Conditioned media 
was obtained from JW fibroblasts following 72 hr treatment with TGF (TGF CM) or 
vehicle control (VC CM) and sterilised using a 20 μm syringe filter. TGF CM and VC CM 
was stored at 4C for the duration of the experiment. Spheroid growth was measured using 
widefield microscopy and assessed using an in-house automated programme. SW1463 
spheroid areas increased with TGF CM compared to control (A). On days 11 and 14 from 
seeding fold change increased significantly in TGF CM treated spheroids (B). Data shown 
here is the combined median spheroid area (A) and the fold change in spheroid median 
spheroid size at each time-point (B) of n=3 independent experiments. Statistical analysis 
was performed on GraphPad Prism 7 software using ANOVA (* :P<0.05, ** : P<0.01, *** : 






4.2.18 BCL-3 expression is promoted by treatment with conditioned 
media from fibroblasts in a rectal cancer cell line 
Activated fibroblasts are recognised to secrete several pro-inflammatory cytokines 
and growth factors including IL-6. BCL-3 was shown to be upregulated by IL-6 
(Figure 4.11), consistent with previous reports (195). Previous experiments 
showed that CM from fibroblasts resulted in increased spheroid growth of SW1463 
cancer cells. To test if CM upregulated BCL-3, SW1463 rectal cancer cells were 
grown with either normal medium (10 % DMEM), ADM/F12 (supplemented with 
B12, N2 and NAC), conditioned media from vehicle control treated fibroblasts (VC 
CM) or conditioned media from TGF treated fibroblasts (TGF CM). Conditioned 
media was made as before by growing fibroblast cells in flasks until 50-60 % 
confluent, following which fibroblasts were treated with either vehicle control or 
TGF. After 72 hr incubation with drug, cells were washed twice with PBS and 
ADM/F12 (with supplements) was conditioned for 24 hr. SW1463 cells were 
seeded into flasks and grown to 50-60 % confluence at which point media was 
changed to experimental media as described. Cells were grown on experimental 
media for 24 hr before protein lysates were obtained. Lysates were analysed using 
western blot and blots probed with antibodies to BCL-3 and α-Tubulin. Results 
showed that BCL-3 expression was upregulated by treatment with both VC CM 
and TGF CM from the JW and SW fibroblast cell lines but not the SC fibroblasts, 
compared to spheroid medium control (Figure 4.18). These data suggest that BCL-
3 is partially responsive to secreted factors from both non-activated and activated 
(TGF treated) fibroblasts in SW1463 rectal cancer cells. It may be that expression 
of BCL-3 in tumour cells is partially controlled by the stromal compartment in-vivo. 
It was of interest that BCL-3 was upregulated by both VC CM and TGF CM 




why spheroid growth seen in earlier experiments is similar between activated 
(TGF treated) and non-activated (VC treated) fibroblasts. 
 
  
Figure 4.18 BCL-3 expression is increased following exposure to CM from VC or 
TGF treated fibroblasts 
SW1463 rectal cancer cells were grown with either DMEM 10 %, ADM/F12 
(supplemented), conditioned media from vehicle control treated fibroblasts (VC CM) or 
conditioned media from TGF treated fibroblasts (TGF CM) for 24 hr. Conditioned media 
was harvested from JW, SW and SC fibroblasts. At 24 hr protein was harvested for analysis 
using western blot. Results showed that there were increases in BCL-3 expression 
increased with both VC CM and TGF CM from the JW and SW fibroblasts lines. There 
was no increase in BCL-3 with either CM from SC fibroblasts. Western blots are exemplary 




4.2.19 BCL-3 suppression in 3D cultures was not possible using siRNA 
Previous results had shown transient transfection with BCL-3 siRNA resulted in 
radiosensitivity of colorectal cancer cells in 2D (Results 3.2). To determine if siRNA 
transfection of BCL-3 in 3D spheroid cultures increased sensitivity to radiation, 
SW1463 rectal cancer cells were grown in Matrigel. Cells were cultured until 
spheroids formed and were subsequently transfected with BCL-3 siRNA (50 nM) 
vs control siRNA. 48 hr following transfection spheroid cultures were exposed to -
irradiation (2.5 Gy) as per the 2D experimental methods (422). Spheroid areas 
were measured the day following radiation and every two to three days after. 
Protein and RNA was collected and analysed to verify suppression. Results 
showed that following transfection of spheroids in 3D there was a transient 
reduction in BCL-3 mRNA at 48 hr from start of transfection (Figure 4.19 A). BCL-
3 protein expression was then examined following isolation of protein from 
spheroid cultures with results showing that BCL-3 expression was unchanged by 
siRNA transfection (Figure 4.19 B). Not surprisingly, when growth of spheroids was 
assessed following transfection with siRNA and combined with irradiation it was 
shown that there was a robust reduction in spheroid size with irradiation but siRNA 
transfection had no effect (Figure 4.19 C). These results suggest that BCL-3 
transfection in 3D is currently not possible and further work is required to improve 
the efficiency of siRNA in 3D spheroid cultures. Additionally, shRNA in an inducible 
system failed to work, despite considerable effort (data not shown). Therefore, I 






Figure 4.19 Transfection of spheroids with BCL-3 siRNA in 3D does not alter 
radiation sensitivity 
BCL-3 was suppressed in 3D spheroid culture of SW1463 and LS174T. siRNA (50 nM) in 
lipofectamine RNAiMAX was placed on spheroids already in culture for 24 hr. Spheroids 
were irradiated 48 hr after initiation of transfection with 2.5 Gy -irradiation from a Cs137 
source. Growth of spheroids was measured using widefield microscopy and an automated 
area assessment MATLAB code and showed that treatment with siRNA targetting BCL-3 
confered no added radiosensitivity (A). There was clear statistically significant (***) 
decrease in spheroid size with radiation in both contol and BCL-3 siRNA treated spheroids 
compared to their un-irradiated controls. Western analysis of protein from 3D spheroid 
cultures showed that BCL-3 protein expression was not suppressed in SW1463 cells, 
which was confirmed with trial in a second cell line (LS174T) (B). Analysis of BCL-3 mRNA 
showed a statistically significant transient decrease in BCL-3 mRNA at 48 hr following 
transfection (C). Spheroid growth is exemplary data from n = 2 experiments (A). Western 
blots are exemplary from n = 2 experiments (B). mRNA abundance data is means with SD 
of n = 2 experiments (C). Statistical analysis was performed on GraphPad Prism 7 software 






4.2.20 BCL-3 inhibitors did not significantly reduce rectal cancer 
spheroid size 
An alternative approach to suppression of BCL-3 signalling was to use novel 
inhibitors of BCL-3 (a kind gift from Dr. R Clarkson, Cardiff University). These 
inhibitors function by blocking the interaction of BCL-3 ankyrin repeat domain with 
either p50 or p52 NF-B subunits (personal communication). Two inhibitors were 
obtained BCL-3iA and BCL-3iB. It was noted that BCL-3iB, but not BCL-3iA, was 
highly unstable as multiple freeze-thaw cycles resulted in reduced efficacy of the 
compound. Storage and use of BCL-3iB was tightly controlled as a result of these 
findings; however, it was not possible to obtain comparative biological replicates 
and therefore data for the BCL-3iB is not shown. 
Initially, a dose response to BCL-3iA was performed in SW1463 rectal carcinoma 
cells grown in spheroid culture. SW1463 cells were seeded in Matrigel as a single 
cell suspension at 200 cells/50 L Matrigel. Spheroids were allowed to organise 
before being treated with BCL-3iA every two days for the length of the experiment 
(14 days) and imaged on day 7, 11 and 14 from seeding. Spheroid area was 
assessed using an automated MATLAB script (Appendix 6). Results showed that 
there was a small, dose dependent but non-significant decrease in spheroid size 
most apparent at the final timepoint of 14 days (Figure 4.20 A). It was observed 
that there was a maximal level of spheroid growth suppression at 10 μM, 
suggesting that 10 μM would be the most appropriate dose to take forward into 
irradiation experiments. 
Additionally, these data appeared to corroborate cell yield experiments performed 
in 2D culture that showed BCL-3 knockdown reduced cell yield (data not shown). 
As no significant effect on spheroid size could be determined using the inhibitors, 
further work is being performed with the focus ablating BCL-3 in colorectal cancer 





Figure 4.20 BCL-3 inhibitor non-significantly reduces growth of SW1463 rectal 
cancer spheroids 
SW1463 cells were seeded into Matrigel and grown as 3D spheroids. Spheroids were 
treated every 48 hr, for the duration of the experiment with BCL-3 inhibitor (BCL-3i). 
Spheroids were imaged on day 7, 11 and 14 following initial seeding. It was observed that 
increasing concentrations of BCL-3iA reduced the area of SW1463 spheroids (A), however 
this was not significant for all doses compared to control (DMSO) treated spheroids. The 
data suggested the effect was most pronounced following 14 days of treatment and 
statistical analysis was performed at this timepoint. Exemplary images following automated 
image assessment are shown (spheroids over-layed in a pink mask following analysis) (B). 
Spheroid area data are means of 4 independent experiments. Image data are exemplary 
data from the automated image analysis pipeline (n=4). Statistical analysis was performed 





4.2.21 Analysing the effect of BCL-3 expression on the DNA damage 
response 
4.2.21.1 BCL-3 suppression promotes increased and persistent 
H2AX foci formation following radiation in HCA7/P colon 
cancer cells 
DNA damage results in the formation of irradiation induced foci (IRIF). 
Phosphorylation of H2AX occurs early in the cellular response to DSBs at the site 
of damage, and measurement of the H2AX foci can be used as a measure of 
radiation sensitivity of cancer cells, as those cells with impaired DDR have 
persistent H2AX foci formation (423). As such H2AX foci formation provide a 
valuable and robust readout of DDR function. 
Following difficulties in regulating BCL-3 in spheroid culture, it was decided to 
investigate the effect of BCL-3 expression on the DNA damage response (DDR) 
which could be performed in 2D culture. Therefore, the effect of BCL-3 suppression 
on the DNA damage response following -irradiation was analysed by assessing 
H2AX foci formation. HCA7/P cells were chosen as they have high levels of BCL-
3, are responsive to combined BCL-3 suppression and irradiation and are relatively 
easy to image due to their large nuclei (Figure 4.4). BCL-3 was suppressed using 
siRNA in HCA7/P cells grown on coverslips in 6 well plates (Methods 2.2.1). Cells 
were irradiated at 48 hr following transfection with 2.5 Gy and compared to control 
un-irradiated cells. Cells were fixed with 4 % paraformaldehyde for 10 minutes, 
permeabilised using 0.01 % TritonX for 5 minutes and blocked with 1 % BSA for 
30 minutes, prior to being stained with H2AX antibody and DAPI (1:10000). 
Coverslips were mounted onto slides using mowiol with DABCO and dried 
overnight in the dark. Cells were imaged using confocal microscopy and mean 




that BCL-3 knockdown significantly increased the number of foci per nucleus at 
30 min after radiation exposure compared to control (Figure 4.21). Interestingly, 
BCL-3 suppression appeared to increase both the speed at which foci were formed 
after radiation (0 min time-point) and led to persistent H2AX foci (higher numbers 
of H2AX foci in BCL-3 suppressed cells at 6 hr and 24 hr compared to control 
siRNA), although these data was not statistically significant at these later time-
points. (Figure 4.21). Representative immunofluorescence images are shown for 
each condition analysed (Figure 4.21).  
Therefore, these data show for the first time that BCL-3 suppression results in an 
increase in H2AX foci formation at 30 min following -irradiation, which suggests 
that BCL-3 may be involved in DSB repair. 
 
 
Figure 4.21 BCL-3 knockdown increases phosphorylated H2AX (H2AX) foci 
formation following -irradiation 
HCA7/P were transfected with BCL-3 siRNA or control siRNA on glass coverslips in 6 well 
plates and exposed to radiation 48 hr after transfection. Cells were fixed at the time-points 
shown 0 hr, 0.5 hr, 6 hr and 24 hr (0 hr time-point was placed on ice straight from irradiator 
and lysed immediately) and stained using H2AX antibody and DAPI. Cells were imaging 
with a confocal microscope and H2AX foci were counted per nuclei (n>30 nuclei per 
condition) and mean foci per nuclei analysed. Analysis of HCA7/P cells showed increases 
in initial foci formation, a higher maximal number of foci and prolonged foci formation in 
cells with BCL-3 suppression after treatment with irradiation. Only the 30 min maximal time-
point was statistically significant for increased maximal foci formation in HCA7/P cells. 
Confocal images for HCA7/P represent foci formation at 30 min following exposure to 
irradiation in control and BCL-3 siRNA transfected cells. Data is from triplicate experiments 
combined. Statistical analysis was performed on GraphPad Prism 7 software using ANOVA 







4.2.21.2 BCL-3 suppression increases H2AX formation in 
SW1463 cells 
The role of BCL-3 is known to be context and cell type specific. Therefore, to 
determine whether this was a cell specific phenomenon a second colorectal cancer 
cell line was analysed. SW1463 rectal cancer cells were treated as previously 
(Results 4.2.21). In addition to the steps outlined before, coverslips were coated 
with poly-L-lysine due to SW1463 cells adhering poorly to coverslips. Coverslips 
were treated for 30 minutes with 0.001 % poly-L-lysine before being dried and used 
as above. SW1463 cells were fixed and analysed at the 30-minute post-irradiation 
time-point, the time-point were H2AX foci formation was observed to be 
statistically significantly increased following BCL-3 suppression in the HCA7/P cell 
line. It was observed that BCL-3 suppression significantly increased the mean foci 
per nucleus in irradiated SW1463 cells. Interestingly, it was also noted that while 
unirradiated control siRNA cells showed very low numbers of H2AX foci, 
unirradiated BCL-3 knockdown cells showed increased numbers of H2AX foci. 






Figure 4.22 Rectal cancer cells SW1463 demonstrate increased H2AX foci after 
BCL-3 suppression and irradiation. 
SW1463 rectal cancer cells were transfected with BCL-3 siRNA or control siRNA on glass 
coverslips in 6 well plates and exposed to radiation (2.5 Gy) 48 hr after transfection. Cells 
were fixed at 0.5 hr following the end of irradiation. Cells were stained using H2AX 
antibody and DAPI. After mounting coverslips on glass slides using mowiol, cells were 
imaging with a confocal microscope. H2AX foci were counted per nuclei (n>30 nuclei per 
condition) and mean foci per nuclei analysed. Analysis of SW1463 cells showed increased 
foci/nuclei in cells with BCL-3 suppression after treatment with irradiation. Confocal 
images for SW1463 cells represent foci formation at 30 min following exposure to 
irradiation in control and BCL-3 siRNA transfected cells. Data is from two independent 
experiments combined. Statistical analysis was performed on GraphPad Prism 7 software 




4.2.21.3 Does BCL-3 inhibit homologous recombination? 
Further investigations were performed to analyse the mechanism by which BCL-3 
suppression increased radiation sensitivity. PARP inhibitors are known to be highly 
effective in cells with defective components of the HR DSB repair pathway (424). 
BCL-3 suppression was shown to increase the magnitude of H2AX foci formation 
at 30 minutes following radiation, suggesting a defect in DSB repair. It was 
hypothesised that If BCL-3 suppression increased the sensitivity of cells to PARPi 
this may suggest that BCL-3 was regulating HR. 
To test this hypothesis, BCL-3 was suppressed using siRNA (50 nM) in suspension 
in 24 well plates in SW1463 cells, as these cells were high BCL-3 expressing cells 
and showed increases in H2AX foci following irradiation (Figure 4.22). At 48 hours 
following transfection cells were treated with the PARPi, veliparib (ABT-888), for 
24 hours following which cells were transferred back onto normal medium. Cell 
viability was measured 96 hours following PARPi treatment (425), using a crystal 
violet stain (Methods 2.3.2) and quantified with a spectrophotometer at 594 nm. It 
was observed that BCL-3 suppression did not sensitise SW1463 cells to PARPi 
(Figure 4.23). PARPi treatment resulted in a reduction in cell viability at a dose of 
>10 M in SW1463 for both non-targeting and BCL-3 siRNA treated cells. 
These data suggest that as BCL-3 knockdown does not sensitise cells to PARPi, 
the mechanism by which BCL-3 suppression increases radiosensitivity may not be 
through HR. The mechanism by which BCL-3 promotes radiation resistance is yet 






Figure 4.23 BCL-3 suppression does not sensitise rectal cancer cells to Veliparib 
(PARP inhibitor) 
SW1463 rectal cancer cells were transfected with BCL-3 siRNA or control siRNA and 
following 48 hr of transfection treated with Veliparib (PARPi) or vehicle control. Veliparib 
was used at logarithmic concentrations (0.01, 0.1, 1, 10 and 100 M). Cell viability was 
measured 4 days following drug treatment using a crystal violet assay. Results showed that 
BCL-3 suppression did not sensitise cells to PARPi. Data shown is combined data from 
n=2 independent experiments. Statistical analysis was performed on GraphPad Prism 7 





The aim of this chapter was to investigate the role of BCL-3 in irradiation in rectal 
cancers using both ex-vivo tissue specimens, in-vitro and spheroid models of rectal 
cancer. Initial observations, from rectal cancer tissue biopsies collected as part of 
the ASPIRE study, suggested that BCL-3 expression in tumour biopsies correlated 
with the subsequent response of the tumour to LCCRT, as measured by the AJCC-
CAP TRG (Appendix 3 American Joint Committee on Cancer/College of American 
Pathologists Tumour Regression Grade). These preliminary results from the 
ASPIRE study and work is ongoing to analyse the whole cohort of patients’ 
biopsies to assess whether there is a correlation between BCL-3 expression and 
therapeutic response. However, this result was sufficiently interesting to 
investigate whether BCL-3 expression conferred resistance to irradiation induced 
cell death. 
BCL-3 is thought to be upregulated by IL-6 through STAT3 (195). In the tumour 
microenvironment CAFs are recognised to secrete IL-6. Further data from the 
ASPIRE cohort study showed that in those tumours with a partial response to 
irradiation, cancer cells are surrounded by dense fibrotic tissue. 3D models of 
colorectal cancer are thought recapitulate some of the features found within the 
tumour microenvironment, including cell-cell interactions and cell matrix 
interactions (418). Therefore, to examine if BCL-3 was regulated by fibroblasts in-
vitro, a cancer spheroid model was developed. Results from the cancer spheroid 
model showed that there were small increases in spheroid growth when co-
cultured with fibroblasts or fibroblasts that had undergone activation with TGF. 
However, the co-culture of CAFs with cancer spheroids did not result in resistance 
to irradiation of the spheroids. Previous data has shown that stromal cells 
contribute to therapy resistance in-vivo and in-vitro (426). The model used in 




low numbers of fibroblasts with the tumour spheroids. This was due to utilisation 
of media components and disruption to the matrix with large number of fibroblasts 
(images not shown). Additionally, it was not possible to determine BCL-3 
expression in the spheroids when in co-culture with fibroblasts due to being unable 
to separate the two cell types for western blot and being unable to examine BCL-
3 expression by confocal due to antibody limitations. Given that the CAFs were 
thought to be signalling to the cancer spheroids in a paracrine mechanism (427), 
further investigation was performed to see if conditioned media from fibroblasts 
could promote growth of cancer spheroids in this 3D system. Results identified that 
conditioned media increased spheroid growth and that when cells were cultured 
with conditioned media in 2D there was a small increase in BCL-3 expression. 
Further investigation is necessary to analyse if BCL-3 is upregulated at the 
transcriptional level, using qRT-PCR, following growth in 2D or 3D spheroids with 
fibroblast conditioned media. Additionally, as CM experiments showed a greater 
effect on growth, work could be performed to analyse the effect of fibroblast 
conditioned media on the radiation response of rectal cancer spheroids. Although, 
this data would have to be interpreted with caution as the BCL-3 dependent effect 
on radiation response would likely be minimal given the small increases in BCL-3 
expression observed after spheroids were grown in conditioned media. 
The 3D spheroid model was also limited as it was not possible to knockdown BCL-
3 using siRNA. As we described in the published report (422), it was possible to 
introduce fluorescently tagged siRNA into spheroids but this did not result in robust 
changes in mRNA levels (only at 48 hr) or importantly protein levels. The key 
feature of this model is to have spheroids that grow before inhibiting BCL-3 activity 
combined with irradiation. Therefore, methods that induce permanent knockdown 
(shRNA) or knockout (CRISPR) of BCL-3 may not be suitable for these 




efficiency as well (Legge et al, 2018 accepted in Disease Models and Mechanisms 
with revisions). Ideally, an inducible system such as a doxycycline-inducible 
shRNA could be used to induce knockdown of BCL-3 prior to additional treatments 
such as irradiation. Additionally, it was found that over-expression of BCL-3 did not 
induce radioresistance within rectal or colon (preliminary data not shown) tumour 
cells. BCL-3 is a highly post-translationally modified protein, particularly by 
phosphorylation (203), and it could be that the over-expressed protein does not 
have the same level of modification in a saturated system. Alternatively, it could be 
that despite normal process and PTM of BCL-3, over-expression of BCL-3 occurs 
in a system where BCL-3 is already saturated, leading to no additional function 
with over-expression. The use of a novel BCL-3 inhibitor failed to increase radiation 
sensitivity in the rectal cancer spheroid model. These inhibitors are thought to 
inhibit the interaction between BCL-3 and atypical NF-κB homodimers. Currently, 
it is not clear if the effect of BCL-3 on radiation sensitivity is dependent on its 
function as a transcriptional co-regulator with atypical NF-κB subunits or through 
an alternative function. Given the BCL-3 inhibitor failed to induce sensitivity to 
radiation it is suggested that the mechanism of action may be NF-κB independent. 
In summary, the 3D spheroid model is a useful model to examine the regulation of 
cancer spheroid growth by other cell types in conjunction with treatments such as 
irradiation. Further work also needs to be completed to examine the phenotype of 
CRC spheroids with fibroblast conditioned media and irradiation. 
Following the observation from tumour biopsies that BCL-3 expression correlated 
to TRG, cell viability assays were performed using RNA interference of BCL-3 to 
investigate if suppression of BCL-3 in rectal cancer cells led to an increase in 
radiation sensitivity. Importantly, results from this chapter show that BCL-3 
knockdown in-vitro induces radiosensitivity in rectal and colon cancer cells, 




cancers. This corroborates other published work which has shown that BCL-3 
suppression sensitises cells to other types of DNA damaging agents, such as UV 
radiation (239) or alkylating chemotherapy (428). In one of these studies the 
mechanism was p53 dependent, which is unlikely to be the case in the cell lines 
investigated here, which have either WT or mutant p53. Interestingly, stable over-
expression, performed in a rectal cancer cell line with low basal expression of BCL-
3, failed to induce resistance to radiation. The reason why increased expression 
had no effect may principally be as a result of prior saturation of BCL-3 interacting 
partners such as atypical NF-κB homodimers (discussed in Introduction 1.6.5), 
alternative transcriptional regulators or possibly histone modifiers. Furthermore, to 
examine the effect of BCL-3 in radiation in more detail, experiments were 
performed to analyse H2AX foci formation after irradiation in cells with loss of 
BCL-3. BCL-3 knockdown increased H2AX foci significantly following irradiation 
compared to control. Phosphorylation of H2AX or H2AX is a key regulatory event 
in the DDR (367, 368). H2AX foci formation following irradiation are a critical 
measure of a cells’ sensitivity to irradiation, as cancer cells that clear H2AX foci 
quickly being more resistant to irradiation (429, 430).  
The use of DNA damaging agents in rectal cancer is a mainstay of current therapy. 
However, there is significant failure of therapy in some patients with poor or absent 
response to therapy (Introduction 1.2.1.2). Local recurrence rates in rectal cancer 
have been significantly reduced with optimisation of surgical technique and 
addition LCCRT. However, overall survival and disease-free survival have not seen 
such significant improvements. Response to therapy is a marker of better 
prognosis for patients with rectal cancer and so perhaps now the focus should be 
on improving the TRG to give patients the best prognosis. The data presented here 




radiation and other DNA damaging agents and therefore identifying clinically 



















Colorectal cancer remains a major source of mortality in westernised nations, 
particularly the UK. Rectal cancer is the most common anatomical location of CRC 
and while surgery remains the principal therapeutic option, in LARC, patients are 
offered pre-operative chemoradiation. This therapy aims to reduce local 
recurrence and induce tumour regression, which confers with it an improved 
prognosis. Critically, a large proportion of patients fail to respond to this therapy, 
leaving them at risk of the side effects and the sequelae from therapy itself but also 
with a worse prognosis. Stratification of patients into those who will respond to 
therapy and those who will not respond would enable patient treatment to be 
tailored. Additional therapy could be instigated in those patients who were not 
expected to respond, improving treatment efficacy and tumour regression, leading 
to better prognosis. The atypical IκB protein, BCL-3, is a co-regulator of NF-κB 
transcription. It is known to be upregulated in a subset of colorectal cancers, with 
high expression of BCL-3 also known to confer a poorer prognosis for patients 
following therapy (240, 241); however, its role in the survival and response to 
treatment of rectal cancer was unknown. The aim of this project was to investigate 
the role of BCL-3 in evasion of apoptosis and therapy response in rectal cancer. 
Data shown here identifies that suppression of BCL-3 expression (regulated by 
fibroblasts from the tumour microenvironment in a paracrine manner) could 
increase the therapeutic response in rectal cancer patients. 
5.1 BCL-3 and apoptosis 
The aim of the first chapter was to understand the role BCL-3 plays in apoptosis. 
Recent data, from this group, showed BCL-3 to be anti-apoptotic in colon cancer 
cells (257). Evasion of apoptosis is a critical hallmark of malignancies and enables 
cell proliferation to go unchecked (224). The investigations described here 
identified that BCL-3 is found at the BCL2L11 promoter alongside p52, where it 




histone acetylation, leading to downregulation of Bim transcription and evasion of 
apoptosis. It has been shown previously that BCL-3 functions to repress 
transcription through interaction with HDACs (162, 219, 231). Interestingly, 
previous studies have shown that Bim transcription is repressed by non-canonical 
NF-B heterodimers, p52:RelB, in association with HDAC4 (153). This led to 
resistance to apoptosis, promoting drug resistance (153) and propagated 
autoimmunity by blocking apoptosis in immune cells (431). There is also evidence 
from a BCL-3 knockout mouse model showing that activated T cells die rapidly, 
mediated via Bim upregulation (237). Given the various mechanisms by which 
BCL-3 has been shown to interact and alter the function of NF-B homodimers 
there are several alternative mechanisms which may explain how BCL-3 may be 
repressing Bim. 
 
Figure 5.1 Model of BCL-3 function in apoptosis in colorectal cancer cells 
A When highly expressed, BCL-3 represses gene transcription when bound to NF-κB 
homodimer subunit p52 at the Bim promoter. This is associated with lower levels of 
acetylated H3 at the Bim promoter. B Following BCL-3 loss/inhibition, Bim undergoes 
transcription with associated increases in acetylated H3 at the promoter, resulting in 





It has been shown in multiple myeloma cells that the non-canonical NF-B complex 
associate with the chromatin de-acetylase, HDAC4, maintaining repressive 
chromatin around the BCL2L11 gene and resulting in reduced Bim transcription 
(153). The preliminary data presented here shows that BCL-3 suppression 
increases levels of histone 3 acetylation. Acetylation of histones plays a 
fundamental role in several processes including gene transcription (432, 433). 
BCL-3 is known to act as a bridging protein to other cofactors, such as lysine 
acetylases or de-acetylases (216). Therefore, it is possible to hypothesise that 
BCL-3 could facilitate histone deacetylation leading to more repressive chromatin 
at the Bim promoter, which following the depletion of BCL-3 results chromatin 
decondensation and in Bim transcription. This could be NF-κB independent, as the 
increased histone acetylation could lead to better access for alternative 
transcription factors aside from NF-κB. Further work could investigate the 
dynamics of how BCL-3 regulates Bim transcription by performing ChIP with 
canonical NF-B subunits to see if there was exchange of NF-B dimers at the 
BCL2L11 promoter following BCL-3 suppression. Additionally, the putative role of 
BCL-3 and regulation of transcription via modulation of chromatin acetylation could 
be investigated in more detail. RNA-seq could be performed following BCL-3 
suppression combined with histone acetyl transferases (HAT) or histone de-
acetylases (HDAC) inhibition to assess sets of genes where BCL-3 interacted 
independently of histone acetylation and those where transcription of genes was 
controlled by BCL-3 and could be blocked or augmented by the inhibitors.  
The role of BCL-3 as a co-regulator of gene transcription by the atypical NF-κB 
subunits is context dependent, with evidence suggestion repressive and activating 
roles with both p50 and p52 homodimers in differing cell types (169, 208, 211).  
An alternative mechanism suggested to that above, is that BCL-3 suppression 




homodimers exchanged for canonical heterodimers, leading to Bim transcription. 
This is plausible as p52 suppression also increases Bim expression. However, the 
data shown here does not delineate whether the effect of both BCL-3 and p52 
knockdown on Bim is a joint effect or through separate mechanisms.  
Blocking Bim expression may lead to a greater effect in cells with wild-type KRAS 
or BRAF, as it is known that tumours harbouring mutations in these genes 
constitutively activate ERK1/2 leading to Bim degradation (311). Interestingly, the 
greatest effect in this study was observed in the HCA7/P cell line, which lack either 
a KRAS or BRAF mutation. Further work could analyse apoptosis in additional 
KRAS WT cells following BCL-3 suppression. Understanding which pathways are 
important in the efficacy of BCL-3 targeting is important for future therapeutic 
development, and for identifying which patients would most benefit. 
The fact that BCL-3 inhibition could alter chromatin accessibility also suggests that 
BCL-3 expression could be important in determining therapeutic resistance. 
5.2 BCL-3 and irradiation 
Results from the second chapter showed BCL-3 suppression sensitises cells to -
irradiation, increasing the magnitude and persistence of H2AX foci and could also 
be explained by BCL-3-induced modulation of chromatin acetylation. Chromatin 
acetylation plays an important role in the DDR (434). Inhibition of HDACs has been 
shown to radio-sensitise tumour cells and results in an increased and prolonged 
H2AX foci formation (435); the results from chapter 2 replicate this phenotype. 
BCL-3 has been previously shown to interact with HATs and HDACs such as 
TIP60, CBP/p300 and HDAC1. Studies examining BCL-3 and HDAC1 show that 
gene transcription is repressed as a result of this interaction but did not analyse 
the function of this interaction in DDR (162, 219, 231). Interestingly, evidence 




on gene transcription (436). HDACs regulate DSB processing, checkpoint 
activation and degradation of DDR proteins and it could be that BCL-3 acts in 
conjunction with HDACs, such as HDAC1, to facilitate chromatin de-acetylation, 
resulting in abrogation of these functions (437). This would explain the phenotype 
that was observed in the study where loss of BCL-3 could impair the DDR leading 
to increased H2AX foci formation and prolongation of H2AX foci in nuclei 
following irradiation. 
Conversely, BCL-3 interacts with HATs such as TIP60. BCL-3 bridges TIP60 to 
p50, through interaction with all 7 ARs, which leads to enhanced transcription by 
the BCL-3:p50 complex (216). TIP60/KAT5 is a lysine acetyl-transferase that has 
numerous substrates in the DDR, such as histones, ATM or NOTCH1; critically, 
TIP60 facilitates chromatin acetylation following DNA damage, particularly H4 
acetylation, with inhibition of this function leading to impaired recruitment of DNA 
repair proteins to DNA damage (438, 439). Currently, it is unknown what regulates 
BCL-3 to perform these functions and given BCL-3 is primarily controlled by PTM, 
it may be PTM plays a role. Interestingly, NOTCH1 has seven AR, and undergoes 
acetylation following binding to TIP60. It could be that BCL-3 is also acetylated 
following binding with TIP60 after irradiation, in a manner similar to NOTCH1, 
possibly leading to inhibition of TIP60-induced chromatin acetylation (439). 
Furthermore, analysis of the BCL-3 protein sequence reveals it has two putative 
ATM phosphorylation sites, the first site sits within the second AR and the second 
site sits in the proline-serine rich region at the c-terminus. BCL-3 may be 
phosphorylated in a manner similar to p65, which is phosphorylated by ATM on 
conserved ATM-phosphorylation consensus sites, resulting in its activation (379). 
Recent work, analysing BCL-3 phosphorylation did not examine these sites but it 
may be that BCL-3 is phosphorylated as a result of DNA damage by activated ATM 




recognised protein-protein binding motifs and it could be that by phosphorylating 
BCL-3, within an AR, alters the ability of BCL-3 to bind to other proteins, such as 
HDAC1 or TIP60. Alternatively, the C-terminal domain of BCL-3 is well recognised 
to contain other phosphorylation sites that lead to BCL-3 translocation, stability and 
its function as a cofactor with NF-B subunits. It may be that ATM phosphorylation 
in the C-terminus primes BCL-3 for further phosphorylation by other kinases. 
Further investigation is required to understand the role of BCL-3 in chromatin 
remodelling, identify the protein interactions important for this function and the 
BCL-3 PTMs implicated in the DDR. This would lead to investigating whether 
targeting this function is important for sensitising to therapy. 
There may be alternative mechanisms by which BCL-3 exerts its effects in 
radiation. The finding that BCL-3 knockdown promotes formation of H2AX foci 
following -irradiation suggests alteration to the DDR. Cells with competent repair 
machinery are able to compensate to some extent for increasing damage, whilst 
also maintaining low levels of un-repaired DSBs resulting in lower levels of foci 
formation. However, evidence shows that cells with aberrant DDR machinery, had 
linear increases in un-repaired DSBs, marked by increased formation of H2AX 
foci. A similar phenotype is observed when BCL-3 is suppressed, suggesting that 
BCL-3 suppression results in defects in DDR. Irradiation induced DNA damage 
leads to a variety of lesions clustered together (440, 441), resulting in significant 
H2AX foci formation. Results showed that BCL-3 suppression increased H2AX 
foci formation after irradiation. Increased or persistent H2AX foci formation, after 
irradiation, is correlated with reduced cell survival as a result of unrepaired DNA 
damage (442). Additionally, increased duration and persistent of H2AX foci is 
known to be a marker of more complex DSBs generated by physical or chemical 
insults (443). DSB complexity plays a role in cell survival after radiation, with more 




to undergo increased IR-induced apoptosis (444). Therefore, it could be that BCL-
3 is altering the repair (likely not to be through HR as BCL-3 suppression failed to 
induce sensitivity to PARPi) of a particular type of lesion resulting in increased 
complexity of the DSB, which would result in the observed alterations to H2AX 
foci formation. 
Other mechanisms involving BCL-3 in the response to DNA damage may include 
interaction with other members of DDR such as RAD1, part of the 9-1-1 complex 
that senses DNA lesions (376). Interestingly, in other species, BCL-3 has been 
shown to be evolutionarily upregulated in Tibetan boars living at high altitude as 
an adaption to high levels of DNA damage sustained from UV radiation in these 
animals (445). It may also be that BCL-3 modulates DNA damage-induced p53 
activation through upregulation of HDM2 (239), however, this is unlikely in this 
model as p53 is both WT and mutated in the cells analysed, which show the same 
Figure 5.2 Model of BCL-3 function in DNA damaging therapy response 
A In cells with high levels of BCL-3 promote increased resistance to DNA damaging 
therapies. Possibly through promoting inaccessable chromatin through association with 
histone de-acetylases. BCL-3 may also be phosphorylated by ATM following irradiation. B 
Following loss of BCL-3 there is increased sensitivity to DNA damaging agents. It is 
suggested that BCL-3 loss results in increased chromatin accessability leading to the 





response to BCL-3 suppression (LS174T – p53 WT; SW1463 and HCA7/P – p53 
mutant). The data presented above showed that a novel BCL-3 inhibitor, which is 
designed to inhibit the interaction of BCL-3 with p50 or p52 did not result in 
increased radiosensitivity in the tumour spheroid model, potentially corroborating 
the evidence discussed above that BCL-3 may be functioning in a NF-κB 
independent manner in DDR. 
In summary, this work suggests that high expression of BCL-3 in rectal cancers 
could lead to therapy resistance and that by targeting BCL-3 in tumours, this may 
offer an opportunity to sensitise tumours to current therapies. Further work is 
required to define interactions of BCL-3 and members of DDR and determine if 
inhibitors can disrupt this interaction or inhibitor the downstream outcomes of BCL-
3 (HDAC inhibitors). 
BCL-3 regulates both apoptosis and radiation resistance through different 
mechanisms in colorectal cancer. Clinically, the importance of this work is 
considerable. Significant benefits to patient prognosis can be achieved by 
improving response to therapy, which could be achieved by targeting BCL-3. 
Additionally, given that BCL-3 may predict response to neo-adjuvant LCCRT, 
expression of BCL-3 could have utility as a biomarker of response. As a biomarker 
it could be used to stratify those patients with low expression who could progress 
to LCCRT and those with high expression who would progress straight to surgery. 
Further work is required to assess this in detail. BCL-3 could also be used to stratify 
the use of adjuncts to LCCRT such as the putative use of HDAC inhibitors to block 
the downstream effects of BCL-3 upregulation. 
In conclusion, BCL-3 is a potent survival factor in CRC and inhibition of BCL-3 may 




















6.1 Appendix 1 
6.1.1 ASPIRE STUDY PROTOCOL 
Does aspirin increase the clinical response to pre-operative chemo-
radiotherapy [CRT] in rectal cancer? 
 
Prof Ann Williams: Professor of Experimental Oncology  
Prof Chris Paraskeva: Professor of Experimental Oncology, Head of School 
Mr Mike Thomas: Consultant Colorectal Surgeon, Bristol Royal Infirmary 
Miss Katherine Gash: Clinical Research Fellow in Colorectal Surgery, Chief Investigator 
of the study 
Summary 
The overall purpose is to determine whether aspirin increases clinical response to chemo-
radiotherapy [CRT], through targeting the Lgr5+ cancer stem cell population. In vivo and in 
vitro approaches will be combined to help understand the role of cancer stem cells in 
resistance to treatment and late relapse. Previous laboratory studies have shown that 
through inhibiting both the COX2/PGE2 and BCL-3/NF-κB signalling pathways, aspirin is 
able to target cancer stem cells and hence we propose that the adjuvant use of aspirin will 
increase the therapeutic response of rectal tumours to CRT.  
Background Information 
Despite recent advances in treatment, more than 40% of patients who present with 
advanced colorectal cancer will be resistant to current therapies. Hence there is an urgent 
need not only to develop new treatments but also to find ways to improve the long term 
response to existing therapies. Importantly it is the colorectal cancer stem cell [CSC] 
population that is thought to be responsible for fuelling the growth of the tumour leading to 
metastatic disease. Up to very recently research on colorectal CSCs has been limited due 
to the lack of reliable cancer stem cell markers. However, the identification of the Leucine-
rich repeat-containing G-protein coupled receptor 5 (Lgr5) and other putative intestinal 
stem cell markers has made possible the investigation of intestinal cancer stem cells in 
tumour response to conventional treatment [1].  As colorectal CSCs are able to remain 
dormant and to become resistant to the effects of chemo-radiotherapy (CRT), it is the CSC 
that are thought to be responsible for recurrence after R0 surgical resection. Importantly, 
recent work from our lab has shown that the COX2/PGE2 and BCL-3/NF-κB signalling 
pathways can promote the stem cell phenotype [2, unpublished] and hence potentially 
confer resistance to therapies. 
The link between chronic inflammation and cancer is widely accepted and the importance 




inflammation and cancer well established [3]. COX-2 is overexpressed in the majority of 
colorectal cancers and leads to elevated levels of PGE2 which promote many hallmarks of 
cancer including tumour cell survival [4]. PGE2 has been shown to enhance Wnt/β-catenin 
signalling in colorectal carcinoma cells and in normal haematopoietic stem cells, driving 
Lgr5 expression and stem cell function [5-7].  The important chemopreventive properties 
of NSAIDs such as aspirin, which act through inhibiting PGE2, have been known for many 
years and one very striking clinical observation is their ability to cause adenoma regression 
in FAP patients [8]. Recent exciting data from our laboratory shows that PGE2 promotes 
the growth and survival of Lgr5+ colorectal stem cells and suggests that NSAIDs would 
inhibit cancer stem cell survival through suppressing Lgr5 expression [2]. This led to the 
hypothesis that as NSAIDs including aspirin directly target the CSC population (which are 
the cells that become resistant to treatment and drive tumour growth), the use of NSAIDS 
in an adjuvant setting could improve therapeutic outcome. 
The success of surgical resection of rectal tumours has improved significantly with the use 
of pre-operative chemo-radiotherapy, although the reason why some patients with rectal 
cancer respond better to CRT than others remains unknown. Interestingly, radiotherapy 
(RT) has been reported to enhance COX-2 protein expression as well as elevate PGE2 
synthesis in human cancer cells [reviewed in 9]. As COX2-PGE2 signalling drives the 
survival of the CSC population, RT induced PGE2 may contribute to a poor response to 
CRT.  Hence, one way of determining potential response to CRT may be through 
measuring PGE2 levels in the patients prior to therapy. PGE2 is an unstable compound 
that is rapidly metabolised by the 15-hydroxy prostaglandin dehydrogenase (15-PGDH) 
enzyme to the stable PGE-M. Interestingly PGE-M can be quantified in urine samples and 
has been shown to be a reliable indicator of systemic PGE2 levels in a number of studies 
[reviewed in 9]. For example breast cancer patients that received cytotoxic chemotherapy 
had significantly higher levels of urinary PGE-M compared to patients without 
chemotherapy [10]. Further, levels of urinary PGE-M have been shown to be a marker of 
pharmacological activity of NSAIDs [10-12] suggesting that the measurement of urinary 
PGE-M can not only be used as a surrogate marker for disease progression in COX-2 
positive tumours but also as a marker for NSAID efficacy. Therefore measuring urinary 
levels of PGE-M will enable monitoring of the effect of NSAIDs on systemic levels of 
prostaglandins in rectal cancer patients. In addition, we propose to determine the efficacy 
of PGE-M monitoring compared to established markers such as CEA in relation to tumour 
recurrence after surgical resection. 
As NSAIDs may in part reduce cancer risk through suppression of the inflammatory 
response, it is interesting that NSAIDs also target pro-survival NF-κB signalling in tumour 
cells [13]. In this context, it was of interest to note that aspirin but not the COX-2 specific 
inhibitor NS398 suppressed Bcl-3/NF-kB signalling in colorectal cancer cell lines 




Bcl-3 signalling is now emerging as an important survival factor in a number of solid 
tumours [14-18]. Work in our laboratory has recently identified induction of Bcl-3 expression 
in epithelial cells in response to inflammatory cytokines and shown the Bcl-3/NF-kB 
homodimeric complex to promote survival through activation of the AKT pathway (Urban 
et al, submitted). Excitingly, recent data suggest that Bcl-3/NF-kB signalling also enhances 
the stem cell phenotype of colorectal tumour cells [confidential, unpublished data]. As 
aspirin represses both Bcl-3 expression and COX-2/PGE2 activity, this combined effect 
suggests that aspirin could be particularly effective at targeting the Lgr5+ stem cells and 
hence able to increase therapeutic response to CRT.   
The novel aspects of this work are therefore: i) identify whether the regular daily use of 
aspirin acts as an important novel adjuvant for colorectal cancer treatment by blocking both 
the PGE2 and Bcl-3 pathways hence targeting carcinoma stem cell survival ii) the use of 
urinary PGE2 as a possible novel cancer biomarker for tumour response, reporting efficacy 
of NSAID use in combination with CRT and for tumour recurrence.   
The proposed research is highly original and exploits the CRUK group’s recent novel 
discovery that prostaglandins (which enhance the Wnt/B Catenin pathway) and Bcl-3/NF-
kB both up regulate the recently characterised intestinal stem cell marker Lgr5 (a Wnt 
target), thus promoting cancer stem cell survival. Hence, aspirin which works by lowering 
prostaglandin levels may have a dual role in targeting these pro-cell survival pathways and 
inhibiting intestinal cancer stem cell survival, which may be critical for chemoprevention 
and the development of novel therapies through targeting cancer stem cells. 
Study Objective 
Thus the aim of this study is to determine whether the use of aspirin can enhance the 
response to pre-operative CRT in rectal cancer patients. If this cohort study generates 
encouraging results then a larger study, likely to be a randomised trial, will be undertaken. 
Aims 
There are 3 aspects to this proposal:  
1) To investigate whether aspirin can enhance the effect of pre-operative CRT in rectal 
cancer [using clinical end points]. Levels of the PGE2 metabolite PGE-M will be monitored 
to assess efficacy of aspirin [or other daily NSAID use] on systemic PGE2 levels. 
2) To investigate the pre-operative levels of PGE-M during CRT (in patient urine samples) 
to determine whether therapeutic response correlates with prostaglandin levels. In addition, 
measure urinary PGE-M following surgery to investigate whether prostaglandin levels 
correlate with recurrent tumour burden (to assess utility as a biomarker compared with 
established serum markers such as CEA). 
3) To determine whether aspirin [or daily use of NSAIDs] target the Lgr5+ cell population 




allow us to determine the effect of NSAID activity on the survival of cancer stem cell 
population. 
This study is a modification of a previous application (E5900) that was not completed due 
to the voluntary withdrawal of VIOXX (COX-2 specific NSAID). However experience from 
the previous trial has demonstrated feasibility of the study and patient compliance.  
Study Site 
Patients who are receiving treatment at Bristol Royal Infirmary, North Bristol NHS Trust, 
Cheltenham General Hospital, Royal Devon and Exeter NHS Foundation Trust, Abertawe 
Bro Morgannwg University Health Board, or Royal United Hospital Bath, will be invited to 
participate.  This will be a cohort study involving between 50 and 100 patients. The 
research will commence in February 2014 and will last for 36 months. 
The laboratory element of the research will be carried out in the Cancer Research UK 
Colorectal Tumour Biology Research Group in the Cancer Research Labs within the School 
of Cellular and Molecular Medicine, a Cancer Research UK group with more than 20 year 
continuous CRUK programme funding and renowned for producing high quality research. 
This group has direct involvement in clinical trials and a proven research track record as 
leaders in the field of colorectal cancer chemoprevention. 
Subjects and Recruitment 
The aim of this trial is to determine whether regular NSAID use, through suppressing 
systemic PGE2 levels and Bcl-3 activity, can increase the therapeutic response to pre-
surgery chemo-radiotherapy in rectal cancer patients.  
As with normal NHS management:  Patients will have been diagnosed with rectal cancer 
either at their outpatient clinic appointment (where the tumour can sometimes be felt on 
rectal examination or seen with a rigid sigmoidoscope), or at endoscopy.  The probable 
diagnosis will have been discussed with them and biopsies taken.  The patient will then re-
attend clinic to receive the results of the histology and to discuss their management.  
Further investigations will then be requested, (as is routine management), such as an MRI 
scan +/- endo-anal ultrasound scan, staging CT scan.   
At this point, patients will be approached about the study. The study will be fully explained 
to them in clinic and they will be given a Patient Information Sheet (PIS).  The consultant 
surgeon in charge of their care will be carrying out this clinic consultation. Patients will not 
be asked to consent at this point, but will be invited to participate.  The patients will then 
have the opportunity to go away and think about the study and any questions that they 
might have.  
At their next hospital outpatient appointment when they return to discuss the results of their 
investigations, (likely to be within a couple of weeks of their previous appointment), the 




in the research, they will be asked to sign the consent form. They will have the opportunity 
to ask questions and to discuss any concerns regarding the study. This consent process 
will be carried out by either the research fellow, or the consultant surgeon in charge of their 
care (who will all be fully briefed on the study). The consultant who has seen the patient in 
clinic and completed the consent process will inform the research fellow (via telephone) 
that the patient has been recruited.  




Patient informed of probable 
rectal tumour in outpatients 
clinic or endoscopy
Biopsies Taken
Patient attends clinic to discuss 
biopsy results and further 
investigations requested
Invited to participate in study 
Participant Information Sheet given
Patient attends clinic to discuss results of 
scans and treatment options
Asked if they are willing to participate in 
the study


































Patients must be: 
aged 18 years or over (no upper age limit) 
newly diagnosed with primary rectal cancer  
receiving treatment at Bristol Royal Infirmary, North Bristol NHS Trust, Cheltenham 
General Hospital, Exeter NHS Foundation Trust, Abertawe Bro Morgannwg University 
Health Board Wales, or Royal United Hospital Bath 
medically fit enough to undergo pre-operative radiotherapy and surgery 
willing to consent to this treatment (in accordance with the standard NHS management for 
rectal cancer). 
Patients with metastatic disease will be included, as will those with previous colon (but not 
rectal) cancers.  
Patients with synchronous colon tumours or other simultaneous cancers will be included.  
Exclusion criteria 
Patients will be excluded if: 
they are aged 17 years and under 
they are not fit enough for or not consenting to chemo-radiotherapy and surgery 
they have recurrent rectal cancer. 
Measures and materials 
Having been identified and recruited as detailed above and after full informed consent is 
obtained, patients will be asked to complete a brief questionnaire enquiring about NSAID 
use.  This will ask if the patient takes Aspirin or other NSAIDs (namely Diclofenac/Volterol, 
Ibuprofen, Naproxen, Indomethacin, Mefenamic acid, Celecoxib/Celebrex, Meloxicam, 
Ketorolac, Sulindac, Asasantin Retard or Etoricoxib).  We will then ask about dose and 
frequency of NSAID use.  If patients take no regular NSAIDs there will be no further 
questions for them to complete.  It will be completed in outpatient’s clinic with the help of 
the colorectal cancer nurse specialist, the research fellow or the consultant surgeon. 
Based on the results of this questionnaire, patients will be stratified into three groups 
according to their regular NSAID use: those taking daily Aspirin; those taking daily NSAIDs 
other than Aspirin; those not taking daily NSAIDs (either because it has never been 
suggested or because they have contra-indication to their use).  
As this study does not require additional treatment, all patients will undergo standard 
treatment of pre-operative chemo-radiotherapy plus surgery. Those that are on daily 




radiotherapy (as would be normal clinical practice). They will be asked to inform the PI if, 
for any reason, they need to stop taking their medications.  Patients will be free to withdraw 
at any time. It is important to determine whether patients treated with a combination of 
chemo-radiotherapy and NSAIDs respond better than those treated with chemo-
radiotherapy alone. Patients will not be asked to change their pattern of medication to take 
part in this study.  
Patients will be given Paracetamol or opiate based pain control after surgery as is required.  
Patient data collected will be stratified according to NSAID use (control / irregular NSAID 
use n≥20; daily NSAID use (non-Aspirin) n≥20; daily Aspirin n≥20).  
Many patients in this age group take Aspirin or other NSAIDs and we would not expect 
significant problems.  Nevertheless any patient showing common side-effects (for example 
dyspepsia) will be advised by their clinician and an external independent assessor will 
monitor detailed morbidity data after every 5 patients and compare this to known figures. 
Any adverse events will be reported as per the Sponsor’s procedures, 
(http://www.bristol.ac.uk/red/research-governance/registration-sponsorship/specific-
advice/adverseevent.html). 
All patients recruited will be discussed at the colorectal multidisciplinary team meeting at 
their hospital, (Bristol Royal Infirmary/North Bristol Trust/Cheltenham General Hospital/ 
Exeter NHS Foundation Trust/ Abertawe Bro Morgannwg University Health Board/ Royal 
United Hospital Bath), as is the case for all colorectal cancer patients. The MDT will make 
the decision as to whether it is appropriate to offer them pre-operative chemo-radiotherapy 
prior to undergoing surgery. [The research fellow regularly attends these meetings]. 
Urine Samples 
A single void urinary sample was requested from patients at the start of the study, when 
attending CRT appointments, and when attending their outpatient clinic appointments once 
they have completed the course of pre-operative chemo-radiotherapy.  These specimens 
were collected and stored at -80’C. When the recruitment process is complete (ethical 
approval is valid until January 2017- a further 18 months), as part of the ongoing study, the 
level of PGE-M in urine samples will be determined as a surrogate for NSAID efficacy and 
levels analysed for biomarker potential.   
Blood Samples 
During the patients’ routine treatment for rectal cancer, several blood tests are usually 
taken as part of their normal cancer management. We would ask that an extra blood sample 
bottle is filled on two occasions when they are already having blood taken. One sample 
would be requested prior to CRT and one post CRT. We will always endeavour to take the 
blood samples for research purposes at the same time as blood is being taken for the 
patient's routine cancer management.  There is a small possibility that the patient may not 




would ask if they are willing to have an extra blood test (although this situation is unlikely). 
Similarly to the urine specimens, the blood samples were stored (having been spun in a 
centrifuge and the serum removed and deposited in an ependorf) and will undergo analysis 
once recruitment has closed. 
Tissue Samples 
All patients will be asked for their consent to provide tissue samples for use in the study.  
1) Tissue from the biopsy specimen taken when the patient was originally diagnosed with 
rectal cancer will be requested from the pathologists. 
2) Tissue from the resected tumour specimen (after surgery) will be taken, once the 
pathologists have complete their full analysis of the tumour and have determine the stage 
of cancer etc., so as to guide any future treatment. Only tissue which is surplus to 
requirements will be used. 
3) Normal mucosa from within the surgical specimen resection margins will be collected 
and will act as an internal control.  
Response to radiotherapy will be classified according to the pathology report from the 
excised tumour specimen (range: no response to complete therapeutic response). 
However, it is normal clinical practice for patients to undergo pre-radiotherapy MRI scans 
of the pelvis to aid in treatment planning. If patients in this study undergo pre or post-
radiotherapy MRI scans (as part of their normal NHS care), we will ask for access to the 
data to aid assessment of the shrinkage in tumour volume. This will be done by the 
research fellow (via a hospital computer), reading the radiology report which details tumour 
measurements. The only data which we would need to obtain from this report is the graded 
response (by the radiologist) of the tumour to radiotherapy (e.g. no response, partial 
response etc.). The patients’ actual medical case notes will not be looked at. 
We will study tissue samples in the lab (at University of Bristol, Department of Cellular and 
Molecular Medicine). We will process the tissue to slides and the proliferative and apoptotic 
index of the tumour cells calculated pre and post-RT for both control and treatment groups.  
Immunohistochemical staining/in situ hybridisation will allow analysis of Lgr5+ cells, other 
CSC markers and surrogate markers of tumour response and normal mucosal healing to 
be assessed.  
At post-surgery follow up clinics we will collect additional urine samples to monitor urinary 
levels of PGE-M enabling us to compare efficacy as a surrogate marker of tumour burden 
with more established markers such as CEA.  
Laboratory experiments;  
Tissue 




Bcl-3, NF-κB FGFBP-1 and related co-factor Bag-1 
Ki67 (proliferation associated antigen) 
Apoptotic cell markers  
E-cadherin (marker of cellular differentiation) 
CSC markers including Lgr5 
Reporters of wnt activity including Β-catenin  
PG receptor 1-4 
Blood/Urine 
PGE2 metabolite PG-M 
Tumour derived DNA 
Markers including CEA and above  
Safety Assessments  
As the study will not alter the patients’ clinical management there are no direct safety 
assessments required for patients. The research fellow and professors at the laboratory 
who will be handling specimens have all attended induction in the School of Cellular and 
Molecular Medicine, which covers aspects of safety. All students and staff are issued with 
a copy of the School’s Safety Manual which makes reference to the relevant University 
Codes of Practice. This manual must be read and signed, along with relevant COSHH 
(Control Substances Hazardous to Health) regulations, prior to commencing work in the 
lab. The induction covers specific areas including use of radiochemicals, COSHH 
regulations, high-speed centrifuges and pathogenic micro-organisms. All laboratory staff 
have been immunised against Hepatitis B.  
Study Personnel  
The University of Bristol and the proposed academic supervisors, Prof Paraskeva & Prof 
Williams, have an established track record of collaboration with Bristol Royal Infirmary and 
the clinical supervisor Mr MG Thomas. The importance of research carried out in Bristol 
has been internationally recognised as providing unique human colorectal epithelial cell 
models for identifying the biological consequences of genetic changes associated with 
colorectal carcinogenesis [refer to 1,2]. A combined in vivo and in vitro approach is used to 
study the cellular and molecular biology of colorectal carcinogenesis. The group have a 
strong reputation in the field of chemoprevention supported by Cancer Research UK 
programme funding, with work form the laboratory contributing to the initiation of National 
and International clinical trials. 
The research we propose will expand and develop earlier work done by the Cancer 




role of the COX2/prostaglandin and Bcl-2/NF-κB signalling pathway in promoting the 
survival of cancer stem cells.  
This importance of this study relates to the fact that, despite the huge advances in the 
management of colorectal cancer, there are still patients who remain resistant to treatment: 
the aim of the project is to investigate ways of targeting the cancer stem cell population, 
thought to be critical in repopulating the tumour after therapy, leading to local recurrence 
after resection as well as late metastatic disease. 
Monitoring  
The study will be monitored and audited in accordance with the R&D governance 
procedures of the University of Bristol, who have delegated this role to UH Bristol. All study-
related documents will be made available on request for monitoring and audit by the trust, 
University and REC. 
Ethical considerations  
It is not anticipated that there will be any major ethical issues for this study. Patients will all 
have participated with informed consent. Some patients may have up to one week to decide 
if they wish to participate in the trial due to the narrow window between diagnosis and 
surgery. This cohort is small and some patients may have longer than a week to consider 
their participation.  
There is no risk of the study interfering with a patient’s definitive treatment, (i.e. surgery), 
as prior to us receiving the tissue the sample will be examined by a pathologist at the 
hospital in which the patient is receiving treatment. The pathologist will record all of the 
information needed to stage the tumour / guide any further treatment. There is a chance of 
some discomfort from having blood samples taken, but as previously stated, we will 
endeavour take the patients' blood at the same time as it is being taken for their routine 
NHS investigations. 
Ethics and R&D approval  
The study will be performed subject to Research Ethics Committee (REC) approval and 
local Research and Development (R&D) approval.  
Research governance  
This study is sponsored by the University of Bristol.  
Finance & Indemnity 
This study is being funded by: 
The Royal College of Surgeons- One Year Surgical Research Fellowship 
The David Telling Charitable Trust 




These grants are administered through the University of Bristol and University Hospitals 
Bristol NHS Foundation Trust. 
The laboratory is funded by a Cancer Research UK Programme Grant. 
The University has Clinical Research Insurance to cover the liability of the University to 
research participants. In the event that something does go wrong and a participant is 
harmed during the research study there are no special compensation arrangements. If a 
participant is harmed and this is due to someone's negligence then they may have grounds 
for a legal action for compensation against Bristol University or the NHS Trust or one of the 
other parties to the research, but they may have to pay their own legal costs. 
Reporting and Dissemination  
It is anticipated that the results of the study will be disseminated in the form of peer 
reviewed publication and presented at scientific/academic meetings locally, nationally and 
internationally.  
Conflicts of interest 





6.2 Appendix 2 
6.2.1 TNM staging of colorectal cancer 
Tumour 
Tx: Primary tumour cannot be assessed 
T0: No evidence of primary tumour 
Tis: carcinoma in-situ 
T1: tumour invades submucosa (through muscularis mucosa but not into the 
muscularis propria) 
T2: tumour invades muscularis propria 
T3: tumour invades through the muscularis propria into the pericolorectal tissues 
T4a: tumour invades through the visceral peritoneum 
T4b: tumour directly invades or adheres to other adjacent structures or organs 
Node (at least 12 regional lymph nodes recovered to be accurate) 
Nx: regional lymph nodes (LN) cannot be assessed 
N0: no regional LN metastasis 
N1a: metastasis in 1 LN 
N1b: metastasis in 2-3 LN 
TNM staging of colorectal cancer – 8th edition 
AJCC stage Tumour Node Metastasis 
0 Tis N0 M0 
I T1-T2 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 

































IVA Any T Any N M1a 
IVB Any T Any N M1b 




N1c: no regional lymph nodes are positive but there are tumour deposits in the 
subserosa, mesentery or nonperitonealised pericolic or perirectal/mesorectal 
tissues 
N2a: metastasis in 4-6 LN 
N2b: metastasis in 7 or more LN 
Metastasis 
M0: no distant metastasis 
M1a: metastasis confined to 1 organ or site without peritoneal metastasis 
M1b: metastasis to 2 or more sites without peritoneal metastasis 





6.3 Appendix 3 






Tumour regression grade (TRG) systems 
Response AJCC Dworak Mandard Ryan 
Complete 
regression 
No viable cancer 








cancer cells or 
single cells or 






Single cells or 
rare small 
groups of cancer 














more than single 
cells or rare 





























































6.4 Appendix 4 
6.4.1 BCL2L11 gene sequence 
NF-κB consensus sites marked in blue 




























































































































































































































































6.5 Appendix 5  
6.5.1 SDS-PAGE gel composition 
 
  



























 Stack Buffer 
0.5M Tris 
pH6.8/0.4% SDS 
     
1.0 
ddH20 4.4 5.8 7.7 8.7 2.2 































6.6 Appendix 6 
6.6.1 Automated spheroid assessment MATLAB script 




%The main figure 
ss = get(0,'ScreenSize'); 
h.h = figure('CloseRequestFcn', @closeWindowMode); 
%h.h = figure; 
  
set(h.h,'Position',[ss(3)/2-(ss(4)/2)-50 50 ss(4)+100 ss(4)-150], 
'Visible','off'); 
  
%Two panels, one folgr\f gr the image, the other for the controls 
%h.h_im_plain_p = uipanel('Position',[0.01 0.01 0.7 
0.98],'FontSize',12); 
h.h_im_cont_p = uipanel('Position',[0.01 0.01 0.7 
0.98],'FontSize',12); 
h.h_cont_tg = uitabgroup('Parent',h.h,'Position',[0.72 0.27 0.28 
0.72]); 
h.h_dis_p = uipanel('Position',[0.72 0.01 0.27 
0.25],'FontSize',12); 
h.h_det_t = uitab('Parent',h.h_cont_tg,'Title','<html><font size=4 
color="black">Spheroid analysis transmitted light','Tag','1'); 
%h.h_fluor_t = uitab('Parent',h.h_cont_tg,'Title','<html><font 
size=4 color="black">Fluorescence Image','Tag','2'); 
% h.h_export_t = uitab('Parent',h.h_cont_tg,'Title','<html><font 
size=4 color="black">Export','Tag','3'); 
h.h_im_cont_p_ax = axes('Parent',h.h_im_cont_p,'Position',[0 0 1 
1],'Visible','on'); 
%h.h_im_plain_p_ax = axes('Parent',h.h_im_plain_p,'Position',[0 0 
1 1],'Visible','off'); 
  
cont_top = 0.9; 
bt_h = 0.055; 
gap = bt_h + 0.015; 
edit_offs = 0.01; 
  
  

























%% Getting files 
[im_fname, im_pname,load_cnd] = 
uigetfile({'*.tif;*.tiff;*.jpg;*.jpeg;*.png;*.bmp;*.lif'}, 'Load 
image'); 
if load_cnd == 0 






%bioformats open Lif 
lif_name=strcat([im_pname, im_fname]); 
[pathstr,lif_name,ext] = fileparts(lif_name); 
if strcmp(ext,'.lif') 
    lif_name=strcat(lif_name,'.lif'); 
    data=bfopen(char(lif_name)); 
    omeMeta = data{1, 4}; 
    numberOfChannels=omeMeta.getChannelCount(0); 
    try 
        
scaling=double(omeMeta.getPixelsPhysicalSizeX(0).getValue()); 
    catch 
        scaling=double(omeMeta.getPixelsPhysicalSizeX(0).value()); 
    end 
    if numberOfChannels==1 
        im=data{1,1}; 
    else 
        loadMultichannelLif 
        data=allData; 
        im=data{1,1}; 
    end 
     
    preProcessImage; 
     
elseif strcmp(ext,'.tif') 
    im = imread(strcat([im_pname, im_fname])); 
    if size(im,3) == 3 
        im = rgb2gray(im); 
         
    end 
    data=1; 
end 
n_rows = size(im,1); 
n_cols = size(im,2); 
  
%Buttons and controls TRANS 
set(h.h,'Position',[ss(3)/2-(ss(4)/2)-50 50 ss(4)+100 ss(4)-150], 
'Visible','on'); 








left','Position',[0.1, cont_top-gap*pos, 0.54, bt_h-edit_offs]); 
fluorescence=uicontrol('Parent',h.h_det_t,'Style','checkbox','Font
Size',24,'Units','normalized','HorizontalAlignment','left','Enable
','on','Position',[0.75, cont_top-gap*pos, 0.54, bt_h-edit_offs]); 








cont_top-gap*pos, 0.22, bt_h]); 








gap*pos, 0.22, bt_h]); 








gap*pos, 0.22, bt_h]); 








gap*pos, 0.22, bt_h]); 
  
%Change image slider and number 
pos = pos + 1.5; 
image_number = 
uicontrol('Parent',h.h_det_t,'Style','slider','String','Image','Ca
llback',@changeImage,'Min', 1, 'Max', size(data,1), 'Value', 1, 
'SliderStep', [1/size(data,1), 
1/size(data,1)],'FontSize',12,'Units','normalized','Position',[0.1
, cont_top-gap*pos, 0.8, bt_h]); 














%Detect, reset and run all 





Position',[0.05, cont_top-gap*pos, 0.9, bt_h]); 




zed','Position',[0.05, cont_top-gap*pos, 0.9, bt_h]); 





d','Enable','off','Position',[0.05, cont_top-gap*pos, 0.9, bt_h]); 

















','Position',[0.05, cont_top-gap*pos, 0.9, bt_h+0.1]); 
  
  
curr_im = imshow(im,[],'Parent',h.h_im_cont_p_ax); 
dcm = datacursormode(h.h); 
set(dcm, 'UpdateFcn', @dcmCallback); 
drawnow; 
  
    function savePreview(~,~) 
        mkdir(strcat(date,'_Analysis')); 
        prompt = {'Input File Name (without extension):'}; 
        title = 'Save as...'; 
        dims = [1 35]; 
        definput = {'myFile'}; 
        fileName = inputdlg(prompt,title,dims,definput); 
        fileName = strcat(char(fileName), '.png'); 
        fileName = strcat(date,'_Analysis/',fileName); 
        imwrite(im,fileName); 
    end 
  
    function preProcessImage(~,~) 
        im=fstack(im); 
    end 
  




        set(h.h, 'pointer', 'watch') 
        drawnow; 
        
set(cont_image_edit,'String',num2str(round(get(image_number,'Value
')))); 
        im=data{round(get(image_number,'Value')),1}; 
        %metadata = data{1, 2}; 
         
        preProcessImage; 
         
        curr_im = imshow(im,[],'Parent',h.h_im_cont_p_ax); 
        set(display_label_button,'Enable','off'); 
        set(disco_button,'Enable','off'); 
        set(h.h, 'pointer', 'arrow') 
    end 
  
  
    function changeImageNumber(~,~) 
        set(h.h, 'pointer', 'watch') 
        drawnow; 
        
set(image_number,'Value',(str2double(get(cont_image_edit,'String')
))); 
         
        im=data{str2double(get(cont_image_edit,'String')),1}; 
        preProcessImage; 
         
        curr_im = imshow(im,[],'Parent',h.h_im_cont_p_ax); 
        set(display_label_button,'Enable','off'); 
        set(disco_button,'Enable','off'); 
        set(h.h, 'pointer', 'arrow') 
    end 
  
    function detect(~,~) 
        set(h.h, 'pointer', 'watch') 
        drawnow; 
        curr_im = imshow(im,[],'Parent',h.h_im_cont_p_ax); 
         
        focused=im; 
         
        if get(fluorescence,'Value')==0 
            focusedProcessed=imcomplement(focused); 
        else 
            focusedProcessed=focused; 
        end 
        
mask=adaptivethreshold(focusedProcessed,str2double(get(KS_edit,'St
ring')),str2double(get(offset_edit,'String')),0); 
        mask=imdilate(mask,se); 
        mask2=imfill(mask,'holes'); 
        %sizeSieve1In=sizeSieve1/(scaling*scaling); 
        
mask3=bwareaopen(mask2,round(str2double(get(sizeFilter1_edit,'Stri
ng')))); 
        D = -bwdist(~mask3); 
        Ld = watershed(D); 
        bw2 = mask3; 
        bw2(Ld == 0) = 0; 




        D2 = imimposemin(D,extendMin); 
        Ld2 = watershed(D2); 
        bw3 = mask3; 
        bw3(Ld2 == 0) = 0; 
         
        %sizeSieve2In=sizeSieve2/(scaling*scaling); 
         
        
bw4=bwareaopen(bw3,round(str2double(get(sizeFilter2_edit,'String')
))); 
        mask4=imclearborder(bw4); 
        mask5=immultiply(focusedProcessed,mask4); 
         
        [B,L,N,A] = bwboundaries(mask4); 
        
properties=regionprops(L,focused,'Area','Centroid','Eccentricity',
'Perimeter','FilledArea','Solidity'); 
         
        hold on 
        for k=1:length(B), 
            boundary_Master = B{k}; 
            line(boundary_Master(:,2), boundary_Master(:,1),... 
                'color','r','LineWidth',1,'Parent', 
h.h_im_cont_p_ax); 
        end 
        hold off; 
         
        %im=mask4; 
        %curr_im = imshow(im,[],'Parent',h.h_im_cont_p_ax); 
        set(h.h, 'pointer', 'arrow') 
        set(display_label_button,'Enable','on'); 
    end 
  
    function clearOutlines(~,~) 
        set(h.h, 'pointer', 'watch') 
        drawnow; 
        clearvars B L properties mask5;  
        im=data{str2double(get(cont_image_edit,'String')),1}; 
        preProcessImage; 
        curr_im = imshow(im,[],'Parent',h.h_im_cont_p_ax); 
        set(display_label_button,'Enable','off'); 
        set(disco_button,'Enable','off'); 
        set(h.h, 'pointer', 'arrow') 
    end 
  
    function displayLabels(~,~) 
        figure('Visible','off'); temp=imshow(L,[]); 
        %map(255,:,:)=[0,0,0]; 
        map(1,:,:)=[0,0,0]; 
        %colormap(map); 
         
        %set(temp,'AlphaData',mask5); 
        set(temp,'AlphaData',focusedProcessed); 
         
        colormap(map); 
         
        centroids = cat(1, properties.Centroid); 
         




        for k = 1:length(centroids) 
            try 
                text(centroids(k,1), centroids(k,2), sprintf('%d', 
k),'FontSize',14); 
            catch 
            end 
             
        end 
        hold off 
%         hold on 
%         for k=1:length(B), 
%             boundary_Master = B{k}; 
%             line(boundary_Master(:,2), boundary_Master(:,1),... 
%                 'color','g','LineWidth',1); 
%         end 
%         hold off; 
   
        drawnow 
        img=getframe(gcf); 
        curr_im = imshow(img.cdata,[],'Parent',h.h_im_cont_p_ax); 
        set(disco_button,'Enable','on'); 
    end 
  
    function runAll(~,~) 
        progress = waitbar(0,'Processing bits and bobs'); 
         
         
        for allData=1:size(data,1); 
            excelData=[]; 
            name=omeMeta.getImageName(allData-1); 
             
            im=data{allData,1}; 
            preProcessImage; 
            focused=im; 
             
            if get(fluorescence,'Value')==0; 
                focusedProcessed=imcomplement(focused); 
            else 
                focusedProcessed=focused; 
            end 
             
            
mask=adaptivethreshold(focusedProcessed,str2double(get(KS_edit,'St
ring')),str2double(get(offset_edit,'String')),0); 
            mask=imdilate(mask,se); 
            mask2=imfill(mask,'holes'); 
            %sizeSieve1In=sizeSieve1/(scaling*scaling); 
            
mask3=bwareaopen(mask2,round(str2double(get(sizeFilter1_edit,'Stri
ng')))); 
            D = -bwdist(~mask3); 
            Ld = watershed(D); 
            bw2 = mask3; 
            bw2(Ld == 0) = 0; 
            extendMin = imextendedmin(D,2.5); 
            D2 = imimposemin(D,extendMin); 
            Ld2 = watershed(D2); 
            bw3 = mask3; 




             
            %sizeSieve2In=sizeSieve2/(scaling*scaling); 
            get(sizeFilter1_edit); 
            
bw4=bwareaopen(bw3,round(str2double(get(sizeFilter2_edit,'String')
))); 
            mask4=imclearborder(bw4); 
            mask5=immultiply(focusedProcessed,mask4); 
             
            [B,L,N,A] = bwboundaries(mask4); 
            
properties=regionprops(L,focused,'Area','Centroid','Eccentricity',
'Perimeter','FilledArea','Solidity'); 
             
            %scaling 
            scaling; 
            for i=1:length(properties); 
                
properties(i).Area=(properties(i).Area)*(scaling*scaling); 
            end 
             
            %Data Export organisation 
            nameList=cell(1,length(properties)); 
            for t=1:length(properties) 
                nameList(t)=name; 
            end 
             
            propsEx=struct2cell(properties); 
            propsEx=propsEx.'; 
            propsEx2=[nameList' propsEx]; 
            %propsEx2; 




             
            %Save Data 
            mkdir(strcat(date,'_Analysis')); 
            
writetable(testExport,strcat(strcat(date,'_Analysis\'),strcat(date
,'_Analysis'),'.xlsx'),'sheet',strrep(char(name),'/','-')); 
             
             
            figure('Visible','off'), temp=imshow(L,[]); 
            %set(temp,'AlphaData',mask5); 
            set(temp,'AlphaData',focusedProcessed); 
            map(1,:,:)=[0,0,0]; 
            colormap(map); 
             
            centroids = cat(1, properties.Centroid); 
             
            hold on 
            for k = 1:length(centroids); 
                try 
                    text(centroids(k,1), centroids(k,2), 
sprintf('%d', k),'FontSize', 14); 
                catch 
                end 




            hold off 
            img=getframe(gcf); 
            
imwrite(img.cdata,strcat(strcat(strcat(date,'_Analysis\'),strrep(c
har(name),'/','-'),'_',mat2str(allData),'.png'))); 
             
            waitbar(allData/size(data,1),progress); 
        end 
        if isvalid(progress) 
            close(progress) 
        end 
         
    end 
  
    function runDisco(~,~) 
         
        for loop=1:25 
            map=circshift(map,1); 
            displayLabels; 
             
        end 
              
    end 
  
    function loadMultichannelLif(~,~) 
         
        prompt = {'Pick channel to analyse'}; 
        dlg_title = 'Channel Picker thing'; 
        num_lines = 1; 
        defaultans = {'1'}; 
        channelAssignment = 
inputdlg(prompt,dlg_title,num_lines,defaultans); 
         
         
        reader=bfGetReader(lif_name); 
        omeMeta = reader.getMetadataStore(); 
        reader.setSeries(1); 
        iPlaneEnd=reader.getIndex(reader.getSizeZ-
1,(str2double(channelAssignment{1}))-1,0)+1; 
        iPlaneBeg=iPlaneEnd-(reader.getSizeZ-1); 
         
         
         
        allData=cell(reader.getSeriesCount,1); 
        for series=1:reader.getSeriesCount 
            data2=data{series,1}; 
            data3=cell(reader.getSizeZ,2); 
            j=1; 
            for i=iPlaneBeg:iPlaneEnd; 
                data3{j,1}=data2{i,1}; 
                j=j+1; 
            end 
            j=1; 
            for i=iPlaneBeg:iPlaneEnd; 
                data3{j,2}=data2{i,2}; 
                j=j+1; 
            end 




            allData{series}=data3; 
            data3=[]; 
        end 
         
    end 
  
    function closeWindowMode(~,~) 
        % Asking the user if the process should be repeated 
        quest_res = questdlg('Analyse another Lif 
File?','Continue?','Yes','No','Yes'); 
        switch quest_res 
            case 'Yes' 
                delete(h.h) 
                clear all 
                SpheroidMeasureTransmitted_2017_08_04 
            case 'No' 
                delete(h.h) 
        end 
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